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Physiology-guided coronary revascularisation is associated with improved outcomes however it 
is unclear if physiological indices can reliably assess individual lesions in the commonly-




3-D printed serial disease phantoms were assessed within an in vitro model of circulation. FFR of 
a lesion was predicted from the size of step-up on pressure-wire pullback in the presence of serial 
lesions (FFRapp) and compared to phantoms with no accompanying lesion (FFRtrue). A 
mathematical model to minimise error in predicting FFRtrue (FFRpred) was developed in 32 
phantoms and validated in another 20 phantoms. In 54 patients with serial disease, resting and 
hyperaemic pressure-wire pullbacks were performed, with FFR, iFR, Pd/Pa of each stenosis 
measured by the trans-lesional gradient in each index and FFRpred derived mathematically, as in 
the in vitro study. These indices were compared to the ‘true’ trans-lesional gradient of each index 
following stenosis isolation by PCI of one of the stenoses or using a disease-free sidebranch. In a 
subset of 27 patients, Doppler average peak flow velocity (APV) was also measured before and 
after stenosis isolation, to calculate hSR (hSR=DP/APV, where DP=trans-lesional pressure 
gradient). In a further subset of 24 patients, prospective CT coronary angiography was performed 
prior to stenosis isolation by PCI to assess the value of a novel non-invasive FFRCT-derived PCI 




Both in vitro and in the clinical cohort, individual stenoses are underestimated and misclassified 
in serial disease, proportional to total FFR. Mean errors for FFR, iFR and resting Pd/Pa were 
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33.3%, 19.8% and 23.4% respectively, and 14.3% for FFRpred (P<0.001). Stenosis 
misclassification rates based on 0.80, 0.89 and 0.91 thresholds were 17%, 24% and 20% for 
FFR, iFR and Pd/Pa respectively. With FFRpred only 11% of stenoses were misclassified. 
Apparent and true hSR correlated strongly (R=0.87, P<0.001), with 7% of stenoses 
misclassified, thus suggesting that serial stenoses largely behave as resistors in series (providing 
further validation of the principles upon which our mathematical solution was based). In the 
subset of patients that had a prospective CT scan, applying a novel interactive PCI planning tool 
to FFRCT outputs results in significant improvements in the estimation of stenosis severity with 




Physiological assessment of stenoses in the presence of serial CAD is prone to significant 
underestimation, proportional to the cumulative burden of disease within the vessel. All invasive 
pressure-derived physiological indices, resting and hyperaemic, are prone to significant error 
and stenosis misclassification when used conventionally. Doppler-based resistance indices are 
less prone to this error but utilisation is limited by difficulties in obtaining Doppler traces. The 
finding that serial stenoses generally behave as resistors in series supports the use of an FFR 
correction equation, derived using our 3D-printed in vitro study, that does not require 
measurement of coronary occlusive pressure. Applying this correction equation to routine 
pressure wire pullback measurements significantly reduces error in estimating true stenosis 
significance and has significant clinical utility. In addition, we demonstrate and validate a non-
invasive FFRCT-derived PCI planning tool that aids more accurate prediction of true stenosis 
significance in serial CAD compared to contemporary invasive and non-invasive methods. The 
next step is to establish multi-centre clinical utility and outcome studies of the improved 
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There is growing evidence that the greatest benefit of revascularisation for coronary artery 
disease (CAD) is derived from targeting myocardial ischaemia. Traditionally, functional 
assessment to identify patients with CAD was based on non-invasive tests prior to angiography1. 
This has subsequently evolved to identifying vessels with functionally significant disease at the 
time of angiography, such as with Fractional Flow Reserve (FFR) and Instantaneous Wave-Free 
Ratio (iFR)2-4.  
 
CAD is the result of atherosclerosis, which is systemic in nature, and therefore an element of 
serial/diffuse disease is common, with estimates suggesting a prevalence of 25-40% in all 
angiograms5,6. There is often a need to identify the physiological significance of individual 
lesions when deciding on a revascularisation strategy, but this is potentially challenging because 
of physiological interplay between serial stenoses that alters the apparent significance of each 
lesion. 
 
The background to this thesis describes the basis of ischaemia-guided revascularisation and the 
tools with which we assess the physiological significance of stenoses. I will describe the 
physiology of serial stenoses and the problems posed when judging the physiological 
significance of individual stenoses. I will go on to discuss current and emerging techniques that 
may be used to assess the functional significance of individual lesions when planning 













Traditionally, the extent of coronary artery disease (CAD) has been assessed using the invasive 
coronary angiogram. However, there is growing evidence that the benefit of revascularisation, 
above and beyond optimal medical therapy, is derived from targeting myocardial ischaemia7. 
Traditionally, functional assessment to identify patients with CAD was based on non-invasive 
tests prior to angiography1. This subsequently evolved to identifying vessels with functionally 
significant disease at the time of diagnostic angiography using invasive flow-based indices such 
as Coronary Flow Reserve (CFR) and Invasive Pressure-Flow based resistance indices, such as 
Hyperaemic Stenosis Resistance (hSR) and Basal Stenosis Resistance (BSR). The most recent 
iterations of ischaemia testing on a per-vessel basis have come in the form of  pressure-derived 
indices of ischaemia and coronary flow-impairment, with tools such as Fractional Flow Reserve 
(FFR) and Instantaneous Wave-Free Ratio (iFR)2-4 (See figure 5.1). 
 
 
Figure 5.1: An illustration of the evolution of ischaemia testing with a question remaining about 





5.1.1 Fractional Flow Reserve, FFR 
 
The pressure drop in a vessel (ratio of distal coronary to aortic pressure, Pd/Pa) during maximal 
adenosine-induced hyperaemia, when the reduction in flow in the distal vessel is assumed 
proportional to the change in pressure across it, is referred to as Fractional Flow Reserve (FFR) 
and is the most widely used pressure index of vessel ischaemia. FFR was initially validated over 
two decades ago against non-invasive surrogate markers of ischaemia in the setting of stable 
angina8. Since then, there has been increasing evidence demonstrating that visual assessment of 
angiographic stenosis severity is prone to significant error and does not reliably correlate to 
underlying functional significance, leading to a misclassification of stenoses in around a third of 
lesions1,9. As a consequence, Ischaemia-guided revascularisation with FFR appears to confer 
significant clinical and prognostic benefit over management based on angiography alone, 
particularly for stable angin2,4,10-12, but also the non-culprit NSTEMI settings13. 
 
5.1.2 Resting Indices of Stenosis Severity: Resting PdPa & iFR 
 
Resting Pd/Pa Ratio 
The ratio of whole cycle distal coronary pressure to aortic pressure at rest (Pd/Pa) was originally 
used by Gruentzig to rationalise balloon angioplasty decisions14. Although clinical outcome data 
is absent, one study found accuracy of >80% when compared against FFR15 and recent subgroup 
analyses of the VERIFY and CONTRAST studies suggested resting Pd/Pa and iFR correlate 
almost perfectly16,17. With more and more data emerging to show near perfect agreement of iFR 
and PdPa17, there is drive to suggest using it in a similar fashion to iFR with a threshold of 
PdPa≤0.91 suggested to correlate excellently with IFR≤0.8917. 
 
iFR 
iFR is defined as average Pd/Pa during the latter 75% of diastole (minus the last 5ms), when 
resistance is purported to be constant and pressure can be assumed proportional to flow, without 
the need to modulate resistance with adenosine-induced hyperaemia7. iFR-guided management 
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has recently been shown to have comparable investigator determined revascularisation rates to 
FFR, in a relatively low-risk group of patients, with data awaited on more complex subsets 11,12. 
 
New Resting Indices of Stenosis Severity 
Recently, resting pressure–derived indexes such as resting full-cycle ratio (RFR) and diastolic 
pressure ratio (dPR) have been introduced to assess the functional significance of epicardial 
coronary stenosis. Evidence is accumulating to suggest all resting indices are equivalent (iFR, 
RFR, dPR and Pd/Pa) with a similar diagnostic accurancy18 19. Infact it has been suggested that 
all these indices could well be grouped under the title: ‘Non-Hyperaemic Pressure Ratios 
(NHPR)’. 
 




Coronary Flow Reserve (CFR) was one of the first measures of stenosis severity. CFR is defined 
as the ratio of baseline to hyperaemic flow in a coronary artery. CFR takes into account both the 
epicardial and microvascular resistance. An impaired CFR has been shown to be correlated with 
worse prognosis and a state of ‘low flow ischaemia’20.  
Measuring CFR requires us to measure intracoronary flow either by Doppler-tipped guidewires 
or by thermodilution techniques. Given CFR cannot differentiate between epicardial and 
microvascular coronary resistance, it is not a stenosis specific marker and cannot therefore be 
used to identify the functional significance of individual stenoses in serial disease. Doppler-






Once flow is measured reliably, establishing the resistance of an individual stenosis becomes 
possible. The ‘resistance’ of an individual lesion should theoretically be an individual property 
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of a stenosis and independent of pressure and flow conditions within a simple vessel.  The 
resistance of an individual stenosis, by analogy with Ohm’s Law is given by the change in 
Pressure across it (∆P) divided by the Flow Velocity through the vessel (Q). This ratio in 
hyperaemic conditions is termed the ‘Hyperaemic Stenosis Resistance’ (hSR). The hSR of a 
stenosis has been shown to be more accurate than FFR and CFR at detecting reversible perfusion 
defects seen using non-invasive modalities21, has been shown to be better than its equivalent 
measured at rest (‘Basal Stenosis Resistance’, BSR)22 and is often considered by some to 
represent the ‘gold standard’ for ischaemia resulting from an individual stenosis. 
 
The resistance (hSR) of a lesion should theoretically be an independent property of a stenosis, 
independent of flow conditions and disease elsewhere within a vessel: much like a resistor 
within an electrical circuit. Whether the hSR of a stenosis does indeed behave in this fashion is 
yet to be established in the form of data. If it does, it may be an ideal tool with which to assess 
the true significance of individual lesions in the presence of serial coronary artery disease. 
 
5.2 THE PROBLEM OF SERIAL CORONARY ARTERY 
DISEASE 
 
As described in section 5.1, serial/diffuse disease is common, with estimates suggesting a 
prevalence of 25-40% in all patients5,6. In the presence of serial disease, that an interventional 
cardiologist would consider treating separately, there is the need to identify the physiological 
significance of individual lesions. This is a challenge and an unmet clinical need is because of 
physiological interplay that alters the apparent functional severity of each lesion leading to 
potential error. 
 
5.2.1 Factors Influencing the Pressure Drop Across A Stenosis 
 
 
To understand serial stenosis interplay, we must first understand the factors that lead to pressure 
changes across a lesion (DP). DP is determined by several factors that are governed by principles 
 17 
enshrined in the Bernoulli equation and Poiseuille’s Law. As summarised in figure 5.2, DP 
across a stenosis, as demonstrated in seminal canine experiments23, can be summarised as DP = 
fQ+sQ2, where DP = change in pressure, f = the frictional coefficient of a lesion, s = the 
separation coefficient of a lesion and Q = Blood Flow through the stenosis. This relationship, 
including both the frictional and separation coefficients, embodies the Bernoulli principle and 
Poiseuille’s Law and is determined largely by specific lesion geometry. Aside from how the 
specific shape of a stenosis affects these coefficients, it is worth considering the other important 
factors: 
- Luminal Narrowing: This contributes to both frictional (f) and separation coefficient (s) 
of a lesion. According to Poiseuille's law, DP across a stenosis is the product of volumetric flow 
rate and viscous resistance (R), with the latter defined as R = 8ηL/πr4, where η is the viscosity of 
the fluid, L is the length of the vessel, and r is the radius of the vessel24. Although blood flow in 
smaller vessels may depart from this relationship, for most epicardial vessels under a 
physiological range of pressures, resistance and hence DP, varies inversely with the fourth power 
of vessel radius. 
- Lesion Length: This contributes linearly to viscous resistance (by Poiseulle’s Law) and to 
the viscous coefficient of the equation in figure 5.2. Although the impact on DP may not be as 
profound as the degree of stenosis, lesion length is important, especially in long diffusely 
diseased segments.   
- Flow Conditions: In fluid dynamics, laminar flow is "orderly" and turbulent flow is 
"random". Within a pipe, flow is laminar, however in the presence of a stenosis, flow separation 
increases as eddy currents begin to form and flow becomes non-laminar beyond a certain 
threshold (the ‘Reynolds Number’) with subsequently increased flow separation25. Such changes 
in flow conditions form the basis of the flow separation coefficient in figure 5.2. 
- Flow Velocity: This factor is influenced by changes in downstream resistance. We know 
from work by Uren et al that as a stenosis is removed, resistance falls and hyperaemic flow 




Figure 5.2: Factors Influencing the Pressure Gradient Across a Stenosis. Pressure gradients 
across a stenosis can be described by a relationship from the energy losses by viscous friction 
and flow separation23, which takes the form DP = fQ+sQ2, where DP = change in pressure, f = 
frictional coefficient of a lesion (influenced by lesion length and diameter stenosis), s = 
separation coefficient of a lesion (influenced by diameter stenosis and the laminar flow 




5.2.2 The unique physiology of serial stenoses 
 
 
Based on these principles described in the previous section, any significant accompanying 
disease will, in turn, increase total resistance, regardless of whether that disease is upstream or 
downstream of the stenosis in question. Therefore, it follows that the significance of stenosis may be 







Figure 5.3: Serial Stenosis Interplay. Diagrammatic representation of how serial stenosis 
interplay can result in erroneous results from a pressure wire. Both lesions contribute to total 
vessel resistance. In absence of either lesion, flow is greater and therefore ∆P across the 
remaining lesion is likely to be underestimated. 
 
 
The presence of stenoses elsewhere, particularly if closer together, can also alter flow conditions 
significantly such that laminar flow becomes more turbulent with subsequent energy loss (and 
therefore pressure). The degree to which altered flow conditions influence DP depends on the 
individual frictional (f) and separation (s) coefficients of the stenoses within the serially diseased 
vessel (Figure 5.2). In a serially diseased vessel, DP and thus the individual contribution of an 
individual stenosis to overall FFR, are therefore likely to be determined by not just DP = fQ+sQ2 
but also total vessel resistance and the alteration of these laminar fluid dynamics. 
 
5.2.3 Theoretical solutions to overcome the FFR interplay of serial stenoses 
 
 
Various theoretical solutions have been examined to define an algorithm for determining the 
individual contribution of each stenosis to total vessel FFR (‘FFRtrue’, were each stenosis present 















Bruyne et al to show that FFRpredicted from the theoretical equation made some improvements in 
identifying FFRtrue27. This method required knowledge of coronary occlusive wedge pressure 
between stenoses, whereby: 
 
predicted FFR = (Pd − [(Pm/ Pa)×Pw])/([Pa−Pm]+[Pd−Pw]) 
Where: Pm is the pressure between the 2 stenoses, Pd is the most distal pressure, Pw is the 
wedge pressure (all measured during maxi- mum hyperaemia) 
This solution was subsequently validated in a small clinical study by Pijls et al, where a pressure 
wire was used as a standard angioplasty wire in the assessment of 32 tandem lesions, enabling a 
wedge pressure measurement during ballooning of each lesion. They found improved accuracy 
in identifying the attributable FFRtrue of individual lesions28. 
 
This technique, whilst well validated, is difficult to use in clinical practice and considered 
impractical and cumbersome29 because it involves ballooning arterial segments to measure a 




5.3 CURRENT METHODS IN PHYSIOLOGICAL 




5.3.1 Ignoring the Problem 
 
 
The presence of serial stenosis interplay is often ignored, with measurement of intracoronary 
pressure between, and distal to, sequential lesions being used to erroneously estimate what each 
lesion contributes to total FFR, with significant theoretical limitations (Figure 5.3). Measuring 
intracoronary pressure between lesions (without ballooning to measure wedge pressure) 
disregards the fact that total vessel resistance is greater in the presence of an accompanying 
stenosis (with subsequent underestimation of pressure gradients). Furthermore, the presence of 
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an accompanying lesion, particularly up to a certain distance apart, also impacts flow conditions 
and turbulence within the vessel (contributing to coefficient ‘s’ in Figure 5.2).  
 
 
5.3.2 The ‘Educated Guess’ 
 
 
Another commonly adopted, but imperfect solution, is to make a visual ‘educated guess’ 
regarding which segment is most significant, in the presence of a vessel with FFR≤0.80, and 
treating this first. Following initial PCI, the FFR is repeated, with further PCI performed if 
FFR≤0.8. This is based on an interpretation of data by Pijls et al, who, in a 750-patient registry, 
showed that FFR after stenting was a significant predictor of events at 6 months. The study 
showed that patients with post-PCI FFR>0.95 had an event rate of 4.9%; whereas in the group 
with post-PCI FFR of 0.80-0.90, event rate was 29.5% (p=0.001)31. Whilst these data support 
ensuring the best possible physiological result, they do not tell us how to achieve this with serial 
disease. By attempting to identify the lesion that has the “most functional significance”, there is 
a possibility that an accompanying lesion is under-estimated and therefore the wrong 
revascularisation strategy is chosen, for example if a Left Main Coronary Artery (LMCA) 
stenosis is mistakenly underestimated. A ‘lesion-specific’ physiological strategy, that 
counteracts serial stenosis interplay, would therefore be theoretically superior to a strategy that 




5.3.3 FFR Pullback Manouvre 
 
Pulling back a pressure wire under fluoroscopy is increasingly performed to assess for 
increments in coronary pressure (∆P), with the assumption that ∆P is indicative of lesion 
significance. This method, illustrated in figure 5.4, was examined by two observational 
studies32,33, in which PCI strategy was guided by stenting the stenosis with the greatest ∆P . Kim 
et al found that in 131 stable patients with total vessel FFR≤0.80, PCI was safely deferred in 
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61.1% of lesions based on FFR after initial targeted PCI with no clinical events related to 
deferral. Park et al studied 52 patients (104 lesions) and found the practice of treating the lesion 
with greatest ‘∆P’, re-measuring FFR and carrying out further PCI until FFR>0.8 is also 
associated with good clinical outcomes32.  
 
Figure 5.4: The Pressure-Wire Pullback Manoeuvre. Representation of manual pullback method 
in a Right Coronary Artery with the FFR change seen on the console at each point. The largest 
pressure gradient (∆P) corresponds to proximal lesion on image A with an ‘apparent’ ∆FFR 
attributable to the distal lesion of 0.16. Upon treating the proximal lesion (image B), a repeat 
pullback reveals the ∆P of the distal lesion was originally underestimated (the ‘true’ ∆FFR 
attributable to the lesion being 0.31). 
 
The method of treating the greatest ∆P following manual pullback does however have potential 
pitfalls: 
- Although underestimation is more common, rarely overestimation is possible: this has 








than the ‘DFFRtrue’27,30,32,33. A potential reason for this is that increased flow turbulence in serial 
disease may be more influential than the increased vessel resistance that usually causes 
underestimation. Overestimation means stenting the largest ‘∆P’ could result in stenting 
functionally non-significant stenoses. 
- Treating the greatest ‘∆P’ following manual pullback has potential for operator error. For 
example, there is natural tendency to pause pullback for fluoroscopic guidance, half-way 
through identifying a gradient. This can result in artefactual plateaus with misinterpretation of 
one pressure gradient as two. Additionally, operators may only pull back through segments they 
believe visually significant1,9. 
 
Without the ability to accurately assess the true physiological contribition of each lesion at the 
outset, it may be that after treating the lesion contributing the greatest ‘∆P’, a physiologically 
significant lesion will still remain. 
 
 
5.3.4 iFR Pullback 
 
 
As described earlier, iFR is a resting pressure-wire based index of coronary blood flow 
impairment that doesn’t require the need to modulate resistance with adenosine-induced 
hyperaemia7 with iFR-guided revascularisation recently shown to have comparable outcomes to 
FFR, in a relatively low-risk group of patients11,12. 
 
It has been suggested that serial stenosis interplay and alteration in flow conditions may be 
amplified in hyperaemic conditions. This is based on an interpretation of canine experiments by 
Gould et al that demonstrated the DP = fQ+sQ2 relationship. These experiments showed that for 
a fixed lesion, when flow transitioned from rest to hyperaemic flow, the pressure-velocity 
gradient increased23,34. Proponents of iFR therefore argue that serial stenosis interplay is 
potentially less at rest, with iFR in particular having added spatial resolution advantages over 
Pd/Pa, since it isn’t calculated from pressures averaged over several cardiac cycles and diastolic 
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resistance may be lower than whole cycle resistance. On this basis, iFR has been used to study 
serial disease in a small cohort of 32 coronary arteries35. In this study, pressure wire pullback at 
rest was used to demonstrate how iFR changed along each artery; this was then used to virtually 
remove the accompanying lesion, with the residual ‘expected iFR’ correlating well with 
‘observed iFR’ after PCI (incidental resting Pd/Pa was not assessed in this study). This led to the 
development of the ‘iFR Scout’ software (Volcano, Phillips Inc), based on the manual pullback 
maneuver performed for FFR (Figure 5.4), and aims to predict the residual iFR were one lesion 
removed and presumes that the change in iFR across a stenosis remains unchanged regardless of 
co-existent disease. A subsequent multi-centre utility study has shown the clinical utility of this 
software36 but the comparative value of iFR both on clinical outcomes and versus other 
physiological indices in serial disease is yet unknown. The value of iFR pullback has also not 
yet been validated in large-scale studies of a more severe spectrum of serial disease when 
stenosis interplay is likely to be more significant.  
 
This thesis includes a study that systematically tests the hypothesis that serial stenosis interplay 
is lessened at rest. As such evidence supporting or refuting resting indices grows, there will be 
an opportunity to establish for certain whether resting indices are more accurate in serial/diffuse 
disease. In the meantime, iFR in serial disease has the potential to provide a solution to 
overcome some of the difficulties in assessing the relative lesion significance in serially diseased 
vessels; we eagerly await further data, including our own, to support this notion. 
 
 
5.4 PHYSIOLOGY GUIDED MANAGEMENT OF LEFT MAIN 
CORONARY ARTERY DISEASE: AN IMPORTANT EXAMPLE 
OF SERIAL STENOSIS INTERPLAY  
 
 
5.4.1 Evidence for FFR Assessment of the LMCA 
 
The seminal validation study of FFR for the identification of myocardial ischaemia was 
performed in stable patients against a combination of non-invasive ischaemia tests, but only 
enrolled two patients with LMCA disease8. Subsequently, evidence has grown from trials 
 25 
demonstrating improved outcomes by FFR-guided-PCI versus angiography alone: again these 
have all excluded LMCA disease2,10,4. The reasons excluding LMCA stenoses is unclear but is 
almost certainly contributed to by the complexities of physiologically assessing LMCA stenoses 
when present alongside serial stenoses in downstream daughter vessels. 
 
Despite this evidence continues to mount to suggest that physicians are poor at identifying 
physiologically significant lesions by angiography alone1,37. A recent study of over 4000 
coronary lesions with both angiography and FFR, found that coronary angiography alone mis-
estimates physiological severity when using a FFR threshold of 0.8 in over a third of 
angiographically intermediate stenoses1. This observational study included 152 patients with 
LMCA and found visual-functional mismatch to be just as common, with a particularly high 
lesion underestimation. Hamilos et al reported the largest observational study on the utility of 
FFR in LMCA lesion assessment38: patients with angiographically equivocal LMCA disease 
who underwent adjunctive pressure wire assessment were enrolled. Patients with FFR>0.80 
were managed with medical therapy and those with a FFR ≤0.80 underwent CABG. They found 
equivalent clinical outcomes in both groups, suggesting an LMCA FFR threshold of 0.80 may 
be used to defer revascularisation. A recent meta-analysis of observational data (525 patients 
from 6 studies) drew similar conclusions39. 
 
Whilst significant observational data suggests FFR-guided revascularisation should be 
performed for the LMCA, several criticisms can be made of current observational data. The 
studies didn’t use a uniform FFR threshold, hampering extrapolation to contemporary practice. 
In addition, observational data is prone to the pitfalls of non-randomized data, including 
selection bias, which cannot be overcome by meta-analyses. One of the arguments against the 
use of FFR to guide LMCA revascularisation is that the risk of plaque rupture events may not be 
related to the haemodynamic significance of a stenosis but is instead determined by underlying 
plaque composition.  In other words, deferring revascularisation of the LMCA on the basis of a 
FFR>0.80 may leave a group of patients at risk of myocardial infarction. Although there has 
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been no signal of excess MI/death in the vast majority of FFR trials, the recently presented 
FUTURE trial (NCT01881555) did include LMCA disease in 11% of patients, with a signal for 
excess mortality in the FFR-guided arm (although it is only speculation to suggest the events 
came from deferred LMCA stenoses). Whilst we await robust randomized data on FFR in 
LMCA disease, the FUTURE trial data should make us wary of the potential consequences of 
LMCA plaque rupture compared to a more distal plaque rupture event, and the observational 
FFR data of LMCA revascularisation to date are likely underpowered to detect this. 
 
5.4.2 Theoretical Challenges to Physiological Assessment of the LMCA 
 
Coronary blood flow is related to the size of the viable myocardial bed subtended40. FFR takes 
account of the myocardial mass perfused as it is the ratio of blood flow to a given mass of tissue 
in the presence of a stenosis (Qs) to blood flow to the same mass of tissue if the vessel were 
unobstructed (QN): whereby FFRmyo=Qs/QN. The LMCA territory constitutes the vascular beds of 
the left anterior descending (LAD) and left circumflex (LCx) arteries41 and, in the absence of 
obstructive disease in each branch, the ratio of flow in each is determined by the resistances of 
their respective vascular beds. As the minimal resistance in a vascular bed can be assumed to be 
independent of any upstream stenosis42, the FFR of a LMCA stenosis should be identical, whether 
measured in the LCx or LAD. However, in the presence of any downstream disease, FFR will be 
determined by the LMCA stenosis as well as disease in each limb. Given that atherosclerosis tends 
to affect the whole coronary tree, LMCA disease is usually accompanied by additional 
downstream disease in the LAD and/or LCx43. In such cases, the LMCA and distal stenosis should 
be considered to act as serial stenoses30,44.  
 
As discussed, ischaemia assessment of individual lesions in the presence of serial stenoses is 
problematic because of the complex inter-dependence of each lesion that affects their relative 
severity, even when there is a disease-free sidebranch (e.g. LMCA stenosis co-existing with a 
stenosis in the mid-LAD but with a disease-free LCx). The presence of disease distal from the 
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LMCA is generally associated with underestimation of stenosis severity, and may lead to 
inadvertent deferral of LMCA revascularisation33. The potential influence of distal disease is 
frequently ignored when drawing conclusions on the functional significance of LMCA stenoses 
with significant consequences in this critical setting. 
 
Whilst potential interaction is recognized, the practice of measuring LMCA FFR by placing the 
wire in the disease-free daughter vessel has been shown to be a reliable method in in vitro studies 
with only minimal interference from downstream disease in the diseased-branch44-46. Fearon et al 
went on to demonstrate this in their in vivo study by interrogating LMCA stenoses in 25 patients 
following PCI of the LAD+/-LCx. FFR was measured in the LAD and LCx before and after 
creation of downstream lesions by inflating balloons within newly-placed stents. They then 
compared ‘true’ FFR measured in the disease-free vessel and compared this with the ‘apparent’ 
FFR measured in the diseased-vessel. They found the true LMCA FFR was significantly lower 
than apparent FFR (0.81vs.0.83, p<0.001), although the authors interpreted this as clinically 
insignificant and at the upper-end of the natural test-retest variability of FFR. From this relatively 
small study, the authors concluded that in most cases when there is a disease-free branch of the 
LMCA, downstream disease within the other branch doesn’t have a clinically significant impact 
on LMCA FFR with the pressure wire positioned in the disease-free vessel, unless disease within 
this branch is very severe (FFR<0.45), and that an FFR value of >0.85 in the disease-free side-
branch would mean the LMCA lesion can be safely assumed functionally non-significant44. 
Whilst this seems reassuring, there remains concern that any significant difference in the 
continuous variable of FFR may be associated with important outcome differences. Whilst these 
studies are small and prone to theoretical flaws, for the purpose of LMCA disease with serial 
disease in only 1 daughter vessel, this method is, for now, an acceptable solution for this unique 




Figure 5.5: Illustration of the disease-free sidebranch method to isolate the true significance of 
the Left Main stenosis when accompanied by serial disease in one downstream vessel (in this 




5.4.3 Best Practice in Left Main Physiological Recordings 
 
General Technical Considerations  
Physiological assessment in general, mandates meticulous preparation with zeroing of aortic 
pressure, equalizing the guide catheter pressure with wire pressures before seating the guide 
catheter in the LMCA. However, since the guiding catheter could obstruct flow, particularly for 
ostial LMCA lesions, it should be disengaged once hyperaemia is induced, to reduce the effects 
of ‘pressure-damping’. If this is proving difficult then the use of an additional wire within the 
other branch can be used to stabilize the distance from the catheter to the LMCA ostium. 
 
For induction of hyperaemia, a continuous intravenous infusion is recommended, because when 
unseating the guide catheter, adequate administration of adenosine to distal microvasculature can 
be otherwise challenging.  In addition, as shall be detailed later, the use of intravenous adenosine 
also enables an FFR pullback manouvre. Intravenous adenosine infusions, particularly when 
entering from the peripheral venous circulation, can produce several patterns of Pd/Pa responses47. 
In order to overcome such variability, Johnson et al identified a stable period during adenosine-
induced hyperaemia, called the “smart-minimum’’ (lowest ‘5 cardiac-cycle’ average), that was 











LMCA disease often have contractile impairment which can result in elevated central venous and 
right atrial pressures. Since FFR assumes venous pressure is negligible, if measured venous 
pressures are significantly elevated, FFR values need to be interpreted cautiously regardless of the 
vessel being interrogated48. 
 
‘Isolated’ Left Main stenosis  
In the scenario of isolated LMCA disease (or ‘LMCA equivalent’ with contiguous downstream 
disease), there is no theoretical difference in measuring LMCA FFR when the wire is placed in 
either branch. FFR pullback manoeuvres should however be performed from both the distal LAD 
and LCx (see figure 5) because the physiological significance of downstream disease shouldn’t 
be presumed from visual estimation alone1,9  
 
Left Main stenosis and epicardial disease in one downstream branch 
When concomitant to a LMCA stenosis, a significant stenosis is present in only one downstream 
branch, measuring the true FFR is still potentially confounded. As described earlier, the practice 
of measuring LMCA FFR by using a disease-free daughter vessel (figure 5) has been shown to be 
a relatively reliable with only minimal interference from downstream disease in the diseased-
branch (unless this is severe: >90% diameter stenosis or FFR<0.45)44-46. 
 
Left main stenosis and disease in all downstream epicardial branches 
In the absence of a disease-free branch, serial lesion interplay becomes particularly challenging 
with a significant likelihood that distal stenoses can alter flow, and in turn the pressure gradient, 
across the LMCA30. At present, in patients having LMCA PCI, the practice of treating the greatest 
DFFR following manual FFR pullback appears to be the best available method and has been shown 
to be safe and reduce unnecessary revascularisation with acceptable outcomes at a mean follow-
up period of 9 months33. We therefore recommend that for any LMCA stenosis, the pressure wire 
should be advanced distally in both epicardial branches to determine both FFR values. Following 
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this, a fixed rate pressure wire pullback should be performed in both branches so as to allow 
estimation of physiological significance and length of all lesions. Recommendations following 
these pullback manoeuvres are summarised in Figure 5.6. Information from this physiological 
assessment should lead to all revascularisation strategies being considered, not just PCI; 
particularly in the context of Diabetes or high Syntax Score and with the help of a Heart Team. 
 
  
5.4.4 Imaging LMCA disease as a surrogate of physiology? 
 
 
Intravascular Ultrasound (IVUS) 
IVUS-guided-PCI has been associated with better outcomes, due to improved vessel sizing for 
optimal stent deployment49. It is therefore attractive to also use intravascular imaging as a 
diagnostic tool if sufficient correlation to physiological measures can be found. As such, several 
studies have assessed the use of Minimum Luminal Area (MLA), derived from IVUS values, for 
inferring the functional significance of LMCA disease. Jasti et al were the first to show this 
correlation in a study of 55 patients50. Perhaps due to the smaller perceived variation in LMCA 
length, diameter and eccentricity, there is better concordance between IVUS and FFR in the 
LMCA compared to other vessels51. Subsequently, other studies have demonstrated the 
relationship between the degree of MLA reduction and subsequent MACE rates, with the 
multicenter LITRO study showing that an IVUS-MLA of 6mm2 could be used for safely deferring 
LMCA revascularisation, yielding acceptable long-term clinical results52. Despite such data, there 
remains significant variability regarding which IVUS cut-off values correlate best with FFR.  
 
Apart from the impact of demographics on the normal reference range, this significant variation 
in IVUS MLA values can be explained physiologically, because the pressure drop across a 
narrowing is governed by several other factors in addition to the MLA (Figure 2). Nonetheless, 
the literature does suggest that using IVUS thresholds in the large range of 4.5-7.5mm2 provides 
some improvement to angiography alone in determining the functional significance of a LMCA 
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stenosis, provided a true LMCA cross-sectional cut is obtained53,54. It is important to keep in mind 
that the studies supporting using thresholds as low as 4.5mm2 were conducted in populations with 
only Asian patients, who may have relatively small hearts, with the authors of the study 
recognizing that the global applicability of the results maybe limited53.  
 
Optical Coherence Tomography (OCT) 
OCT offers greater spatial resolution at the cost tissue penetration, and thus potentially clearer 
delineation of the intima-luminal limit, with data showing more accurate and reproducible 
assessment of lesion diameter when compared to IVUS using phantom stenosis models55. Whilst 
there is no data correlating OCT-derived LMCA luminal dimensions with FFR, there is 
suggestion from a study by Gonzalo et al56 that OCT is moderately efficacious versus IVUS in 
identifying hemodynamically severe coronary stenoses in smaller epicardial vessels with 
MLA<3mm2. However, as with other studies attempting to use intravascular imaging as a 
surrogate for physiology, they found specificity levels were too low to use as a substitute to FFR 
for functional assessment. 
 
5.4.5 Algorithm for Physiological Assessment of LMCA Disease 
Incorporating the Disease Free Side-branch 
 
Based on the evidence described in 5.5.3, when LMCA disease is present alongside downstream 
serial disease, the following algorithm can be utilised for physiological assessment in this unique 




Figure 5.6: A suggested decision-making algorithm when confronted with LMCA disease, 
taking into account various combinations of downstream disease 
 
 
As evident in this algorithm, there is still significant uncertainty in physiologically assessing 
LMCA disease when there is downstream serial disease. At present, the best available 
recommendation is to treat largest step-up and re-measure, despite the potential flaws of this 
method (illustrated in figure 5.3 and 5.4). 
 
 
5.5 NON-INVASIVE FFR BY COMPUTED TOMOGRAPHY 
(FFRCT) 
 
5.5.1  An Introduction to FFRCT 
 
Coronary computed tomographic angiography (CTA) is now established as a clinically valuable 
non-invasive anatomical test for the detection and exclusion of significant coronary disease with 
a number of multicentre trials showing coronary CTA to be an ideal test for the exclusion and 






















to its relatively low positive predictive value of 48% and inability to determine functional 
significance58, its use has generally (but not exclusively59) been restricted to patients with chest 
pain at a low-intermediate risk of having coronary artery disease (CAD)60. 
 
For patients at higher risk and those found to have significant CAD during CTA, patients often 
proceed to invasive coronary angiography. For these patients undergoing invasive coronary 
angiography, it has been shown that over a half are found to have no significant disease61 and 
even once significant CAD is detected on invasive angiography, there is growing evidence that 
the benefit of revascularisation is only derived from targeting myocardial ischaemia7, with 
further evidence awaited from the ongoing ISCHEMIA trial (NCT01471522).  
 
As already discussed in section 5.1, we are in an era of ischaemia guided revascularisation with 
FFR representing the gold standard of physiological assessment of CAD at the time of diagnostic 
angiography. In recent years, it has now become possible to estimate FFR from standard coronary 
CTA datasets. This technique has been developed by the company HeartFlow (Redwood City, 
CA, USA) and is termed FFRCT. The derivation of FFRCT is based on computational fluid 
dynamics (CFD) which involves applied mathematics, physics and computational software to 
visualize how fluids interact with adjacent objects. Computational fluid dynamics relies on the 
Navier-Stokes equations which describe how the velocity, pressure, temperate and density of a 
moving fluid are related. The scientific principles of Computational Fluid Dynamics behind the 
calculation of FFRCT and have been extensively published62,63 and are beyond the scope of the 




Figure 5.7: Method of  FFRCT Computation:. 1. Coronary CT angiography images acquired 
using standard protocols. 2. Anatomical model enabling construction of a tetrahedral mesh 
resulting in millions of discrete points for computation of coronary pressure and flow, including 
branch points. 3. Physiological model of coronary circulation created with specified inflow and 
outflow boundary conditions with resting coronary flow is based on myocardial mass. 4. 
Modelling of maximal hyperaemia to reflect expected reduction in peripheral resistance 
resulting from adenosine administration. 5. Numerical solution of Navier-Stokes equations that 
govern the fluid dynamics of blood flow so that Fractional flow reserved is computed. 6. 3-D 
computation of FFRCT throughout the coronary artery tree under simulated maximal hyperaemia 
 
FFRCT diagnostic accuracy  
Following on from the basic validation of the model64, a series of studies designed to test the 
diagnostic performance of FFRCT against invasive FFR have been performed including the 
Diagnosis of Ischaemia-Causing Stenoses obtained via NoninvasivE Fractional FLOW Reserve 
(DISCOVER-FLOW), The Determination of Fractional Flow Reserve by Anatomic Computed 
Tomographic Angiography (DeFACTO) study and Analysis of Coronary Blood Flow Using CT 
Angiography: Next Steps (NXT Trial) .  
 
The DISCOVER-FLOW Trial was a study of 103 patients with suspected or known CAD who 
underwent coronary CTA, ICA and FFR at 4 sites 65. Of the 156 vessels for which invasive FFR 
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was performed, an FFRCT £0.8 was shown to have an accuracy of 84.3%, sensitivity of 87.9 %, 
specificity of 82.2 %, a positive predictive value of 73.9% and a negative predictive value of 
92.2% against an invasive FFR measurement of £0.8. This compared favourably to simple 
coronary CTA assessment of the stenoses which had a significantly lower accuracy of 58.6% a 
positive predictive accuracy of 48.6%. Following this, the DeFACTO study66 was designed to 
evaluate the diagnostic performance of FFRCT against invasive FFR in stable patients with 
suspected native coronary artery disease who were scheduled for invasive coronary angiography 
within a 60-day timeframe. Of the 252 patients in 5 countries, 137 (54.5%) were found to have an 
abnormal FFR determined by ICA. The diagnostic accuracy of FFRCT and coronary CTA was 73% 
(95% CI 67%-78%), which did not meet the primary endpoint of 70% of the lower bound of the 
95% confidence interval. Despite this, FFRCT showed superior discrimination against a coronary 
stenosis severity of ³ 50% (AUC 0.81 vs. 0.68). When vessels interrogated by FFR were compared 
against FFRCT and coronary CTA alone, FFRCT showed superior diagnostic ability with sensitivity 
of 80% and specificity of 61%. The third major trial evaluating the diagnostic performance of 
FFRCT was the NXT Trial67. This evaluated the diagnostic accuracy of FFRCT in 251 patients, each 
with at least one luminal stenosis on coronary CTA of between 30-90% in a vessel ³ 2mm. The 
diagnostic accuracy, sensitivity, specificity, PPV and NPV for FFRCT was 86%, 84%, 86%, 61% 
and 95% respectively. A notable difference from the DeFACTO trial was that the NXT study used 
an improved iteration of the FFRCT algorithms and the cardiac CT acquisition protocols and 
invasive FFR measurement protocols were standardized across all sites, factors which were 
believed to have adversely impacted on the results of the DeFACTO study.  
 
Clinical utility and patient outcomes from FFRCT  
Although the DISOVER FLOW, DeFACTO and NXT Trials suggested that FFRCT had the 
potential ability to enhance the diagnostic capabilities of coronary CTA, its use as a clinical tool 
had not been formally evaluated. Curzen et al. therefore elected to study whether or not the routine 
availability of FFRCT would change clinical decision compared to the results from coronary CTA 
 36 
alone68.  In this study, 3 interventional cardiologists assessed the CTA report in order to reach a 
consensus management strategy for 200 consecutive patients who had undergone coronary CTA 
in the NXT trial. The cardiologists were then shown the FFRCT data for each case and again 
produced a consensus management of which vessels and lesions were significant. The prescribed 
CTA-derived management strategy was changed in 36% of cases, with a reduction in PCI rates 
seen in 30%, and a change in the PCI target vessel treated in 18%. These results were very similar 
to those derived from the original RIPCORD study, examining invasive angiography and FFR9. 
 
The largest FFRCT study to date is PLATFORM, a prospective cohort study of 585 patients69. It 
was designed to test whether the routine evaluation of patients with suspected CAD by coronary 
CTA/FFRCT as their default test, would result in lower rates of ICA showing no obstructive 
disease, without any consequence in terms of major adverse cardiac event rate compared to routine 
clinical care. The study participants were enrolled in two consecutive cohorts assigned to receive 
standard care testing or CTA/FFRCT testing. In the invasive cohort, 100% of patients underwent 
invasive coronary angiography in the pre-specified routine care invasive arm, with 73.3% showing 
no significant obstructive disease. By contrast, only 39.4% of patients allocated to CTA/FFRCT 
required invasive coronary angiography based upon this test, of whom only 31.6% showed no 
obstructive disease. PLATFORM therefore showed that coronary CTA/ FFRCT has the ability to 
reduce the number of stable patients who require invasive coronary angiography that shows no 
significant coronary disease at invasive angiography. The other important result from 
PLATFORM was that at 1 year no MACE events had occurred in the 117 patients whose coronary 
angiograms were deemed unnecessary based on reassuring coronary CTA/FFRCT findings 70. 
 
 
5.5.2 A Role in Serial Disease? 
 
In cases where CT images are good, it may be possible to make a thorough assessment of 
individual stenosis geometry, and therefore an accurate estimation of the frictional and 
separation coefficient of a stenosis (Figure 5.2). Modelling flow and pressure changes from this 
precise anatomical knowledge lends itself to assessing true stenosis significance, independent of 
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disease and flow conditions elsewhere in the vessel. As discussed, FFRCT has largely been 
developed and validated in vessels with single/discrete stenoses, but these inherent advantages 
of CT and the underpinning CFD theory make FFRCT–related innovations potentially an ideal 
tool for unpicking serial stenosis physiology before a guidewire has entered the body. 
 
A small sub-study of the NXT trial, looking at 18 vessels with serial stenoses compared trans-
lesional FFRCT gradients against trans-lesional FFR values after manual pullback71. Whilst this 
showed a degree of correlation, the invasive FFR values, against which trans-lesional FFRCT 
values were compared, are themselves substantially flawed. A validation of trans-lesional FFRCT 
values against the true invasive trans-lesional FFR values (with the lesion present in isolation) is 
yet to be done. Once this step is realised (within this thesis), the iterative and machine learning 
processes built into the underlying technology may make a future FFRCT solution to serial 






5.6 AIMS & OBJECTIVES 
 
 
The broad aim of this thesis is to understand and optimise how to physiologically assess the 
significance of individual stenoses in serial/diffuse coronary artery disease. In order to achieve 
this aim, this thesis will address the following objectives: 
 
1) Improve our understanding of the nature of serial stenosis interplay and the factors that 
influence this using a 3-D printed model of serial CAD (‘Error’ when measuring a biological 
variable can be defined as an unbiased assessment of the difference against the normal 
biological variability of the index and therefore the existence of this potential error needs to be 
objectively assessed). Once established, I aim to develop and test an algorithm to correct for 
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serial stenosis interplay when using the commonest invasive physiological tool of FFR 
(Experimental Chapter 6) 
 
2) Compare various commonly used invasive physiological indices in assessing serial CAD 
and understand serial stenoses further using simultaneous measurements of Doppler flow and 
pressure. Following this we can truly understand the value of the correction equation created 
(Experimental Chapter 7) 
 
3) Assess the value of both conventional FFRCT and a novel FFRCT-derived PCI Planning 
tool in serial CAD. Estimating Fractional Flow Reserve from Cardiac CT (FFRCT) is growing in 
popularity with growing evidence to support its use as an adjunct to conventional assessments. 
This thesis provides us with an opportunity to explore whether the underpinning CFD principles 
behind FFRCT can help overcome the complexities in assessing serial CAD (Experimental 
Chapter 8) 
 
After addressing these 3 objectives in the respective experimental chapters, we will be in a 
position to begin assessing the clinical utility of any novel solutions developed (Experimental 
Chapter 9) and also suggest future directions of research (Synthesis, chapter 10) for this 












6. EXPERIMENTAL CHAPTER: IN VITRO ASSESSMENT OF 
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Introduction   
 
Growing evidence supports ischaemia-guided revascularisation for coronary artery disease 
(CAD)7. Ischaemia assessment has now evolved from assessment of myocardial territories using 
non-invasive imaging to being able to assess physiological disease in specific vessels, at the time 
of diagnostic angiography. This involves calculating the ratio of distal coronary pressure to aortic 
pressure at maximal hyperaemia (Fractional Flow Reserve, FFR)8, at rest during the entire cardiac 
cycle (Pd/Pa)72 or at rest during a defined-phase of diastole (Instantaneous Wave-Free Ratio, 
iFR)73. Physiology-guided revascularisation appears to confer significant clinical and prognostic 
benefit over management based on angiographic appearance alone4,10,74. 
 
Whilst these pressure-derived indices are well established and validated for vessels with single 
lesions, given the systemic nature of atherosclerosis, coronary stenoses are often found in tandem 
with other focal or diffusely diseased segments within the same vessel. In such instances, the 
decision to revascularise and the mode of revascularisation chosen rely on identifying the true 
individual contribution of lesions and not just the cumulative impact of disease in the entire vessel. 
However, each diseased segment affects the fluid dynamics of the other, which makes it difficult 
to apply conventional physiological techniques to identify the true significance of a lesion within 
a serially diseased vessel27,75. Knowing the true functional significance of each stenosis enables 
the appropriate stenosis to be targeted and helps ensure the correct revascularisation strategy is 
chosen, whether this is PCI, CABG or medical therapy. 
 
Theoretical solutions have been developed that involve complex formulae28 using measurements 
of intracoronary pressure at various points in the artery and determination of coronary wedge 
pressure, which in turn is acquired during transient balloon occlusion of the vessel27,30. The 
rationale for incorporating a wedge pressure measurement was to standardise and account for 
variability in collateral flow across a stenosis30. A major drawback of this technique, which has 
limited the adoption of these formulae in clinical practice, is that in order to obtain a wedge 
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pressure measurement, it is necessary to balloon occlude the coronary artery, which carries a risk 
of dissection. This could have clinical sequelae if angiographically undetectable at the time, or if 
detected, may mandate stenting regardless of the results of physiological assessment. Other 
solutions to this problem have relied on the identification of a large disease-free side branch44,46 
to separate the true significance of a proximal stenosis, although this scenario is only applicable 
to Left Main Coronary Artery (LMCA) disease. Furthermore, the relative accuracy of hyperaemic 
versus resting indices, such as iFR35, in the context of serial disease is unknown. 
 
The aim of this study was firstly to develop an in vitro model based on 3D-printed configurations 
of tandem disease that is a realistic representation of pulsatile coronary circulations in hyperaemic 
conditions. Using these results, we aimed to characterise the factors that influence serial stenosis 
haemodynamic interplay and incorporate them in theoretical models to improve prediction of the 
true FFR of individual stenoses, without the need for wedge pressure measurements or 
angiographic guesses of stenosis and vessel diameters. We then sought to test such a solution 





Creating a Model of Tandem Coronary Artery Disease 
To model tandem disease and accurately control for variable stenosis geometry and the many 
factors that affect the  pressure drop across a stenosis (figure 6.1), phantom tubes were created by 
3-D printing (Objet 500 Connex3™, 600x600x1600dpi) from the biocompatible ‘TangoPlus 
FullCure PolyJetÒ’ photopolymer material (Objet ltd, Israel) that has been shown to adequately 
model arterial compliance76 (see figure 6.1). The tubes created were 150mm long, with an internal 
diameter of 5mm and wall thickness of 2mm to simulate the dimensions and compliance of a 




Figure 6.1: Top: Photograph of Objet 500 3-D printer used for creation of coronary phantoms.  
Bottom Part A: Photographs of a tube modelling two serial lesions and a tube with the 
corresponding single stenosis; number representing % diameter stenosis. Part B: Schematic 
representation of these stenosis, showing the variables that were adjusted by 3-D printing 
 
A continuous flow model of coronary circulation was created to facilitate accurate measurement 
of pressure changes (figure 6.2). Continuous inlet pressure was created by using an electrically-
driven water pump and capacitance chamber that connected to an aorta modelled from Polyjet 
tubing, with aortic pressure kept fixed. Polyjet tubing, modelling the LMCA, then branched off 
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the aorta with the 3-D printed phantom attached, ensuring any connections themselves did not 
pose additional resistance (figure 6.2).  A fixed length low compliance silicon tubing was added 
downstream of the phantom tube and calibrated to create similar resistance to the coronary 
microcirculation during adenosine induced hyperaemia. Distilled water was used as the fluid for 
all experiments, in line with previous in vitro models of coronary circulation41,77 that presume 
Newtonian conditions are maintained within coronary arteries under physiological conditions78. 
The use of 3D-printing enabled all stenoses to have a fixed geometry to reduce variability in other 
factors influencing the pressure drop across a stenosis23. 
 
Measurement of FFR  
Using this set up, a pressure wire (Phillips VolcanoTM) was normalised to aortic pressure and 
advanced distal to the serial lesions. FFR was calculated as the ratio of distal coronary pressure to 
aortic pressure, with conditions presumed equivalent to hyperaemia given the continuous flow set-
up with fixed and minimal distal resistance. The pressure-wire was pulled back through the lesions 
at 1 mm/s using a modified pullback device (Philips VolcanoÔ R100) to generate FFR pullback 
curves with all experiments repeated in triplicate; mean values from these are quoted throughout 
(figure 6.2). Each 3D-printed configuration of tandem disease (varying in length of stenoses, 
separation and severity) was then replaced with the corresponding 3D-printed tube containing the 
isolated stenosis to simulate treatment with coronary angioplasty (PCI) (figure 6.2).  
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Figure 6.2: How 3-D printing Was Used to Model Pressure-Wire Measurements in Serial 
Disease. Top: Photographs of a 3D printed tube modelling tandem lesions with a pressure wire 
pullback demonstrating distal coronary pressure (Pd), pressure between lesions (Pm) and aortic 
pressure (Pa). ∆FFRapp represents the apparent pressure gradient across a stenosis when in the 
presence of another. Also demonstrated is the phenomenon of pressure recovery after a tight 
stenosis – showing further evidence of our model replicating in vivo physiology. Bottom Left: 
3D printed tube with the corresponding single stenosis in isolation. ∆FFRtrue represents the true 
pressure gradient across a stenosis. Bottom Right: Diagrammatic Representation of Continuous 
Flow Phantom model used to model serial stenosis haemodynamic interplay. 
 
Validation of in vitro model of Serial CAD within Coronary Circulation 
To ensure our wet laboratory model of coronary circulation was a valid representation of in vivo 
pulsatile coronary physiology, we carried out the following tests of the model before 




The first test to ensure clinical validity is to ensure there is high test-retest reliability, as seen 
with in vivo FFR measurements79.  Triplicate pressure gradient measurements were made for 
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each stenosis created, allowing calculation of intra-class correlation to ensure high test-retest 
reliability. The results of this test revealed a strong intra-class correlation of 0.973 (0.95-0.98) 
for average measures, suggesting good test-retest reliability. 
 
Compliance Testing 
To ensure the 3-D printed tubes could represent coronary vessels, they have to show similar 
compliance to in vivo coronary arteries. To test this, we created pressure-volume loops in a 
blank tube made of the same material (see figure 6.3). The results of this test revealed hysteresis 
that compared favourably to published data on coronary artery compliance76. 
 
Figure 6.3: Graph to demonstrate the pressure-volume loop created during compliance testing 
of the coronary phantom material. Data represent mean ± standard deviation. 
 
 
Comparison of Continuous Flow versus Pulsatile Flow Model 
 
Prior to my work within our wet laboratory, a pulsatile in silico model was created and validated 
in a separate study to assess the contribution of the ventricle to peripheral arterial pressure80. In 
our study, measurements were made using a continuous flow model (figure 6.2) as they were 
easier to obtain. Before doing so, however, we made a comparison of pressure measurements 
across a range of stenoses from our continuous flow model against measurements from this 






















Figure 6.4: Scatterplot with Linear Regression Analysis demonstrating a strong correlation 
between ∆FFR values obtained in the pulsatile flow model and the continuous flow model (P < 
0.001; n =29). 
 
 
Assessing Effect of Stenosis Severity (Luminal Narrowing) on Trans-stenotic Pressure Drop 
 
The effect of luminal area reduction on the pressure drop across each stenosis was assessed and 
compared with previously reported coronary physiological data of pressure drops across 
stenoses in hyperaemic conditions 23 (Figure 6.5). This revealed an exponential relationship 
between luminal narrowing and the pressure drop across a stenosis: similar to the relationship 




Figure 6.5: Scatterplot of the effect of lesion severity on ∆FFRtrue (mean values). 






































Assessing Trans-stenotic Pressure-Flow Relationships 
 
Using pressure gradients as an analogue to blood flow impairment is only possible if the 
relationship between pressure and flow across a stenosis is similarly curvi-linear to that seen in 
vivo. Seminal experiments by Gould et al23 in canines showed pressure gradients and flow 
velocity are related non-linearly (figure 6.6, part A). In order to show our model replicated this 
important physiological trait, we sought to measure flow rate impairment in a cohort of 3-D 
printed serial stenosis phantoms. We did this by measuring volumetric flow rate of water at the 
distal end of phantoms with stenoses and subtracting from flow rate at the distal end of a 
phantom with no stenosis. By plotting flow rate impairment (analogous to flow velocity) against 
pressure gradient, we were able to demonstrate that the curvilinear relationship between pressure 




Figure 6.6: Part A: Representation of relationship between the stenosis gradient and coronary 
flow velocity from the Gould et al experiments of pressure-flow characteristics of coronary 






















stenoses in un-sedated dogs at rest and during coronary vasodilatation23). Part B: Scatterplot of 
the change in pressure across each validation phantom versus the flow impairment it caused. 





Blood in a coronary artery behaves as a Newtonian fluid, much like water, as already discussed81. 
Further evidence of this was incidentally found by discovering the effect of pressure recovery (due 
to the Bernoulli Effect) just distal to severe stenoses, demonstrated in example pullback trace in 
figure 6.2). This phenomenon often exists in vivo, just distal to severe concentric stenoses (e.g. 
Severe Aortic Stenosis). Where any pressure recovery was observed (Figure 6.2), Pd immediately 
proximal to the distal lesion, prior to pressure recovery phase, was taken as the inter-stenotic 
pressure to calculate ∆FFRapp and ∆FFRtrue. 
 
Limitations of the in vitro Coronary Circulation Model 
In an idealised model, we would also want to include phantoms that modelled bifurcations, 
collateral circulation, variable myocardial mass etc. These are complexities to be added in later 
iterations once we establish which factors are most important in serial stenosis interplay. 
 
Measuring FFRapp and FFRtrue using the In Vitro Model 
For a given stenosis, the apparent Pd/Pa gradient (∆FFRapp) is the trans-stenotic pressure 
gradient across a given lesion when the measurement was made in the presence of both lesions, 
whereas the actual trans-stenotic pressure gradient (∆FFRtrue) is when that stenosis is present in 
isolation, with the accompanying stenosis removed (figure 6.2). The extent of serial stenosis 
haemodynamic interplay was assessed by examining the magnitude of difference between 
∆FFRapp and ∆FFRtrue, with various combinations of serial disease. The impact of the following 
on this difference were assessed: 
i) Total FFR (a function of distal pressure, Pd) 
ii) Average severity (% diameter reduction) of both stenoses 
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iii) Length of stenoses (both physical length from 3D-printed geometries and 
physiological length from pullback traces performed at 1mm/s) 
iv) Separation distance between the serial stenoses (in mm)  
v) Position of the stenosis in question (i.e. proximal or distal to the accompanying 
stenosis).  
The existence of pressure recovery was only seen in severe stenoses (>70% diameter stenosis) 
and therefore the impact of the magnitude of pressure recovery (as we do when assessing 
valvular stenoses with echocardiography) was not assessed. 
 
Statistical Analysis 
Data were analysed using SPSS Statistics Version 22 and Graph Pad Prism Version 7.0a for 
Mac OS X. Data are expressed as mean ± SD unless stated otherwise. Paired t tests were used to 
compare continuous variables (the effect on the degree of stenosis underestimation) after 
normality of data was visually assessed using histograms and Q-Q plots. For all statistical 
analysis, P<0.05 is considered statistically significant. An empirical correction equation was 
developed using stepwise simple linear regression modelling. Details of the theoretical 
correction equation are stated in the appendix to this chapter. The incremental value of the 
correction equation compared to ∆FFRapp from a conventional pressure-wire pullback was 
determined by the proportion of cases where an incorrectly classified lesion (according to FFR 





In Vitro Model Validation 
Measurements of trans-lesional pressure drop in the continuous flow model showed high test-
retest reliability (intra-class correlation of three measurements for each lesion 0.97, P<0.05). The 
model demonstrated a non-linear relationship between stenosis severity (quantified by diameter 
stenosis) and pressure gradient. In addition, The compliance and hysteresis loops generated by 
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varying pressure and flow were similar to those reported in vivo82. The model also showed strong 
statistical agreeability (r=0.94, p<0.05) with measurements made in the previously validated 
pulsatile model 80. Furthermore, using volumetric flow-rate measurements distal to the 3-D printed 
phantoms, we were able to replicate accepted pressure drop vs. flow velocity relationships23. 
Validation data is summarised in the supplementary appendix. In addition, as described in Figure 
6.2, the concentric stenosis geometry meant that for severe lesions the phenomenon of ‘pressure 
recovery’ was often observed due to the Bernoulli effect. Where any pressure recovery was 
observed, Pd immediately proximal to the distal lesion, prior to pressure recovery phase, was taken 
as the inter-stenotic pressure to calculate ∆FFRapp and ∆FFRtrue. 
 
Overview of Results 
 
In total, 52 combinations of tandem lesions were analysed in vitro with average stenosis 
diameter stenosis of 55% and overall vessel FFR of 0.66 +/- 0.23. There was a significant 
difference between ∆FFRapp and ∆FFRtrue, with the true contribution of a given lesion being 
underestimated in the presence of an additional lesion 85% of cases. The overall difference 
between the FFRapp and FFRtrue was 17.1% as a proportion of ∆FFRtrue (absolute difference 
0.036+/-0.048) with increasing lesion underestimation and variance between FFRapp and FFRtrue 
with increasing total burden of disease (represented by Total FFR), see figure 6.7. The degree of 
this underestimation was similar (P>0.05), regardless of whether the distal stenosis or proximal 
stenosis was removed.  
 
The 3D-printed model also enabled assessment of other factors on the extent of serial stenosis 
interplay including Lesion length, distance between lesions and physiological length. Results 
showed that none of these other factors correlated significantly with the extent of serial stenosis 
underestimation (P>0.05). Furthermore we found no relationship between the finding of 




Developing Algorithms to Predict FFRtrue 
Our study showed total FFR and the magnitude of the pressure drop (∆𝑃) to be the strongest 
determinants of error in determining the physiological significance of each lesion. Based on these 
findings, two solutions were created to predict the true FFR of each stenosis; one empirically-
derived from regression modelling of the results from this study and the second from mathematical 
modelling of ∆𝑃 and Pd from theoretical principles. 
 
Empirical Regression Model 
Based on the correlations observed in our study, multiple linear regression was performed to 
predict FFRtrue (i.e. residual FFR were the stenosis in question present in isolation) from ∆FFRapp 
following a fixed-rate pullback manoeuvre, using total vessel FFR as an input.  This equation was 
created in a randomly selected derivation cohort of 32 and is summarised as follows: 𝐹𝐹𝑅𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 = 0.9 − 1∆FFR455 − TotalFFR ∗ 0.11=	
Whilst such a regression model is constrained by the parameters used in this experiment, we were 
able to perform proof of concept validation in the remaining 20 tandemly diseased tubes. We 
found the initial discrepancy versus ∆FFRtrue was 17.1% (0.036±0.048) and improved significantly 
to 2.1% (0.005±0.04) with this equation, albeit still with a large degree of variance (Figure 6.7). 
 
Theoretical Model 
The relationship between pressure and flow is curvilinear, but it has been established that most 
physiological measurements during hyperaemia will fall within a relatively linear part of the 
curve. Our theoretical model of FFR estimation was therefore based on the assumptions of a 
linear pressure-flow relationship. In this condition, the haemodynamic equivalent of Ohm’s law 
is applicable, whereby the individual resistances of stenoses and the distal circulation stay fixed 
regardless of other stenoses being removed. Under these conditions, the theoretical FFR can be 
derived, without the need for a wedge pressure if we assume the variability of collateral flow 
across intermediate stenoses is minimal (see Supplementary Appendix for full details): 
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𝐹𝐹𝑅5?@ABCD@A = 1 − ∆𝑃𝑃A + ∆𝑃 
 
In this equation, ΔP refers to the pressure drop across a lesion in the presence of serial disease 
and Pd refers distal pressure. This relationship applies for both proximal or distal lesions and 
depends neither on the perfusion pressure (Pa), nor the distal resistance R, and is solely a 
function of the measured pressure values. Using this equation, evaluation against the n=20 in 
vitro validation cohort yielded a markedly improved discrepancy of only 0.6% (0.006±0.02) 




Figure 6.7: Results Demonstrating the Error in Assessing Pressure Gradients in Serial Disease 
and How This Can Be Corrected by Applying Correction Equations Generated From In Vitro 
Study. Left: In the full cohort of 52 tandemly diseased phantoms (with corresponding tube of 
stenoses in isolation), results demonstrated a significant (P<0.001) underestimation of FFRtrue 
(the more the data-point is above the x-axis, the greater the underestimation of a stenosis). The 
difference between ∆FFRapp and ∆FFRtrue and the variance of this difference was greater with 
increasing burden of total disease in the vessel (lower total FFR). The blue guidance lines 
represent the trend in increasing data heteroscedasticity with lower total FFR. Right: In a 
randomly-selected validation cohort of 20 phantoms, the error in estimating FFRtrue was 
significantly reduced with the statistical regression equation (Eqn 1) with the variance and 
difference even further reduced using the theoretical correction equation (Eqn 2), based on 








The main findings of this study are: 1) A physiologically representative model of serial CAD can 
be created in vitro using a continuous flow model based on 3-D printing. 2) Within our model, we 
have demonstrated that stenosis underestimation commonly occurs when physiologically 
assessing serial CAD, with discrepancy proportional to cumulative disease burden. 3) Using a 
theoretical solution derived from our in vitro experiments, we have created and validated an 
equation to predict to functional significance of lesions, using readily available data from routine 
pressure-wire pullback measurements. 
 
The unique benefits of precisely controlling lesion geometry with 3D-printing have enabled us to 
overcome many limitations of previous work in the field, where stenoses were created with 
external ties and clamps27,77. This has enabled us to show that the factors that most influence the 
error when predicting individual lesion significance in serial disease are total vessel FFR, average 
% diameter stenosis of the tandem stenoses and ∆P across the lesion is question. Other factors 
such as lesion separation and lesion length appear less important, with a statistically non-
significant relationship with lesion underestimation. These findings are unsurprising as the % 
luminal narrowing caused by a stenosis contributes to both the linear and square coefficients 
within the equation that relates stenosis geometry to the pressure drop across it and as stated by 
Poiseuille's law, the resistance to flow is related to the 4th power of radius of the vessel 24. 
 
This study represents a significant advance in evaluating tandem stenoses. For the first time we 
have been able to objectively evaluate the nature of serial stenosis interplay using novel 3D-
printing of coronary artery disease. We have subsequently generated a practical and easy-to-use 
correction equation, not requiring the measurement of wedge pressure between lesions, that is 
solely based on routine pressure wire pullback measurements and shown a significant 
improvement in the prediction of the true physiological significance of lesions. An important 
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next step would be to test this solution within a clinical cohort of vessels with serial coronary 
artery disease. The only previous study with clinical validation of an in vitro solution to use with 
FFR was in a small cohort of 32 patients but with the requirement of measuring wedge pressure 
between stenoses27,30. Importantly, our solution would not need wedge pressure measurements 
and so requires no ballooning or the need to mandate starting PCI before the optimum 
revascularisation strategy is chosen.  
 
In summary, in this in vitro study, we have shown that stenosis underestimation is significant in 
serial CAD, regardless of whether a distal stenosis is accompanied by a more proximal stenosis 
or vice versa. The factors that most influence the extent of stenosis underestimation are stenosis 
severity (luminal narrowing), the change in pressure across a stenosis during pressure wire 
pullback (∆P) and Total vessel FFR (a measure of cumulative disease within the vessel and 
distal coronary pressure, Pd). From these findings, we have developed a mathematical correction 
model that significantly improves the prediction of true lesion significance in serial CAD. The 
next steps will be to carry out clinical validation against contemporary conventional techniques 
within the Catheter Laboratory such as FFR pullback and as iFR pullback35 methods (chapter 7). 




- Tandem stenoses within humans are rarely found in otherwise smooth vessels, as has been 
modelled within our 3-D printed phantoms. The reality is that between stenoses, diffuse 
atheroma acts as a continuous mild stenosis and may hamper its performance in a clinical 
cohort. 
- An ideal model for predicting ∆FFRtrue would be based on the varying curvilinear 
relationships between pressure and flow; but this would not be possible from pressure 
measurements alone. We acknowledge this may be one of the reasons there is still some 
residual error when using a correction equation that is based on a linear pressure-flow 
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relationship in physiological conditions. By doing so, however, we have been able to 
establish a simple model utilising pressure-wire data, without the need for simultaneous 
flow or wedge pressure measurement, that represents a significant improvement to 
current methods as evident in validation cohort of 3-D printed phantoms. 
- The use of resting physiological indices, particular iFR, has been growing for the 
assessment of serial disease, with proponents suggesting that without hyperaemia, there 
is less serial stenosis haemodynamic interplay. Before universal adoption, the FFR 
correction model would require an assessment of its performance against other 






This study demonstrates that estimation of the true stenosis significance in serial disease is prone 
to significant underestimation using FFR, regardless of whether is there is accompanying distal 
or proximal disease. 3D-printed modelling of tandem disease has enabled us to generate and test 
a mathematical equation to improve estimation of the true physiological impact of each stenosis, 








Supplement to Chapter 6: Theoretical Model Derivation 
 
Consider the pressure and resistance distribution in a vessel with tandem lesions pre and post-
PCI (Figure below). For illustration it is assumed that the distal lesion (R2) is treated in this 
derivation, however, the outcome is identical if the proximal lesion in removed instead. 
 
Since it is assumed that the resistance of the untreated lesion remains unchanged (i.e. R1 and R2 
are independent) and flow remains constant throughout the vessel (i.e. no side-braches between 
the lesions), Ohm’s law applied to pre- and post-PCI setting leads to:         𝑄5?@ = ∆GHIJKL       and   𝑄5MND = ∆GHOPQKL  
which can be combined to give                  RHOPQRHIJ = ∆GHOPQ∆GHIJ      
 (1) 
In addition, similar expressions can be written for the distal resistance Rd (which is assumed to 
be fixed): 𝑄5?@ = 𝑃A𝑅A 𝑄5MND = 𝑃4 − ∆𝑃5MND𝑅A  
which combine to give 














Equations (1) and (2) can be used together to eliminate flows ∆𝑃5MND∆𝑃5?@ = 𝑃4 − ∆𝑃5MND𝑃A  
Rearranging for ∆𝑃5MND yields the following expression 
 ∆𝑃5MND = ∆GHIJGSGUV∆GHIJ (3) 
Now, using the definition of post-PCI FFR 𝐹𝐹𝑅WMA@X = 𝑃4 − ∆𝑃5MND𝑃4 = 1 − ∆𝑃5MND𝑃4 = 1 − ∆𝑃5?@𝑃A + ∆𝑃5?@ 
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Background: Physiological indices such as fractional flow reserve (FFR), instantaneous wave-
free ratio (iFR) and resting ratio of distal coronary to aortic pressure (Pd/Pa) are increasingly 
used to guide revascularisation in the catheter laboratory. Physiologically characterizing 
individual stenoses in serial coronary artery disease is however prone to error and an unmet need 
in the era of ischaemia-guided revascularisation. This study aimed to compare the accuracy of 
commonly used pressure-based indices (during hyperaemia: FFR; at rest: iFR and Pd/Pa) and a 
combined Doppler and pressure-derived resistance index (Hyperaemic Stenosis Resistance, 
hSR) in serial disease. Using these results, we aimed to develop and test a correction equation 
that prospectively enables more accurate physiological prediction (FFRpred) of the significance 
of serial stenoses. Methods: 54 patients with angiographic serial coronary stenoses were 
enrolled. Resting and hyperaemic coronary pressure was measured distal and proximal to each 
stenosis, with “apparent” FFR, iFR, Pd/Pa, and FFRpred derived for each stenosis. The “true” 
stenosis significance by each index was assessed following PCI of the accompanying stenosis or 
a large disease-free daughter branch (e.g. in the case of serial disease involving the Left Main 
and LAD arteries but with a disease-free Circumflex artery) . In 27 patients, Doppler Flow 
Velocity (APV), was also measured to calculate hSR (hSR=DP/APV, where DP=trans-lesional 
pressure gradient). Results: Mean errors for FFR, iFR and Pd/Pa, as a proportion of true 
measurements for each index, were 33.3%, 19.8% and 23.4%, with underestimation inversely 
proportional to total vessel FFR (R=0.5, P<0.001). This corresponded to stenosis 
misclassification rates of 16.7%, 24% and 20% for FFR, iFR and Pd/Pa on the basis of the 
respective 0.80, 0.89 and 0.91 thresholds. Using FFRpred reduced the error to 14.3% with only 
11.1% of stenoses misclassified.  Apparent hSR correlated strongly with true hSR (R=0.87, 
P<0.001), with only 7.4% of stenoses misclassified. Conclusion: Assessing stenosis severity 
based on trans-lesional pressure gradients alone is prone to significant underestimation in serial 
disease, for both hyperaemic and resting pressure-based indices. The Doppler-based resistance 
index hSR is less prone to error but utilization is limited by difficulties obtaining Doppler traces. 
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Using an FFR correction equation can reduce error to a similar extent and can be used with 





The functional significance of coronary artery disease (CAD) is frequently assessed at the time 
of diagnostic angiography with pressure based indices such as fractional flow reserve (FFR) and 
instantaneous wave-free ratio (iFR), with good evidence that management based on these 
physiological measurements is superior to a strategy based on angiography alone3,4,12,74,83,84. The 
data supporting physiology-guided revascularisation are largely derived from studies that only 
included vessels with single discrete lesions. The reality, particularly within elderly and diabetic 
populations, is that serial and diffuse CAD is common5,85,86. Serial CAD is important and likely 
to affect physiological assessment of an individual stenosis: any additional resistance proximal 
or distal to a stenosis will affect the trans-lesional pressure gradient at any point, with the 
problem further compounded by complex fluid dynamics.30,86. 
 
The techniques most commonly used to overcome this problem is that of the FFR or iFR 
pullback (iFR Scout™, Philips Volcano)35. Both pressure-wire pullback techniques assume that 
the pressure gradient across a lesion is unaffected by the presence of the accompanying disease, 
with the proponents of the resting index iFR suggesting that serial stenosis interplay is less 
during resting conditions. Whilst these techniques are widely used and have been shown to 
better identify functional significance than the visual appraisal on an angiogram33, the possibility 
still exists that important stenoses will be misclassified with incorrect revascularisation 
strategies being embarked upon without knowing the true eventual significance of individual 
stenoses86.  
 
Pressure and flow-based indices of the resistance of individual stenoses are theoretically 
independent of a coexistent disease, with serial stenoses behaving like resistors in series within a 
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circuit. Hyperaemic Stenosis Resistance (hSR) has been shown to be more accurate than single 
modality indices at detecting reversible perfusion defects seen using non-invasive modalities21 
and has been previously been proposed not only as the best stenosis-specific physiological 
index22, but also as an independent reference-standard to assess the accuracy of physiological 
indices of stenosis significance87. Resistance indices such as hSR, despite their inherent 
strengths, have never been assessed in serial CAD, with widespread utilization and further 
studies likely to be limited by the technical challenges of routine measurements of Doppler flow 
velocity. 
 
This study aimed to assess the accuracy of indices based on trans-lesional pressure gradient 
alone at predicting the true significance of individual stenoses, in the presence of serial disease. 
The diagnostic accuracy of these indices was also compared to those of the resistance index 
hSR, with the aim of testing the hypothesis that serial stenoses can behave as resistors in series. 
Based on this, we also aim to derive, validate and test the value of a correction equation to 





Patients undergoing elective angiography+/-PCI for stable angina were enrolled. Patients were 
chosen based on having 2 stenoses (>30% diameter stenosis by quantitative coronary 
angiography, QCA) separated by a normal segment of at least 10mm, where the operator would 
consider treating the stenoses separately. Exclusion criteria were: patients with previous 
coronary artery bypass grafting, recent acute coronary syndrome (<4 weeks) and significant 
valvular disease. All patients were enrolled at Guys and St Thomas’ NHS Foundation Trust. All 
patients provided written informed consent and ethical approval was obtained from the UK 
Health Research Authority and local Research Ethics Committee (Ref:15/LO/2011). 
 
Catheter Laboratory Study Protocol 
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Conventional coronary angiography was performed via the right radial artery or right femoral 
artery. All patients received 1-2mg of diazepam before local anaesthetic was administered and 
arterial puncture took place.   Those patients who had radial access received 0.5-1mg of 
Isosorbide dinitrate into the radial artery before cardiac catheters were advanced. All patients 
received prior loading with two antiplatelet agents and intra-arterial heparin to maintain an 
activated clotting time of greater than 250s seconds. Intracoronary isosorbide dinitrate (500mcg) 
was administered prior to all pressure wire recordings.  All research recordings were made via 
guiding catheters.  In the large majority of cases 6F catheters were used, however in some 
patients in whom Left Main stem revascularisation was planned, 6F catheters were upgraded. 
 
Pressure Wire Pullback Measurements 
Guidewire pressure sensors were normalized in the coronary ostia before advancement into the 
distal epicardial vessels. Distal wire position was documented fluoroscopically such that 
subsequent pullbacks and measurements were made from the same position.  For the majority of 
cases, a fixed rate pressure wire pullback was performed from the distal to the proximal vessel 
during IV adenosine-induced steady state hyperaemia (140mcg/kg/minute, onset of hyperaemia 
adjudged using invasive pressure waveform changes88) using a sterile modified IVUS pullback 
device (Philips Volcano R100) to pull back the pressure wire at a fixed speed of 1mm/s.  
Hemodynamic parameters and distal Pd/Pa were allowed to normalise before the vessel was re-
wired and pullback repeated in basal conditions. The change in iFR and FFR across each 
stenosis within the serially diseased vessel was termed ∆iFRapp and ∆FFRapp respectively. 
∆PdPa was also calculated post hoc from the resting pullback. 
 
Options for Induction of Hyperaemia 
For the majority of cases, regardless of whether additional Doppler flow measurements were 
made that needed intracoronary (IC) adenosine, IV adenosine was used for induction of 
hyperaemia and hyperaemic pressure-wire pullbacks. IV adenosine-induced hyperaemia was 
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adjudged to be adequately reached based on distal pressure waveform changes we have 
demonstrated in our study ‘Is Heart Rate Response a Reliable Marker of Adenosine-Induced 
Coronary Hyperaemia?’ (See Appendix Chapter A). In this study we demonstrated that the best 
determinant of hyperaemia came from having 2 out of 3 of: 1) Ventriculisation of the distal 
pressure waveform, 2) Disappearance of distal dicrotic pressure notch, 3) Separation of mean 
aortic and distal pressures. 
 
Intracoronary adenosine was used in all cases where simultaneous pressure-Doppler flow 
measurements were made. This was to enable Doppler signals to be optimised at each 
measurement point (keeping an adenosine infusion running for this period of time would be 
uncomfortable for the patient). Use of intracoronary adenosine in these cases enabled us to 
compare FFR values from intravenous and intracoronary adenosine. In keeping with established 
literature89,90, we demonstrated in 19 cases that FFR values obtained are not significantly 
different by paired analysis and correlated very well (R=0.97), see figure 7.1. Based on these 
findings, intracoronary measurements of FFR through a vessel were considered reliable for cases 
where intravenous pressure-wire pullback measurements were not made. 
 
 
Figure 7.1 Correlation between mean FFR after intravenous (FFRiv) and intracoronary (FFRic) 

















Following pressure wire measurements, operators judged whether pre and post-isolation 
measurements with a 0.014” dual pressure-Doppler sensor guide wire (ComboWire, Volcano 
Philips) were safe (see figure 7.2). This wire is 0.014” in diameter and is 185cm in working 
length (figure 6.10) and comes with an offset and non-offset choice, where the pressure 
transducer and flow velocity sensor are 0cm and 1.5cm apart respectively.  In the included 
studies, the softer tipped non-offset wire was used, unless the serial stenoses being studied were 
≤1.5cm apart. Before use the modular plug (for pressure) and the pin plug (for flow velocity) are 
connected to the pimmette of the ComboMap console (model 6800), which enables 
simultaneous recording and display of multiple signals. 
 
 
Figure 7.2: ComboWire XT technical drawing with Screen display of on ComboMap Console 
(Yellow trace = distal coronary pressure (from the ComboWire); Red trace = aortic pressure 
(from fluid filled catheter); Grey-scale area = Doppler flow velocity signal; Blue Envelope = 
Instantaneous peak velocity envelope) 
 
 
Before insertion of the Combowire, the fluid-filled pressure transducer was positioned to 
0mmHg and the ComboWire pressure was zeroed. The tip of the ComboWire was advanced so 
it just protruded out of the guide catheter and the two pressure signals were compared.  If there 
were any differences the ComboWire pressure was normalized to the fluid-filled catheter signal. 
The tip of the wire was then negotiated to the distal epicardial vessel, occasionally using a 
standard ‘workhorse’ guidewire for guidance. Using fine rotational movements, the ComboWire 
was manipulated to obtain an optimal flow velocity signal (recognized from the shape of the 
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Doppler envelope and the Doppler sound emitted from the ComboMap console). This is 
challenging and involves a steep learning curve for the interventional cardiologist and therefore 
only experienced consultant operators carried out these measurements.  
 
Triplicate measurements of pressure and flow (average peak Doppler velocity, APV, cm/s) were 
taken, both at rest and with intracoronary adenosine (100mcg for left coronary artery; 60mcg for 
right coronary artery), beyond the distal stenosis, at the midpoint between both stenoses and 
before the proximal stenosis with the Doppler signal carefully optimized at each stage. This 
enabled us to generate trans-lesional values for resistance (hyperaemic stenosis resistance, hSR 
= (Pa-Pd )/ APV during hyperaemia91).  Cases where clear Doppler traces could not be obtained 
were excluded from analysis. 
 
Identifying ‘True’ Values of Stenosis Physiological Significance 
To compare the apparent physiological measurements with true measurements, one of two 
methods were used. Where possible, the pressure wire pullback and pressure-Doppler 
measurements were repeated following PCI of one of the 2 stenoses (the treated lesion was 
chosen by the operator using standard practice). In cases where serial stenoses straddled a large 
disease free sidebranch and where PCI was not planned (eg. left main and LAD disease where 
the patient was referred for CABG), the disease-free vessel was assessed to identify the true 
Pd/Pa, iFR, FFR and hSR. While there are some theoretical issues with this method based on 
different volumes of subtended myocardium, previous data has shown it to be a reliable method 
of assessing LMCA ∆FFRtrue provided the total FFR of the serially diseased vessel is not 




Figure 7.3: Summary of catheter laboratory protocol 
 
 
Testing the in vitro Derived Algorithm to Predict FFRtrue (FFRpred) 
 
As described in chapter 6, we derived the following equation to predict the true ∆FFR of a 
stenosis: 
 
𝐹𝐹𝑅𝑝𝑟𝑒𝑑 = 1 − ∆𝑃𝑃A + ∆𝑃 
 
In this equation, ΔP refers to the pressure drop across a lesion in the presence of serial disease 
and Pd refers to distal coronary pressure. This relationship applies for both proximal or distal 
lesions and depends neither on the perfusion pressure (Pa), nor the distal resistance R, and is 
solely a function of the measured pressure values. 
The main assumptions underpinning this equation (i.e. the applicability of the hemodynamic 
















is minimal) were tested in this catheter laboratory study using measurements of total vessel and 
trans-lesional hSR values, as described earlier in this methods section. This clinical study also 
enabled validation of the equation in a clinical cohort of serial CAD and comparison with 
conventional resting and hyperaemic pressure-wire pullback methods of assessing serial 
stenoses. In the appendix relevant to chapter 7, I run through a clinical example of the equation 
to demonstrate how it can be of significant clinical utility. 
 
Statistical Analysis 
Data analysis was performed using SPSS Version 23 (IBM Corp., Armonk, New York). 
Normality was visually assessed (using histograms and Q-Q plots). Continuous data are 
expressed as mean +/- standard deviation and compared using paired t-tests. A two-tailed test of 
significance was performed for all analyses with P<0.05 considered statistically significant.  







85 patients with serial disease were recruited into the study with 54 having successful pressure-
wire measurements before and after stenosis isolation. In 27 patients, combined pressure and 
Doppler flow measurements were possible for determination of hSR before and after lesion 
isolation. 7 combined pressure-Doppler cases were excluded from analysis as clear Doppler 
traces could not be obtained. Total vessel FFR of the 54 vessels studied was 0.72 +/- 0.10. 
Baseline demographics and procedural details of all vessels studied is summarized in Table 7.1. 
There were no statistically significant differences in baseline characteristics between the whole 





Age, Years 63 +/- 11 
Male 47 (87%) 
Hypertension 36 (67%) 
Diabetes 18 (33%) 
Smoker 13 (24%) 
Hyperlipidaemia 45 (83%) 
Previous PCI 24 (44%) 
Mean Lesion Severity (by QCA) 57.9 +/- 11.1% 
Mean Lesion Length, mm 10.0 +/- 5.8 
 Method of Lesion Isolation  PCI 36/54 (67%) 
Disease Free Side-branch 18/54 (33%) 
Mean Lesion Separation, mm 15.9 +/- 7.4 
 
Table 7.1: Summary of patient demographics 
 
Pressure-Wired Based Indices in Serial Disease 
In the 54 patients in whom the change in FFR (i.e. ∆P) was compared before and after isolation 
with one of the two methods, significant underestimation was observed, regardless of whether 
the proximal or distal lesion was considered, with a mean difference between FFRapp and 
FFRtrue of 0.045+/-0.05. This corresponded to a mean error, as a proportion of the true 
hyperaemic ∆P across of the lesion of 33.3%. The extent of lesion underestimation was found to 




In 50 patients, resting pressure wire pullback were also performed for calculation of the change 
in resting Pd/Pa and iFR across each lesion before and after lesion isolation. Again, there was 
significant underestimation with a mean difference between apparent and true values of 0.016+/-
0.04 and 0.011+/-0.03 for iFR and resting Pd/Pa respectively. This corresponded to a mean 
error, as a proportion of the true change in index across a lesion, of 19.8% and 23.4% for iFR 
and resting Pd/Pa respectively. Using FFRpred, the absolute value of underestimation fell to 
0.02+/-0.04, which corresponded to a mean proportional error of 14.3% (See figure 7.4). 
 
Resistance Indices in Serial Disease 
In a subset of 27 patients, apparent and true trans-lesional hSR was calculated before and after 
lesion isolation. In order to assess whether serial stenosis stenoses behave like resistors in series, 
we tested whether the sum of translesional hSR values equals the total hSR in the vessel (Figure 
7.5) and found the sum of the hSR values was not significantly different from total vessel hSR 
(P=0.07). 
 
Trans-lesional hSR values when a stenosis was present alongside another stenosis (hSRapparent) 
was found to correlate strongly with the hSR of the stenosis in isolation (hSRtrue), P<0.001, 
R=0.87, Figure 7.6. Mean absolute error for hSR was 0.19+/-0.3, which corresponded a mean 




Figure 7.4: Collimated scatter plot demonstrating the error in estimating true stenosis severity 
(data points above zero line = lesion underestimation) when using FFR, resting PdPa, iFR and 
FFRpred respectively. Errors shown in absolute terms for each index +/- standard deviation and 
also as a percentage of the true change in that index. 
 
Using cut-off values for FFR of 0.8, iFR of 0.89, PdPa of 0.91 and hSR of 0.8 to identify 
functionally significant stenoses, we found 16.7%, 24%, 20% and 7.4% misclassification rates 
for lesion attributable FFR, iFR, PdPa and hSR respectively (Table 7.2).  
 












Number of lesions 
Misclassified 
12/50 10/50 9 / 54 6/54  2/27 
% Misclassification 24% 20% 17% 11% 7% 
 
Table 7.2: Table showing rates of stenosis misclassification in serial disease when using FFR, 



































Figure 7.5: Chart plotting hSR of proximal stenosis, distal stenosis, sum of both and total vessel 
hSR. Values given as mean +/- standard deviation. The mean sum of the hSR for both stenoses 
was not significantly different from total hSR (P=0.07) 
 
 
Figure 7.6: Scatterplot showing relationship between hSR of stenosis present in isolation 





The main findings of this study are: 
i) FFR underestimates stenosis significance in serial disease, with the discrepancy 



























1.51 0.67 0.69 1.31
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ii) Resting indices, such as iFR, also result in significant lesion underestimation. Whilst 
absolute errors are smaller, the error as a proportion of true change in iFR is still marked 
iii) All pressure-wire based indices are prone to significant error in serial disease with at 
least 1 in 6 stenoses being misclassified, regardless of the index used 
iv) Combined pressure-flow based resistance indices appear less prone to this error, with a 
significant reduction in misclassified stenoses.  
v) An algorithm to predict true lesion-attributable FFR in serial disease (FFRpred) can be 
created as we have shown that stenoses in serial disease can be assumed to behave as resistors in 
series. Using FFRpred significantly reduces error and misclassifications resulting from all 
pressure-wire based indices in serial disease. 
 
Despite the prevalence of serial CAD and the growing utilisation of physiology-guided 
revascularisation, our study is the first to compare the accuracy of different physiological indices 
in serially diseased vessels, the first to test the value of pressure-flow based resistance indices in 
serial CAD and the first to validate and test the value of a correction equation to use with routine 
hyperaemic pressure-wire pullback measurements. 
 
Existing Data of Pressure-Derived Indices in Serial CAD 
De Bruyne et al have previously demonstrated that whilst FFR is a valid ratio for determining 
the hemodynamic consequences of the total burden of coronary disease within a vessel, the 
simple ratio cannot be applied to predict the FFR of individual stenoses if present in series, with 
significant errors demonstrated in their seminal studies27,30. Whilst their data suggested the 
proximal stenosis is more prone to error in the presence of a distal stenosis than vice versa, our 
data suggested there is no significant difference. De Bruyne et al subsequently derived a 
complex formula requiring measurement of coronary occlusive wedge pressure. Whilst well-
validated, the method is rarely used and considered impractical29. 
In the presence of no definitive solution to using FFR in serial stenoses, an increasingly used 
 73 
physiological method in serial disease is the iFR pressure pullback method with proponents of 
resting indices arguing that stenosis interaction is enhanced during hyperaemia and likely 
minimized at rest. To validate this method, Nijjer et al looked at 32 vessels with serial lesions to 
show a mean difference between iFR apparent (described as ‘ΔiFRexp’ in their study) and 
iFRtrue (described as ‘ΔiFRobs’ in their study) of 0.016+/-0.004. Whilst Nijjer et al state this 
error is small, we demonstrate a similar absolute error in our study (0.016+/-0.04), but that this 
still corresponds to a nearly 20% error with 24% of stenoses misclassified. Given the smaller 
range of resting ΔP vales, a 0.016 unit change has potentially a much larger relative effect on 
resting indices. Overall, our data suggests that all pressure derived indices are prone to 
significant error in serial CAD. The resting indices of Pd/Pa and iFR both appear to perform 
better in terms of relative error but given the lower spatial resolution of these resting indices, 
they appear to result in similarly marked degrees of stenosis misclassification. 
Resistance Indices in Serial CAD 
Our data suggests that the trans-lesional resistance of a stenosis can be considered to be largely 
independent of disease elsewhere within the vessel, with apparent and true trans-lesional hSR 
correlating strongly (figure 7.6). Whilst the correlation is strong and the sum of hSR values does 
not appear to be statistically different from the total vessel hSR, the results do not appear strong 
enough to support the notion that hSR is a gold standard physiological test in serial CAD. This 
may be a reflection of the fact that there is some side-branching and collateral loss of flow that 
limits the ability of serial stenoses to behave perfectly as resistors would in an electrical circuit. 
Nonetheless, hSR does appear to be more robust than pressure-derived indices in predicting the 
true physiological significance of individual lesions, with only 7.4% of stenoses misclassified in 
the presence of accompanying serial disease, when compared to the true hSR of a stenosis with 
the lesion in isolation (table 7.2). Universal utilisation of such indices are however limited by 
challenges of obtaining clear intracoronary Doppler traces. 
The relative independence of trans-lesional hSR values that we have shown in this study lends 
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support to the methodology we have used to derive a correction equation to use with FFR 
pullback methods. This validity of the equation to correct for the errors from hyperaemic 
pressure wire pullback is further strengthened by showing that by using this equation, the 
relative error in estimating true stenosis FFR values is significantly reduced, with a marked 
decrease in the number of misclassified stenoses. 
Clinical Implications and Future Direction 
Our work suggests identifying the individual physiological significance of stenosis is prone to 
error, particular when the total ischaemic burden in a vessel is high (i.e. low FFR or iFR). 
Operators should be wary of this when carrying out FFR and iFR pullbacks and be aware that 
both hyperaemic and resting indices (including iFRScout™) are prone to significant error with 
stenoses often being wrongly misclassified in the presence of serial stenoses. Pressure-flow 
based resistance indices are less prone to this error, but are still prone to a degree of error with 
universal utilization limited by difficulties in obtaining intracoronary Doppler traces.  
 
An easy to use correction equation to use with pressure-derived indices, not requiring 
measurement of intracoronary wedge pressure, has been derived and validated in this study. This 
solution is based solely on routine pressure wire measurements of ∆P and total vessel FFR and 
significantly reduces error, although not to the same extent as for the 3-D printed in vitro 
phantoms (chapter 6). The true clinical utility of this solution now needs assessing in a 
prospectively planned multi-centre clinical utility study.  
 
Limitations 
- Identifying a reference standard, against which all methods of physiologically assessing 
serial CAD, is a challenge. In this study we used the reference standard of the change in index 
across a stenosis when present in isolation, with lesions isolated by PCI or disease free side-
branch. Whilst these methods are established, errors are still possible: the post-PCI effects on 
microvascular tone are not yet established with conflicting views92,93 and the disease-free side-
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branch method is prone to small errors particular with severe disease in the main serially 
diseased vessel44. 
- This is a relatively small study, albeit the largest to examine the various existing and 
novel strategies in the physiological assessment of serial CAD. A larger study in a broader range 
of serial and diffuse coronary artery disease, together with an assessment of differing clinical 
practices when using each index, would be an important next step in truly understanding the 
value of different indices and novel solutions. 
- The results of the correction equation are not as impressive as in the 3-D phantom cohort 
(chapter 6). This may be a result of the fact that in real-life clinical cases of serial disease, 
stenoses have more complexed geometry with diseased side-branches between stenoses. 
Nonetheless, the clinical validation of this pragmatic novel solution does show a significant 





Pressure-derived indices, both resting and hyperaemic, significantly underestimate stenosis 
significance in serial disease, with discrepancy proportional to cumulative disease burden.  
Pressure-flow based resistance indices are less prone to this error, but universal utilization is 
limited by difficulties in obtaining intracoronary Doppler traces. Based on these findings we 
describe a correction equation, to use with routine hyperaemic pressure-wire measurements, that 
reduces the error of pressure-derived indices to a similar extent and should be considered in 


















LAD demonstrating serial lesions. 
 Question about what the residual FFR 
would be due to distal lesion once 
proximal LAD lesion treated 
 
 
distal FFR of 0.75 
(distal Pd of 86.4mmHg) 
hyperaemic pressure-wire 
pullback demonstrating 
apparent DP and apparent 
DFFR 
without model, it would be 
estimated that residual FFR 
from distal stenosis only would 
be 0.90 
 
 𝑭𝑭𝑹𝒎𝒐𝒅𝒆𝒍 = 𝟏 − ∆𝑷𝒑𝒓𝒆𝑷𝒅 + ∆𝑷𝒑𝒓𝒆 = 𝟏 − 𝟏𝟔. 𝟖𝟏𝟎𝟑. 𝟐 = 𝟎. 𝟖𝟒 














8. EXPERIMENTAL CHAPTER: NON-INVASIVE COMPUTED 
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As discussed in Chapter 5.5, CT enables us to make a thorough assessment of individual stenosis 
geometry, and therefore an accurate estimation of the frictional and separation coefficient of a 
stenosis (Figure 5.2). In addition, CT enables the computation and modelling of blood flow 
through diseased coronary arteries (Computational Fluid Dynamics, CFD). These inherent 
advantages of CT and the underpinning CFD theory make FFRCT-derived solution potentially 
ideal for unpicking serial stenosis physiology before a guidewire has entered the body. 
 
In this chapter we therefore aim to address 3 issues: 
i) Can conventional FFRCT outputs (usually presented as a colour-contour map of FFR 
change down a vessel) reliably estimate true individual stenosis significance in serially 
diseased vessels? 
ii) Based on the core principles of FFRCT, CFD and coronary haemodynamics, we aim to 
develop and validate a novel non-invasive FFRCT-derived PCI planning tool, with the 
aim of comparing the accuracy to estimations made from conventional FFR pullback 
and conventional FFRCT outputs. 
iii) We have shown in vivo in Chapter 7 that serial stenoses can be considered to behave 
as resistors in series, with trans-lesional hSR values being largely unchanged by 
disease elsewhere. We therefore aimed to use the underlying principles behind FFRCT 









8.1 Predicting the Physiological Effect of Revascularisation in 
Serially Diseased Coronary Arteries: Clinical Validation of a Novel 





Background: Fractional Flow Reserve (FFR) is commonly used to assess the functional 
significance of Coronary Artery Disease (CAD) but is theoretically limited in evaluating 
individual stenoses in serially diseased vessels. We sought to characterise the accuracy of 
assessing individual stenoses in serial disease using invasive FFR pullback and the non-invasive 
equivalent, FFRCT. We subsequently describe and test the accuracy of a novel non-invasive 
FFRCT-derived PCI planning tool (FFRCT-P) in predicting the true significance of individual 
stenoses. Methods and Results: Patients with angiographic serial CAD scheduled for PCI were 
enrolled and underwent prospective coronary CT angiography with conventional FFRCT derived 
post hoc for each vessel and stenosis (FFRCT). Before PCI, invasive hyperemic pressure-wire 
pullback was performed to derive the apparent FFR contribution of each stenosis (FFRpullback). 
The true FFR attributable to individual lesions (FFRtrue) was then measured following PCI of 
one of the lesions. The predictive accuracy of FFRpullback, FFRCT and the novel technique 
(FFRCT-P) were then assessed against FFRtrue. From the 24 patients undergoing the protocol, 19 
vessels had post hoc FFRCT and FFRCT-P calculation. When assessing the distal effect of all 
lesions, FFRCT correlated moderately well with invasive FFR (R=0.71, p<0.001). For lesion-
specific assessment, there was significant underestimation of FFRtrue using FFRpullback (mean 
discrepancy 0.06±0.05, p<0.001, representing a 42% error) and conventional trans-lesional 
FFRCT (0.05±0.06, p<0.001, 37% error). Using FFRCT-P, stenosis underestimation was 
significantly reduced to a 7% error (0.01±0.05, p<0.001). Conclusions: FFR pullback and 
conventional FFRCT significantly underestimate true stenosis contribution in serial CAD. A 
novel non-invasive FFRCT-based PCI planner tool more accurately predicts the true FFR 






Coronary computed tomographic angiography (CTA) is now established as a non-invasive test for 
the detection of significant coronary artery disease (CAD)57,58.  Owing to a relatively low positive 
predictive value and inability to determine functional significance58, CTA has generally been used 
in patients at a low to intermediate risk with a view to ruling out significant CAD60. When 
coronary atheroma is detected, there is growing evidence that the benefit of revascularisation is 
only derived from targeting myocardial ischaemia7. Ischaemia-guided revascularisation has 
evolved to identifying vessels with functionally significant disease at the time of angiography 
using indices such as Fractional Flow Reserve (FFR)4,8,10. In recent years it has become possible 
to estimate FFR from standard coronary CTA datasets with Fractional Flow Reserve by Computed 
Tomography, FFRCT. Based on computational fluid dynamics (CFD), FFRCT, has been shown to 
increase the positive predictive value of coronary CTA and provide clinicians with a non-invasive 
test to assess coronary anatomy and physiology 65,67,69.  
 
The studies validating both invasive FFR and FFRCT have largely been in vessels with single 
epicardial stenoses67,94. In reality, CAD is often diffuse in nature with serial stenoses across the 
length of a vessel.  Assessment of the contribution of each stenosis is challenging because 
physiological interplay affects the FFR attributable to each stenosis 30,95.Coronary CTA enables 
detailed visualization of lesion geometry and a potential to evaluate the true pressure drop across 
a stenosis by modelling the hemodynamic interplay between serial stenoses 95. FFRCT therefore 
offers the potential to predict the functional significance of individual stenoses within a 
serially/diffusely diseased vessel, and therefore to predict the residual functional disease burden 
following PCI. 
 
In this study, we describe a novel non-invasive FFRCT-derived PCI planning tool (FFRCT-P), which 
models physiological interplay between stenoses. This tool, developed by HeartFlow Inc., is based 
on a reduced order model informed by three-dimensional simulations of blood flow to estimate 
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post-PCI pressure loss. In this study we aimed to: 1) characterise the accuracy of estimating 
individual stenosis significance in serially diseased vessels using invasive FFR pullback and 
conventional FFRCT outputs (usually presented as a colour contour map of FFR change down a 
vessel), and 2) validate the novel non-invasive FFRCT-derived PCI planning tool in a clinical 
cohort of patients with serial disease, with the aim of comparing the accuracy to estimations made 






All patients consented had presented with symptoms of stable angina and had ³2 stenoses on an 
invasive coronary angiogram (>30% diameter stenosis by QCA). Patients were only eligible if the 
stenoses were separated by a normal segment of at least 10mm, if it were felt feasible to treat each 
lesion independently by PCI. Exclusion criteria were age <18 years, pregnancy, eGFR <30, 
previous coronary artery bypass grafting and contraindications to FFR assessment or CTA.  
Cardiac catheterisation was performed within 4 weeks of the prior CTA scan.  The study protocol 




All patients underwent coronary CT angiography using a 2 x 192-slice dual source CT scanner 
(Somatom Force, Siemens Medical Solutions, Forchheim), Germany. Eight hundred micrograms 
of sublingual glyceryl trinitrate was administered to all patients along with intravenous 
metoprolol to achieve a heart rate of <65 beats/min in sinus rhythm and <100 beats/min in atrial 
fibrillation. A total of 85ml intravenous contrast (Omnipaque, GE Healthcare, Princeton, NJ, 
USA) was injected at 5.5 ml/s) by a power injector into the antecubital vein. Descending aorta 
contrast triggered, prospective electrocardiogram (ECG) gated scanning with adaptive padding 
was then performed in a single breath-hold technique after a 10-12 second delay. The scanning 
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parameters included a heart rate dependent pitch of 0.2-0.45 and a gantry rotation time of 
250ms. The tube voltage was selected semi-automatically and automated exposure control was 
used for the tube current. Image slices were reconstructed using a medium sharp kernel (Bv40), 
using model-based iterative reconstruction strength level 3 (ADMIRE; Siemens Medical 
Solutions, Forchheim, Germany). 
 
FFRCT Protocol 
FFRCT analysis was performed by HeartFlow, who were blinded to the invasive angiographic 
and physiological data. FFRCT data were derived post hoc from the CTA dataset using 
methodology that has been previously described 62,67. In summary, FFRCT technology involves 
extraction of a patient-specific geometrical model of the coronary arteries from CTA data. 
Subsequently, this is combined with population-derived physiological models and computational 
fluid dynamics techniques to solve the governing equations of blood flow velocity and pressure 
under simulated hyperaemic conditions 62. FFRCT physiological models are based on three core 
scientific principles: an allometric scaling law relating coronary flow to myocardial mass and 
vessel lumen volume, the principle of flow regulation of vessel size, and an assumption of the 
predictable reduction of microvascular resistance with maximal hyperaemia96. 
 
In this study, HeartFlow FFRCT v2.7 was used. This software runs on the Amazon Web Services 
(AWS) cloud and combines deep-learning artificial intelligence methods97 to aid in identifying 
the lumen boundary, physiological models that incorporate vessel lumen volume, myocardial 
mass data and hybrid 3D-1D computational fluid dynamics methods96. Normal HeartFlow 
FFRCT outputs involve a colour-coded chart of continuous FFRCT values computed along each 
vessel. The apparent change in these discrete values across each stenosis within the serially 
diseased vessel were used to define the attributable FFRCT for each stenosis within the serially 
diseased vessel, using conventional FFRCT methods without the planning tool. 
 
Estimation of FFRCT post-stenting  
 83 
To enable the fast recalculation of FFRCT for different planning configurations of PCI, an 
accelerated method for updating FFRCT was used (based on a reduced order model derived from 
computational fluid dynamics simulations). Without compromising on the accuracy of FFRCT, 
this approach is able to update FFRCT solutions in real-time in response to changes in lumen 
geometry. Initially, idealized vessel lumen radii are calculated by first evaluating % diameter 
stenosis and subsequently calculating the radius at which there would be no lumen narrowing 
(i.e. to achieve a % stenosis of zero). Following this, a patient-specific idealized model is 
constructed using the idealized lumen radii. Finally, a CFD-derived reduced order model is used 
to calculate the updated FFRCT values. 
 
This method involves CFD-derived reduced order model based on a flow-dependent resistance 
model for the epicardial arteries, 𝑅 = 𝑅𝑖𝑛 + 𝑅𝑠𝑙𝑄, where 𝑅𝑖𝑛 and 𝑅𝑠𝑙 are the intercept and slope of 
the resistance-flow relationship, 𝑄 is the flowrate and 𝑅 = 	 mGR    is the resistance posed by the 
epicardial vessel to blood flow. Since these quantities also depend on the epicardial geometry, 
two different flowrates are used to calculate 𝑅𝑖𝑛 and 𝑅𝑠𝑙. In each of the original and idealized 
geometries, two different boundary conditions, the first being hyperaemia as described in the 
previous section and the second being a 40% lower resistance, are applied. If the flowrates 
achieved are 𝑄 and 𝑄∗, and the corresponding resistances calculated from CFD simulations are 𝑅 
and 𝑅∗ then: 𝑅Bn = o∗p	T	p∗oRTR∗  and    𝑅NX = o∗	T	oR∗T	R  
If the flow difference achieved, 𝑄∗− 𝑄, is too low, then the intercept and slope are replaced with 
a 1D CFD model parameterized by lumen area (A), viscosity (𝜇), density (𝜌), as  
𝑅Bn = 8µLπAx  
and   
𝑅NX = ρLdAA{dz  
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These resistances are applied on the updated lumen geometry (where lumen radii in the stented 
region are replaced by their idealized values), to solve for flowrates, pressures and FFRCT. For 
the purposes of this study, FFRCT-P of each stenosis was derived following the retrospective 
application of these calculations to CTA images, blinded to invasive FFR values but with 
knowledge of stent size and position. 
 
Cardiac Catheterization Protocol 
Angiography was performed via the right radial artery using 6Fr catheters. Prior to 
catheterization, all patients received 300mg of aspirin, 600mg Clopidogrel and benzodiazepine 
sedation before local anaesthetic was administered. Following arterial puncture, patients 
received 500 – 1000mcg isosorbide dinitrate into the radial artery before cardiac catheters were 
advanced and a further intracoronary bolus before acquisition of standard diagnostic images. 
 
Invasive Pressure-Wire Data Protocol 
Before insertion, the pressure-wire was zeroed outside of the body, against a fluid-filled guiding 
catheter pressure-transducer positioned at the level of the right atrium. After insertion, the pressure 
sensor was normalised to aortic pressure at the coronary ostium, with the guide disengaged where 
necessary. The pressure wire tip was delivered to the distal part of the serially-diseased vessel, 
with wire position documented fluoroscopically. An IV adenosine infusion was administered at a 
dose 140 mcg/kg/min via an antecubital vein. FFR was defined as the lowest Pd/Pa ratio averaged 
over 5 cardiac cycles following the onset of adenosine47. Following documentation of FFR, the 
pressure-wire was pulled back to the guide catheter at a fixed speed during continuous adenosine 
infusion.  
 
The ‘apparent’ change in hyperaemic pressure gradient across each stenosis following pressure-
wire pullback within the serially diseased vessel was noted with the attributable FFR termed 
‘FFRpullback’. PCI was then performed, with the choice of stenosis treated at the discretion of the 
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operator using their conventional practice. Following re-calibration, pressure-wire pullback was 
then repeated. The subsequent ‘true’ change in hyperaemic pressure gradient across the remaining 
stenosis in isolation was noted with the stenosis-attributable FFR termed ‘FFRtrue’ (i.e. FFR in the 
vessel following PCI of the accompanying serial stenosis). The difference between FFRtrue and 
FFRpullback was indicative of the degree of stenosis underestimation in serial CAD. The relationship 
between the extent of stenosis underestimation and ‘Total Vessel FFR’ (the cumulative FFR in 




SPSS Version 23 (IBM Corp., Armonk, New York) and Prism Graphpad 5.0 (GraphPad Software 
inc. CA) were used for all analyses. Normality was assessed using a visual assessment of 
histograms and Q-Q plots. Continuous data are expressed as mean ± standard deviation and 
compared using paired t-tests. A two-tailed test of significance was performed for all analyses 
with p<0.05 being considered statistically significant.  Correlations were assessed using Pearson’s 




27 patients had prospective CT coronary angiography that demonstrated serial CAD in 30 vessels.  
Of these, 5 patients (6 vessels) were excluded as satisfactory catheter laboratory data could not be 
obtained (reasons were: stenosis deemed too severe to make pressure-wire measurements, vessel 
tortuosity making it difficult to pass pressure-wire and an adverse reaction to adenosine). Of the 
remaining 24 vessels, 19 (79%) had satisfactory computation of FFRCT along the vessel (3 patients 
were excluded due to proximal stented segments and 2 owing to CTA motion artefacts that 
precluded post hoc FFRCT computation). 
 
Patients included in the final analysis had a median age of 64.7 years (89% male). Table 1 
summarizes the patient demographics and details of the serially diseased vessels. FFR of these 
 86 
vessels was 0.67±0.16. Total vessel FFRCT of these vessels was 0.68±0.18. The  Invasive total 
vessel FFR showed good agreement with total vessel FFRCT, in line with previous studies67,69 
(Pearson’s R = 0.71). 
 
With FFR pullback, significant underestimation of lesion severity occurred, regardless of whether 
the proximal or distal lesion was considered, with a mean difference between FFRpullback and 
FFRtrue of 0.06±0.05 (p<0.001). This corresponded to a mean error, as a proportion of the true 
FFR gradient across the lesion, of 42%. For conventional FFRCT outputs along the course of 
vessels, similar significant underestimation of lesion severity occurred, with a mean difference 








Table 8.1 Summary of patient demographics and Lesion Characteristics. Data presented as 
mean values ± standard deviation with percentage prevalence where relevant. PCI = 
Percutaneous Coronary Intervention; QCA; Quantified Coronary Angiography; mm = 
millimetres 
 
Age, Years 64.7 ±12.0 
Male 17 (89%) 
Hypertension 12 (63%) 
Diabetes 6 (32%) 
Smoker 5 (26%) 
Hyperlipidaemia 15 (79%) 
Previous PCI 6 (32%) 
Lesion Severity (by QCA) 58.9% 
Lesion Length, mm 11.3 
Lesion Separation, mm 18.6 
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Estimating True Stenosis Significance with Interactive Planner Tool 
Using the newly developed interactive FFRCT PCI planning tool, we were able to estimate the FFR 
in the vessel (FFRCT-P) following optimal PCI of one of the two serial stenoses (example case 




Figure 8.1: Example case showing colour contour map of FFR change in a serially diseased 
vessel with improvement in estimation of true stenosis significance with interactive planner Tool 
Left: Example of conventional FFRCT output for a serially diseased LAD (serial stenoses 
labelled) prior to simulated PCI. The FFRCT value between and distal to stenoses is suggested to 
be 0.93 and 0.80 respectively. Right: Results of true measured FFR at point ‘X’ after PCI of 
stenosis 2, comparing favourably with FFRCT-P, following application of novel planner tool. 
Using conventional FFRCT and FFRpullback the underestimation would have been more significant 















Use of FFRCT-P resulted in a significant improvement in the correlation between the predicted 
FFRCT and FFRtrue, following PCI of one of the two serial stenoses (R=0.44 with conventional 
FFRCT, improving significantly to R=0.75 with FFRCT-P; see Figure 8.2). Whilst there was good 
direct correlation of per-stenosis FFRCT-P to FFRtrue (Pearson’s correlation coefficient 0.75; 
p=0.001; figure 8.2), in a few cases there was significant over/under-estimation, particularly 
when the baseline total vessel FFR was <0.7). 
 
 
Figure 8.2: Scatterplots demonstrating how planner tool improves estimation of FFRtrue 
Legend: Scatterplots demonstrating improved estimation of FFRtrue across all patients with 
FFRCT-P (p = 0.001). Left: Comparison of FFRCT-P and measured FFR post PCI. Right: 
Comparison of conventional FFRCT before PCI with measured FFR post-PCI (FFRtrue). 
 
By applying the interactive planner tool on a geometry matching the stent location in the 
subsequent PCI, the absolute value of underestimation fell to 0.01±0.05, which corresponded to 




Figure 8.3: Categorical scatter plot comparing errors in estimating true stenosis significance 
(mean error +/- SD) with invasive FFRpullback versus conventional FFRCT versus results from 
FFRCT with the PCI planning tool (FFRCT-P). Also shown are percentage errors for each 
physiological tool as a proportion of the true FFR change, derived following isolation of a 






In this study, we have shown that (i) using an unadjusted trans-lesional gradient from conventional 
FFRCT outputs leads to significant underestimation of stenosis significance in serially diseased 
vessels, similar to invasive FFR pullback methods and (ii) applying a novel interactive PCI 
planning tool (FFRCT-P), results in a significant improvement in the accuracy of predicting the 
residual ‘true’ FFR contribution of stenoses following treatment of accompanying serial stenoses. 
To our knowledge, this is the first description and validation of this novel non-invasive method to 
predict the haemodynamic outcome of a PCI procedure.  
 
Serial and diffuse coronary artery disease is common, particularly within ageing and diabetic 



































There are however several recognised limitations of physiological assessment of serial coronary 
artery disease. A simple explanation for this is that a stenosis provides resistance to blood flow, 
manifesting as a post-stenotic drop in pressure that is magnified in hyperaemic conditions to give 
the true FFR when present in isolation. When another stenosis or diffusely-diseased segment, 
maximal hyperaemia (and therefore measurement of the ‘true FFR’ resulting from the stenoses) 
is not possible due to the additional resistance to flow, with the situation further complicated by 
flow turbulence when stenoses are particularly severe, close together and non-concentric29,95. The 
techniques previously described to overcome these limitations have been complex; requiring 
measurement of coronary wedge pressure 30 or the presence of a disease-free daughter branch 
when serial disease involves the Left Main Coronary Artery 44. While it has been suggested that 
resting indices (eg iFR pullback) might result in smaller absolute errors than FFR in this setting 
35, this is likely to be a reflection of the different operating range of resting indices, which are also 
prone to significant error.  
 
At present, conventional FFRCT outputs are presented as colour coded maps of coronary arteries 
showing how FFRCT values change down the vessel. These colour-coded gradients of FFRCT are 
designed to mirror the changes in measured FFR one would expect with a hyperaemic pressure-
wire pullback within the catheter laboratory. In keeping with this, our results show that unadjusted 
trans-lesional gradients from these conventional FFRCT outputs show a similarly significant 
degree of stenosis underestimation in serially diseased vessels, as is the case with invasive FFR 
pullback. Given that the physiological interplay largely depends on lesion geometry, which in turn 
can be well characterised by CTA techniques, a FFRCT-based technique would be expected to 
have greater potential at predicting the true physiological contribution of an individual stenosis, 
with the added appeal of being a non-invasive technique. Based on this, the FFRCT-derived PCI 
planning tool has been developed to allow real-time recalculation of residual FFR after simulating 
PCI, with the operator able to choose simulated stent position and length. 
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Despite the large and significant reduction in mean error using the novel FFRCT method (FFRCT-
P), the variance of the error due to serial disease is still appreciable (SD +/- 0.05), particularly 
when the cumulative burden of disease in the vessel is high (i.e. total FFR low). These findings 
are consistent with previous meta-analyses of FFRCT diagnostic performance that have shown 
reduced accuracy with more severe stenoses 98. This may be as a result of limited CT visualisation 
of stenosis geometry when stenoses are severe but also variability in microvascular function which 
is difficult to predict from a non-invasive functional-anatomical test. In addition, the geometry of 
the untreated lesion can change post-PCI due to a higher operating pressure and can lead to 
unaccounted changes in FFRCT.  There are several additional issues when using FFRCT in planning 
intervention that may limit the utility of such a non-invasive tool: Firstly, there is a need to have 
an appropriate CT scan within a few weeks of the planned PCI. Secondly, not all prospectively 
acquired CT scans are of adequate quality for FFRCT computation. Within our study, around 20% 
of cases could not have post hoc FFRCT computation due to issues such as phase misalignment. 
This was a rate similar to the NXT trial where 13% of CT scans were unsuitable for analysis owing 
to ‘inadequate image quality’ issues such as phase misalignment, stent-related artefacts and 
blooming67. 
 
Despite these factors, in patients that are able to have an adequate quality prospective CT coronary 
angiogram prior to planned PCI, FFRCT-P still represents a significant improvement to current 
methods of physiologically assessing serial CAD. Furthermore, it has the potential to complement 
contemporary methods of planning PCI, particularly in patients with serial/diffuse CAD, without 
requiring the invasive positioning of a coronary guidewire. Further multi-centre data will be 
needed to evaluate this tool and its impact of clinical decision-making. 
 
Limitations 
The study is limited by its relatively small sample size although it is the first study to provide 
validation of FFRCT and the novel interactive planner tool in serial lesions. In addition, FFRCT has 
not been validated for patients with previous coronary artery bypass, previous stenting within the 
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same vessel or significantly abnormal left ventricular function, and therefore by extension we 
excluded these patients and we cannot extrapolate the results from the FFRCT PCI planning tool 






FFRCT provides a comparable estimation of FFR values obtained from routine invasive pressure-
wire pullback along a vessel and is prone to a similar degree of physiological underestimation in 
serial coronary artery disease. In this study we provide validation for a novel non-invasive FFRCT-
derived PCI planning tool (FFRCT-P) and show it to significantly reduce the error of contemporary 
methods in estimating true stenosis significance within serially diseased vessels following PCI of 




































As described in earlier sections, Hyperaemic Stenosis Resistance, hSR, is an invasive index 
calculated by measurement of both intra-coronary pressure and Doppler flow velocity and so 
overcomes many of the limitations of flow-only and pressure-only based indices21,42,99. It has 
previously been shown to provide a more accurate assessment of ischaemia compared to other 
invasive physiological indices21 and has previously been used as an invasive reference standard 
to compare invasive pressure-derived physiological indices87. In addition, our data suggests that 
the trans-lesional resistance of a stenosis can be considered to be largely independent of flow 
conditions and resistance elsewhere within the vessel. The data suggests that hSR does appear to 
be more robust than the pressure-derived indices in predicting the true physiological significance 
of individual lesions in serial disease, with apparent and true trans-lesional hSR correlating 
strongly. 
 
Despite these strengths of Doppler-derived resistance indices, both on a trans-lesional and total 
vessel level, universal utilization of such indices are limited by challenges of obtaining clear 
intracoronary Doppler traces. With advances in CT and Computational Fluid Dynamics, it is 
possible that hSR values can be derived using computed blood flow and pressure values. We 
sought to compare how total vessel and trans-lesional hSR values compare with CT-computed 






The study population, CT protocol and Cardiac Catheterization protocols used were identical to 
those described in section 8.1. The cases selected for this study needed to have had invasive hSR 
measurements with a prior CT scan that was appropriate for post hoc FFRCT analysis within the 
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vessel of interest. From these cases, invasive hSR and CT derived hSR values were assessed, as 
described below. 
 
Invasive Pressure-Doppler Data Protocol 
Following diagnostic angiography, operators judged the safety of pre and post-isolation 
measurements with a 0.014” dual pressure-Doppler sensor guide wire (ComboWire, Volcano 
Philips). In these cases, the guide wire was manoeuvred to the distal epicardial vessel following 
initial calibration to aortic pressure. Triplicate measurements of pressure and flow (average peak 
Doppler velocity, APV, cm/s) were taken, both at rest and with intracoronary adenosine 
(100mcg for left coronary artery; 60mcg for right coronary artery), beyond the distal stenosis, at 
the midpoint between both stenoses and before the proximal stenosis with the Doppler signal 
envelope carefully optimized at each stage. This enabled calculation of trans-lesional values for 
resistance (hyperaemic stenosis resistance, hSR = (Pa-Pd )/ APV during hyperaemia91).  Cases 
where clear Doppler traces could not be obtained were excluded from analysis. 
 
CT derived hSR 
For each patient, in section 8.1, a three-dimensional anatomic model of the aorta and epicardial 
coronary arteries was generated from coronary CTA images. This model was used to create 
physiological models based on three core principles: an allometric scaling law relating coronary 
flow to myocardial mass and vessel lumen volume, the principle of flow regulation of vessel size, 
and an assumption of the predictable reduction of microvascular resistance with maximal 
hyperaemia96. 
 
Anatomical models were generated with Tetrahedral finite element volumetric meshes generated 
for these models. Boundary conditions that represent the rest of the cardiovascular system were 
applied to prepare the models for the computational fluid dynamics simulations. Finite element 
methods were used to solve the three-dimensional equations governing the dynamics of blood 
which consist of the momentum balance and mass conservation equations. Simulations focused 
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on hyperaemic conditions where the shear rate is high and the blood behaves like a Newtonian 
fluid: blood was therefore assumed to be an incompressible Newtonian fluid. At measured 
vessel locations, cross-sectional areas normal to the flow direction were generated and flow rates 
and pressure values were computed by integrating velocity and pressure components over the 
cross-sectional areas. hSR was derived using men velocity values instead of APV due to the 
difficulty of reproducing Doppler velocity measurement. These mean velocity values were 







10 patients met the inclusion criteria for this study. These vessels containing serial CAD within 
one vessel and had both a prior CT Coronary Angiogram (of sufficient quality for post hoc 
FFRCT and non-invasive hSR estimation) and also successful invasive measurements of  total 
vessel and trans-lesional hSR (using a combined Doppler and pressure guidewire). An example 
case is shown in figure 8.4. 
 
Mean total vessel FFR was 0.63 +/- 0.15 and mean total vessel FFRCT was 0.63 +/- 0.23. Mean 
invasive hSR of the 10 serially diseased vessels was 2.67mm +/- 2.21 mmHg.s/cm. Mean hSR 
as calculated using computed velocity values was 3.19 +/- 2.65 mmHg.s/cm. Total non-invasive 
hSR as calculated using the mean velocity method correlated moderately with invasive hSR (R = 




Figure 8.4: Colour-coded FFRCT output showing how trans-lesional CT-hSR values were 
calculated for each lesion (marked by black spots) and how they were compared to measured 





Figure 8.5: Scatter plot showing the correlation of measured invasive total vessel hSR with non-










































Total hSR Measured by CT (mmHg.s/cm)
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Mean trans-lesional hSR derived invasively was 1.19 +/- 1.40. Mean trans-lesional hSR derived 
non-invasively estimated using CT was 1.59 +/- 1.51. Although Trans-lesional hSR values 
derived invasively showed a trend to correlate with non-invasively estimated hSR, the 
correlation was poor (R=0.28), see figure 8.6. 
 
 
Figure 8.6: Scatter plot showing the correlation trans-lesional hSR measured invasively versus 
the trans-lesional hSR measured using the novel non-invasive method based on CT-derived 







In this study we have shown that a non-invasive CT-derived estimation of total vessel hSR 
correlates moderately with hSR measured invasively using a combined pressure-Doppler 
guidewire. However, trans-lesional hSR values estimated non-invasively shows weak correlation 
with hSR measured invasively. 
 
The differences between CT-derived estimation of total vessel hSR and invasively measured 
hSR can be due to several reasons: 
i) There are challenges in identification of true lumen and stenosis geometry as with 






































Trans-lesional Measured by CT (mean vel mmHg.s/cm) 
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ii) When computing total vessel hSR, mean velocity values were used instead of 
Average Peak Velocity (APV) due to the difficulty of reproducing Doppler velocity 
measurement. Doppler-measured APV values are dependent on the sample volume 
collected by the transducer and on the location of the transducer: the velocity 
magnitude can vary significantly from zero near the vessel walls to a maximum 
velocity value, often near the centre of the lumen. The measurement location can 
therefore yield very variable results near bifurcation regions or in the regions where 
the velocity profile shape was not fully developed. In these regions, a small 
discrepancy in the measurement location can generate big differences between 
measured and estimated velocity magnitudes. 
iii) We computed CT hSR from a mean velocity value by dividing the flow rate by the 
cross-sectional area with potentially big differences between the measured and 
estimated hSR values. Differences in APV can therefore be further magnified when 
computing trans-lesional hSR values as there can also be errors in estimation of 
cross-sectional area. 
 
The error in estimating trans-lesional values of hSR appears even greater than when assessing 
hSR on a total vessel basis. This may be a result of variability in effect of computed flow into 
side branches between lesions and limitations in imaging of diffuse stenoses, particularly those 
stenoses with complex calcific geometry. This could be avoided by having excellent image 
quality of the acquired images, avoiding bifurcation regions as reference locations for 
calculating trans-lesional values, and limiting the measurements to main vessels only. 
 
In summary, when attempting to compare CT-derived trans-lesional hSR values with invasively 
measurements of trans-lesional hSR values using Doppler, there appears to be a promisingly 
moderate correlation on a total vessel basis but the correlation of trans-lesional hSR values is far 
weaker. The errors and poor correlation may arise because of inaccuracies in imaging stenoses, 
estimating flow velocities and because small side-branching between lesions is difficult to image 
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and subsequently compute blood flow for (particularly if uncertainty exists about velocity values 
near bifurcation regions). As imaging technology and computation improves, improvements can 
be made by aiming to compute local velocity values nearer precise measurement locations, with 
the smallest of differences potentially significant. Additionally, improvements can potentially be 
made by running CFD simulations using pulsatile analyses in order to collect peak velocity 




There is a moderate correlation of total hSR estimated non-invasively to that measured 
invasively, with a potential to make iterative improvements in the future to this potentially 
promising index of physiological significance, at least on a per-vessel basis. Currently for serial 
stenoses, the use of FFRCT and CFD should be restricted to the findings in chapter 8.1 as non-

























9. EXPERIMENTAL CHAPTER: CLINICAL UTILITY STUDY  
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Clinical Utility Study Rationale 
 
A major development from this thesis is that of predicting true stenosis significance by applying 
a correction equation to a fixed-rate hyperaemic pressure-wire pullback. Our data, described in 
chapter 7, suggests this correction equation results in a vast improvement, both in terms of the 
FFR error across each stenosis and the rate of stenosis misclassification, with results 
significantly better than other pressure-wire based methods currently used in clinical practice. 
 
Such a solution, to use with routine pressure-wire pullback measurements, is only valuable if it 
changes clinical decision making and is of clinical utility. The feasibility of an outcome-based 
trial is questionable as low event rates for stable coronary artery disease mean such a trial would 
need many thousands of patients to be recruited. Several other measures of clinical utility can 
however be assessed. They include assessing inter- and intra-observer variability of decision 
making with and without the novel solution and also assessing the impact this has on resource 
utilization (revascularisation modality, stent length, stent number). Such a measure of clinical 
utility can be demonstrated using relatively few patients, as demonstrated by the iFR pullback 
registry study (utilising data from the multi-national iFR GRADIENT registry)36 . Accordingly, 
we have been able to assess the clinical utility of a correction equation together with a smoothed 
FFR pullback trace. This was done within a randomly selected cohort of 18 serially-diseased 
vessels. The results of this study are presented in the form of a short stand-alone manuscript (yet 





Physiology-guided revascularisation is growing in popularity, with evidence accumulating over 
the last decade to show improved clinical outcomes in patients with epicardial coronary artery 
disease when revascularisation is guided by hyperaemic or resting pressure-derived physiological 
indices4,10,84,100. However, it is unclear whether pressure-derived indices, such as Fractional Flow 
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Reserve (FFR) and Instantaneous Wave-Free Ratio (iFR), can reliably assess individual lesions in 
serial coronary artery disease (CAD) due to the hemodynamic interplay between stenoses86.  
 
Pressure-derived physiological indices are all recognised to be prone to haemodynamic interplay 
between serial stenoses86, however, proponents of resting indices have suggested hyperaemic 
indices, such as FFR, are more prone35. This potential error when using FFR in serial CAD led 
the pioneers of FFR to develop a theoretical solution that involved complex formulae to determine 
the ‘true’ FFR contribution of each stenosis by using measurements of intracoronary pressure at 
various points in the artery following measurement of coronary occlusive pressure after transient 
balloon occlusion27,28,30. The need for transient balloon occlusion prior to committing to a PCI 
strategy has meant the adoption of these formulae is limited in clinical practice.  
 
Due to this unmet need, we have previously developed and validated a correction equation to use 
with routine FFR pullback measurements, without the need to measure coronary occlusive 
pressure101 and have shown a significant reduction in error when estimating the true FFR 
attributable to a stenosis compared to conventional resting and hyperaemic physiological 
methods102. Whilst these in vitro and clinical validation studies have demonstrated a reduction in 
error and stenosis misclassification when using the novel correction equation, a level of 
uncertainty remains regarding the clinical utility of such a solution. In this study we therefore 
assess how the availability of a smoothed FFR pullback trace, together with corrected pressure 





10 separate attending/consultant operators, working at several European sites, were asked to 
submit their strategies after presentation of different physiological information for a selection of 
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18 elective patients presenting for PCI. In all these cases, at least one vessel had serial CAD, as 
defined by 2 stenoses of at least 30% diameter stenosis separated by at least 10mm, where the 
operator would consider treating them separately by PCI 
 
Catheter Laboratory Protocol 
All patients included in the cohort of serial CAD had coronary angiography performed via the 
right radial or femoral artery using a standard Judkins technique. Patients received prior loading 
with 300mg aspirin and 600mg clopidogrel and intra-arterial heparin to maintain an activated 
clotting time greater than 250 seconds. Intra-arterial isosorbide dinitrate (500mcg) was given as 
standard in all radial-access procedures and intra-coronary isosorbide dinitrate (500mcg) was 
administered prior to all pressure wire recordings.    
 
Pressure Wire Pullback Measurements 
Guidewire pressure sensors were normalized in the aorta before being advanced into the distal 
vessel, with the distal wire position documented fluoroscopically. A resting ratio of distal coronary 
to aortic pressure (Pd/Pa) was recorded at this point, following which IV adenosine was 
commenced to ensure steady state hyperaemia (140mcg/kg/minute, onset of hyperaemia 
confirmed using invasive pressure waveform changes88). 
 
Following this, a conventional ‘FFR pullback’ maneuver was performed, whereby the pressure 
wire was pulled back at a fixed rate from distal to proximal through the serially diseased vessel. 
The change in the hyperaemic ratio of Pd/Pa across each stenosis within the serially diseased 
vessel enabled estimation of the attributable FFR of each stenosis (FFRapp). Following these 
measurements, operators were free to manage the patient in keeping with their conventional 




Creating Corrected Smoothed FFR Pullback Information for ‘FFRpred’ 
Raw pressure pullback data (mean Pa and mean Pd during hyperaemia), as presented on standard 
pressure-wire consoles, were plotted using Matlab software (Mathworks Inc.). In order to assure 
the quality of the trace, artefactual data points giving non-physiologically high or low values were 
filtered out and then the trace was plotted using the Smoothing Spline algorithm, which gave a 
polynomial fit output according to an adjustable smoothing parameter. The output was then 
assessed for goodness-of-fit. See figure 9.1 for example of a typical FFR pullback output. 
 
 
Figure 9.1: Summary of Increasing Information Shown to Operators. ‘Angio’: Operators asked 
to submit answers to various questions about the case following information of how the patient 
presented together with angiographic information only. ‘FFRnorm’: Operators asked to submit 
answers following presentation with FFR information as per their conventional practice (FFR in 
the vessel distal +/- conventional beat-beat FFR pullback data. ‘FFRpred’: 
 
Overlying this smoothed FFR pullback curve, we presented the operator with the corrected 
contributions of each stenosis to total vessel FFR (FFRpred). These corrected contributions were 
derived using our recently developed mathematical solution for serial stenosis interplay, which 
involves input variables that are confined to data derived solely from pressure-wire pullback103. 
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This simple and easy-to-use solution assumes a linear relationship between pressure and flow 
across a stenosis so that the hemodynamic equivalent of Ohm’s law can apply, whereby the 
individual resistance of stenoses and the distal circulation stay fixed regardless of other stenoses 
being removed. Under these conditions, we have shown that the theoretical FFR can be reliably 
derived in all configurations of tandem CAD without the need for coronary occlusive pressure, if 
the variability of collateral flow across intermediate stenoses is assumed to be minimal102. 
 
Post Hoc Analysis of Decision Making 
Following the catheter laboratory procedure, 10 operators were shown the following information 
in sequence for each case (Figure 9.1): 
1) ‘Angio’: Operators were asked to submit answers to various questions about the case 
following information of how the patient presented together with angiographic 
information only. 
2) ‘FFRnorm’: Operators were asked to submit answers following presentation with FFR 
information as per their conventional practice. This usually involved presentation of the 
FFR in the vessel distal to the serial stenoses or a presentation of the beat-beat FFR 
pullback data 
3) ‘FFRpred’: Operators were then asked to submit answers after being presented with a 
smoothed FFR pullback trace with corrected contributions of each stenosis to the total 
vessel FFR (FFRpred). 
With this information, operators were asked to assess whether either of the 2 stenoses were 
significant or not (‘yes’, ‘no’, ‘unsure’) and also which of the 2 stenoses were more significant 
(proximal stenosis, 1, or distal stenosis, 2). Operators were then asked about revascularisation 
strategy with each tier of information (Medical Therapy, CABG or PCI). If PCI was planned, 




Statistical analysis was performed using IBM SPSS 24.0 ® for Apple Macintosh ® (SPSS, Inc., 
Chicago, IL, USA).  Continuous data are presented as mean ± SD. Categorical data are presented 
as numbers and percentages and compared using the chi-square test. In order to determine 
agreement in lesion assessment between observers (inter-observer variability), Fleiss Kappa 
coefficients were calculated. This coefficient describes the degree of agreement between the ten 
observers’ decisions over that which would be expected by chance. A value of 0 denoted random 





Eighteen serially diseased vessels were studied, of which 11 were the LAD, 6 involved the LMCA 
and 1 was the RCA. 78% (14) of patients were male with a mean age of 64.7±10.7 years. The 
average QCA diameter stenosis was 64.6±11.2 % and 60.6±8.9%, for proximal and distal stenoses 
respectively. Mean distal cumulative FFR of the vessels was 0.72±0.10. 10 attending/consultant 
operators had their decision-making reviewed when presented with different physiological 
information. All operators worked in high volume tertiary PCI centers and routinely performed 
FFR measurements for intermediate stenosis assessment as per international guidelines104. 4 
operators worked in London (United Kingdom) and 6 in Milan (Italy).  
 
Operators decision on treatment strategy 
Using angiographic information alone (Angio), operators concluded that 5% of vessels should 
receive OMT, 73% PCI and 22% should be treated with CABG. With conventional pressure-wire 
methods (FFRnorm) these proportions changed to 15%, 68% and 17% respectively. When 
presented with the predicted FFR of each stenosis superimposed on a smoothed pullback trace 
(FFRpred), 17%, 68% and 15% were planned for OMT, PCI and CABG respectively. The 
agreement about treatment strategy between operators was found to be 0.39, 0.64 and 0.77 with 
Angio, FFRnorm and FFRpred respectively (p<0.001). 
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Figure 9.2: Categorized scatter plot demonstrating how certain (S = significant, Unsure or NS = 
not significant) each observer felt about the significance of each stenosis when presented with 
angiographic information only (Angio), conventional FFR measurements (FFRnorm) or 
predicted FFR of each stenosis superimposed on a smoothed pullback trace (FFRpred). 
 
Operators decision on lesion significance 
When asked about whether a lesion was significant, 26% were unsure using ‘Angio’ alone. 
Supplementing observers with FFRnorm did not significantly affect their uncertainty (28%). 
However, when presented with FFRpred, operator uncertainty about the significance of a lesion 
fell to 3% of all lesions (p<0.001), figure 9.2.  
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When asked about which of the two serial stenoses (1, proximal stenosis or 2, distal stenosis) was 
most significant, the interobserver variability was significantly reduced when presented with 
FFRpred (k 0.93) versus FFRnorm (k 0.36) or Angio (k 0.35), figure 9.3 and Table 9.1. 
 
 
Figure 9.3: Bar charts demonstrating agreement between operators when asked whether lesion 1 
is most significant 
 
 




(95% CI 0.276 to 0.414) 
0.356 
(95% CI 0.288 to 
0.425) 
0.932 
(95% CI 0.863 to 1.00) 
P Value <0.001 <0.001 <0.001 
Table 9.1. Table demonstrating decreasing inter-observer variability in decision on which lesion 
was most significant, when presented with FFRpred. P values of < 0.05 used to denote that 
agreement is significantly different from what would be achieved by chance. 
 
Operators decision on number and length of stents 
When operators were asked about the number of stents required, the average stent number per 
patient was significantly lower at 1.3±0.5 stents with FFRpred compared to “Angio” alone 
(1.49±0.57, p<0.001) and FFRnorm (1.50±0.57, p<0.001).  Moreover, the interobserver 
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variability between observers’ choices on number of stents to use was significantly reduced when 




Figure 9.4: (A) Bar Charts demonstrating decreased number of stents with FFRpred compared 
to FFRnorm or Angio alone. (B) Bar Charts demonstrating total stent length with FFRpred 
compared to FFRnorm or Angio alone. 
 
When operators where asked about the total length of stent required for treatment of underlying 
CAD, there was a significant difference between groups. On average, observers opted for shorter 
total stent length with FFRpred (29.5±15.2mm) compared to FFRnorm (34.1±14.4mm, p<0.001) 
and “Angio” alone (34.6±14.3, p=0.036), figure 9.4. Moreover, the interobserver variability was 
significantly reduced when presented with FFRpred (k 0.93) versus FFRnorm (k 0.85) or Angio 
(k 0.83), p<0.001.  
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Overall, compared to Angio, FFRpred changed decision-making in 68% of vessels; with a 
reduction in stent length from 34.6±14.2mm to 29.5±15.2mm, p=0.036. In comparison to 






In this study we have demonstrated the clinical utility of a smoothed FFR pullback trace, together 
with corrected pressure gradients for each stenosis and shown how this novel method can alter 
PCI strategy in real-world clinical scenarios of serial CAD. The main findings of our study to 
support clinical utility are:  
1) FFRpred increased the agreement between operators for treatment strategy in cases of 
serial coronary artery disease and reduced heterogeneity in decision making 
2) FFRpred had a significant impact on the adjudication of stenosis severity, with operators 
feeling more certain about whether a stenosis required revascularisation and also which 
stenosis is more significant 
3) FFRpred resulted in significantly less stent implantation with a significant reduction in 
mean stent length and number 
 
We have previously demonstrated that applying this correction equation (FFRpred) to routine FFR 
pullback data reduces the error in estimating the true FFR contribution of individual lesions and 
associated misclassification according to an FFR 0.80 threshold for revascularisation101. We have 
also shown a reduction in relative error and misclassification in comparison to resting 
physiological indices of iFR and resting Pd/Pa102. Despite the demonstration of a reduction in error 
both within our in vitro model and in clinical cases of tandem disease, there remained some doubt 
regarding whether this would translate to impacting routine clinical decision making. Our study 
therefore makes a significant advance to previous work done, by showing significant clinical 
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utility through reduced ambiguity and increased operator confidence across 10 separate attending 
operators that were previously naïve to the development of the novel correction method. 
 
This novel solution requires smoothing of conventional FFR pullback data together with 
incorporation of the correction equation to allow the identification of the true FFR contribution of 
each stenosis before PCI (figure 9.1). Importantly, for clinical application in PCI planning, FFR 
pullback can be rapidly performed in nearly all Cardiac Catheter Laboratories and requires no 
additional hardware. This is important as an element of serial/diffuse CAD is thought to exist in 
over 25% of all CAD5,6, meaning the utilisation of such a novel solution should be widespread 
and easy to adopt. Our FFR pullback-based solution allows the pressure tracing itself to identify 
the lesions with the greatest influence upon flow impairment, without the need to adopt a new 
physiological index, use new hardware or measure coronary occlusive pressures. An update to 
existing pressure-wire consoles would be sufficient to incorporate this solution by displaying a 
smoothed Pd/Pa pullback curve together with the true FFR contribution of a given stent location 
and the residual FFR in the vessel, were the rest of the disease left alone. Such an update has been 
trialled on the CoroFlow Coroventis platform. Example of clinical utilisation in a case of serial 
CAD is shown in figure 9.5. 
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Figure 9.5: Example screenshot from FFR measurement system incorporating delta FFR 
assessment and calculation of estimated Post PCI FFR result based on localization of distal and 
proximal stent markers. (CoroFlow, Coroventis Research AB) 
 
This is an important improvement in FFR-methodology, which is likely to enable wider and more 
accurate adoption of FFR for complex CAD with serial/diffuse disease. Whilst previous iterations 
of our work have demonstrated a reduction in error versus conventional indices (both resting and 
hyperaemic), our study goes on to describe significant clinical utility of an even greater magnitude 
than that described from the iFR gradient registry of iFR pullback in serial CAD105. The novel 
method now needs prospective assessment to see if it improves clinical outcomes and resource 




In patients with CAD, hemodynamic interplay between serial lesions is a source of error and 
stenosis misclassification. Our study shows the clinical utility of a novel method to correct routine 
FFR pullback outputs by demonstrating increased operator certainty regarding revascularisation 
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10.1 Summary of Findings 
 
In this thesis I have described the following principle findings: 
 
i) Physiological assessment of serial CAD is prone to significant error, mostly in the form 
of lesion underestimation, regardless of whether there is a more distal or proximal 
accompanying stenosis. The extent of this underestimation is proportional to the cumulative 
burden of disease within the vessel (and therefore inversely proportional to total vessel FFR). 
 
ii) Using an in vitro 3-D printed model of coronary circulation and serial disease, I have 
shown that total vessel FFR and the change in pressure across a stenosis are the factors which 
most strongly influence the degree of stenosis interplay during physiological assessment by 
FFR. Based on these findings, and assuming serial stenoses behave as resistors in series (an 
assumption we go on to validate in vivo), an easy-to-use mathematical correction equation was 
created, that significantly reduces this error. 
 
iii) All invasive pressure-derived indices of stenosis severity are prone to significant error in 
serial CAD. Whilst we found the absolute error is smaller with resting indices such as iFR and 
resting Pd/Pa, the misclassification of stenoses due to serial disease interplay was similar, owing 
to the lower spatial resolution at which these resting indices operate. 
 
iv) Using resistance measurements from simultaneous pressure and Doppler flow 
measurements, we have demonstrated that serial stenoses behave as resistors in series, with the 
haemodynamic equivalent of Ohm’s Law applicable. Whilst the analogy is imperfect, we have 
demonstrated that Hyperaemic Stenosis Resistance (hSR) is less prone to the errors and stenosis 
misclassification seen with conventional pressure-based physiological indices. Widespread 
utilisation of hSR will however remain limited due to the complexities and variability in making 
intracoronary Doppler measurements. 
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v) Our mathematical correction model, to use with routine hyperaemic pressure-wire 
pullback measurements, significantly reduces the error of pressure-wire based assessment in 
serial CAD, to a similar accuracy as the Doppler-derived hSR. 
 
vi) We show that using this novel solution, together with a smoothed Pd/Pa pullback trace 
during hyperaemia, results in increased operator certainty regarding revascularisation and PCI 
strategy, together with a significant increase in agreement between interventional cardiologists 
regarding the physiological assessment of individual stenoses. This solution is being 
incorporated onto a pressure-wire platform (CoroFlow, Coroventis AB) that will enable clinical 
implementation and further studies. 
 
vii) FFRCT provides a reliable estimation of the values that would be obtained from routine 
invasive pressure-wire pullback. In keeping with this, unadjusted trans-lesional FFRCT gradients 
are prone to a similar degree of significant serial stenosis underestimation. I subsequently provide 
validation for a novel non-invasive FFRCT-derived PCI planning tool (FFRCT-P) and show it to 
significantly reduce the error of contemporary methods in estimating true stenosis significance 
within serially diseased vessels (assessed following PCI of the accompanying stenosis). CT/CFD 
derived estimations of hSR are however still too inaccurate in their present form to provide a 










10.2 Proposed Algorithm 
 
Based on the findings of our catheter laboratory study, the following algorithm (Figure 10.1) can 
be suggested as a potential interim solution to reduce the error in physiological assessment of 
serial CAD within the catheter laboratory. 
 
 
Figure 10.1: Algorithm summarising the findings of this thesis 
*Denotes that this part of the recommended algorithm is based on work by Fearon et al44 and is 
only valid if total vessel FFR of serially diseased branch is >0.45 
 
 
This proposed algorithm is, however, only really appropriate to an academic institute, such as 
our own, that has access to and experience in using the combined pressure-Doppler based 
guidewires. A truly clinically useful algorithm would be based on simply the use of either a 
pressure-based physiological index, such as that demonstrated with our theoretically-derived 
correction equation (FFRpred), or one that allows accurate non-invasive prediction of residual 
stenosis significance after PCI, such as that demonstrated in our validation of the encouraging 






















become established and fully implemented, the catheter laboratory algorithm described in figure 
10.1 is a reasonable, albeit imperfect, strategy for now. 
 
 
10.3 Resting Versus Hyperaemic Indices? 
 
 
Despite the wealth of guidelines and evidence supporting FFR-guided revascularisation, less 
than 10% of eligible cases have FFR assessment106. This has led many to question whether the 
need for adenosine-induced hyperaemia is a hindrance, with resting invasive indices, particular 
iFR, growing in popularity.  
 
Some have suggested the resting index of iFR is more cost-effective (often citing the saving on 
the cost of adenosine), results in shorter procedure times and is less uncomfortable for the 
patient107. Based on this, proponents of the resting physiological indices have just had to argue 
the case for ‘non-inferiority’ in outcomes versus FFR-guided revascularisation with some recent 
trial data for iFR-guided revascularisation supportive of this standpoint11,12. In parallel to the 
evidence supporting iFR, data is growing to suggest that the resting ratio of Pd/Pa is almost 
identical to iFR16,17 and therefore a Pd/Pa revascularisation versus FFR guided revascularisation 
trial may also yield non-inferior results. This is despite ongoing debate regarding whether 
resting indices provide the same information about stenosis severity as FFR, with studies such as 
our own Thresholds study (see Appendix) suggesting there may be a difference between resting 
and hyperemic indices. Whether or not this is the case, it is clear that we are experiencing a 
rebirth of resting physiological indices and novel indices such as iFR are only driving the 
amount of physiologically-guided revascularisation we are performing, regardless of the 
modality.  
 
One of the few areas where resting indices have claimed ‘superiority’ (not just ‘non inferiority’),  
over hyperaemic assessment, is in the assessment of serial CAD. This has been predominately 
driven by small studies showing a relatively small difference between expected iFR and 
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observed iFR from a straightforward iFR pullback manoeuvre35. Following this, in recent 
months a clinical utility study of iFR pullback has been published that lends support its clinical 
utility36. Despite this, prior to this thesis, there still lacked evidence to support this claim of 
‘superiority’ of resting indices versus hyperaemic resting indices in physiological assessment of 
serial CAD. 
 
Our study represents the first study to compare how various invasive physiological indices 
compare against each other in the assessment of serial CAD. We show that despite a small 
reduction in the error with resting indices, the overall message is that all pressure-derived 
physiological invasive indices are prone to significant errors. Whilst there may be some 
theoretical reduction in serial stenosis interplay in the resting state because of intact auto-
regulatory mechanisms, this is counter-balanced by the fact that iFR and PdPa operate at a lower 
spatial resolution (each stenosis is associated with a smaller pressure gradient at rest) and 
therefore any errors are amplified. 
 
 
10.4 Future Directions 
 
 
When it comes to physiological assessment of serial CAD, there are several areas of 
development that will affect future directions when it comes to the clinical implementation of an 
optimal solution. These are areas I hope to continue being involved with whilst completing my 
clinical training: 
 
i) Physiological-Anatomical Co-registration: Whichever physiological index is used, one of 
the major unmet needs is being able to marry the pullback trace to the angiogram. Recently, 
there has therefore been an increasing drive to co-register physiological data with anatomy, with 




Figure 10.2: Example of physiological coregistration with the coronary angiogram. An 
instantaneous wave-free ratio (iFR) pullback was performed, and using a commercially 
available system (SyncVision, Philips), the pullback is coregistered on the coronary 
angiogram. Each yellow dot represents a change in iFR of 0.01, with the graphic pullback 
depicted on the right of the figure. The distal iFR at the cursor point is 0.49. The cursor can 
be moved to assess the iFR at any point along the pullback, allowing the operator to assess 
the drop in iFR across serial stenoses. (Taken from Modi et al, JAMA Card 201892) 
 
Regardless of whether or not our novel solution (figure 9.5) grows in popularity, any 
physiological PCI planning tool will ultimately need to be incorporated into such a co-
registration solution, such as the one being developed by Philips Volcano. One of the leading 
vendors of FFR (Abbott) has recently developed co-registration capabilities using Optical 
Coherence Tomography (OCT), rather than overlaying physiological information onto the 
angiogram. Adding intravascular imaging and ‘true’ physiological data to an angiogram would 
represent the ultimate solution and not only inform us whether to treat a stenosis but exactly how 
(stent length, diameter etc). 
 
ii) Computational Fluid Dynamics and Non-Invasive Estimations of FFR: 
Despite the growing evidence supporting physiology-guided management of stable CAD, it is 
used in only a fraction of eligible patients 106. Some of the reasons cited include perceived 
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risk/burden to the patient, increased procedural cost and increased procedural time. In addition, 
as described in chapter 8, evidence suggests over 50% of patients referred for invasive coronary 
angiography have no significant disease61. As a result, there has been a quest for establishing 
non-invasive estimations of FFR either from upstream imaging modalities (e.g. FFRCT) or 
recently in the form of deriving FFR exclusively from diagnostic angiography (e.g. Quantitative 
Flow Ratio, QFR 108 109).  
 
These solutions, as described earlier, rely on principles of CFD being used in combination with 
knowledge of precise lesion geometry. Such methods may have an inherent benefit in the 
assessment of the true significance of individual stenoses within a serially diseased vessel, as 
demonstrated by the development of the FFRCT interactive PCI planning tool (FFRCT-P), Chapter 
8.1. The results of our study suggest using methods, such as the FFRCT-P tool, can aid more 
accurate prediction of true stenosis significance of individual stenosis in serial CAD compared 
to contemporary pressure-wire pullback and conventional FFRCT outputs. Further studies are 
necessary in a larger number of patients to demonstrate the clinical utility of this non-invasive 
index. If clinical utility is demonstrated, this tool can be used in all patients to plan PCI and can 
even be displayed on monitors within catheter laboratories when choosing whether to stent a 
stenosis, stent position and stent length. 
 
iii) More Stringent Thresholds to Define Ischaemia and Significant Stable CAD:  
Growing evidence suggests the benefits of revascularisation seem to be greatest in those with a 
high burden of ischaemia7,110. At the same time, the last decade has seen mounting evidence to 
suggest medically managed stable CAD is associated with a good prognosis and more modest 
symptomatic benefit than originally envisaged. As a result, there is now a growing question 
about whether the physiological thresholds we use to guide revascularisation are suboptimal. We 
address this issue in appendix A: ‘Revisiting the Optimal FFR and iFR Thresholds for Detecting 
Significant Coronary Artery Disease’. While the findings of this additional study don’t change 
the findings of this thesis, it may mean fewer lesions (based on their ‘true’ FFR/iFR) may be 
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appropriate for revascularisation. Rightly or wrongly, this may mean less of a tendency to 
revascularise stable CAD, regardless of physiology. 
 
iv) Physiological Assessment of LMCA Disease: As described in section 5.5, the issue of 
downstream serial disease if one of the major reasons why LMCA disease has been largely 
excluded from trials of physiology-guided revascularisation. The problem of stenosis 
underestimation with serial disease may mean misclassifying a potentially significant LMCA 
stenosis when it is actually significant. 
 
Whilst the proposed algorithm described in section 5.6 is of value where there is a disease free 
daughter vessel, LMCA disease is commonly found with downstream serial disease in both main 
branches. The findings of this thesis will enable operators to feel more confident about assessing 
the true physiological significance of LMCA disease, regardless of whether there is 
accompanying disease present in downstream vessels. This will hopefully pave the way to doing 
a trial of physiology-guided revascularisation that finally includes LMCA disease in sufficient 
numbers to form a meaningful conclusion.  
 
 




Physiological assessment and ischaemia testing have long been plagued by the lack of a ‘gold 
standard’ against which to compare. FFR and hSR were validated against non-invasive tests8, 
iFR against FFR73 and now we have come full-circle with non-invasive tests being validated 
against FFR111. The lack of reference standard means the thresholds used for these indices is 
also debated (see our study in appendix A). 
 
Establishing a gold standard of physiologically assessing the significance of an individual lesion 
is similarly challenging. In this thesis, I have shown within the wet laboratory in vitro 
experiments, that lesion isolation is possible by replacing a serially diseased 3D printed phantom 
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with the corresponding discretely 3D printed phantom - providing us with a ‘gold’ reference 
standard against which to assess apparent FFR and corrected FFR. Using the results of this work 
we were also able to create a solution and establish some basic principles. 
 
Comparing various physiological indices and the correction equation in the catheter laboratory 
against a ‘reference standard’ is however more of a challenge. The two methods used to isolate a 
lesion (both methods were used in chapter 7) are described below, together with their strengths 
and flaws:  
 
i) Measurements of apparent and true lesion significance can be made within the serially 
diseased vessel before and after PCI of an accompanying stenosis. This method reflects the 
question many clinicians want answering: once I perform PCI of stenosis ‘X’, what will be 
significance of stenosis ‘Y’? Wherever possible, this method of stenosis isolation was used as 
the reference ‘gold standard’. However, the validity of physiological indices and the dynamic 
state of microvasculature immediately post PCI is occasionally questioned with limited data to 
verify post PCI physiological measurements. The validity of post-PCI physiological 
measurements is certainly an area that needs further validation work in the future. 
 
ii) In the case of a large serially diseased vessel with a disease free branch vessel between 
the serial stenoses, this disease-free branch can be used to isolate the true significance of the 
proximal stenosis. Whilst this method has theoretical flaws, based on the inconsistent volume of 
subtended myocardium, previous data suggests it is reliable method of assessing the ∆FFRtrue of 
the LMCA stenosis. This method was initially validated in animal studies41,45,46. Fearon et al then 
demonstrated this in a clinical study of 91 LMCA lesions following PCI of the LAD, LCx, or 
both. FFR was measured in the LAD and LCx before and after creation of downstream stenoses 
using balloons within newly placed stents and measuring FFR in the disease-free vessel. They 
then compared the true LMCA FFR measured in the disease-free vessel to the apparent FFR 
measured in the stenosed vessel and found the numerical difference was not deemed clinically 
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significant. They concluded that in most cases, downstream disease does not significantly 
impact LMCA FFR when the pressure wire is positioned in the disease-free vessel and using a 
disease-free daughter vessel provides a fairly accurate assessment of the true significance of the 
proximal (LMCA) stenosis44. 
 
Whilst both these methods of isolating the true significance of a stenosis in vivo have potential 
flaws, they both represent the best available reference standard against which to compare 








In this thesis, we have shown that physiological assessment of stenoses in the presence of serial 
CAD is prone to significant underestimation, proportional to the cumulative burden of disease 
within the vessel. All pressure-derived physiological indices, resting and hyperaemic, are prone 
to error and stenosis misclassification. Doppler-based resistance indices are less prone to this 
error but utilisation is limited by difficulties in obtaining Doppler traces. The finding that serial 
stenoses generally behave as resistors in series does however support the use an FFR correction 
equation, derived using our 3D-printed in vitro study, that does not require measurement of 
coronary occlusive pressure. Applying such a correction equation to routine pressure wire 
pullback measurements significantly reduces the error in estimating true stenosis significance 
and we have shown it to have significant clinical utility. 
 
In this thesis I also describe the development and validation of a new non-invasive technique to 
optimise the physiological assessment of serial CAD. This non-invasive  FFRCT-derived PCI 
planning tool can aid more accurate prediction of true stenosis significance in serial CAD, in 
comparison to contemporary invasive and non-invasive methods.  
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The next step will be to establish multi-centre clinical utility studies of these novel invasive and 
non-invasive physiological methods. Eventually, the solutions will need to be co-registered with 
coronary anatomy and tested in the important scenario of LMCA disease, which is frequently 









































































APPENDIX A: REFINING THE ASSESSMENT OF 
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A1: COMPARING THE DIAGNOSTIC ACCURACY OF FFR AND IFR: IS 
IT TIME TO CHANGE TREATMENT THRESHOLDS?  
 
Abstract  
Background: Fractional Flow Reserve (FFR) and Instantaneous Wave-Free Ratio (iFR) are the 
most widely used invasive tests to guide management of stable coronary artery disease (CAD). 
There has been a gradual ‘upward creep’ of revascularisation thresholds for both FFR and iFR, 
compared to initially established thresholds. The resulting increase in revascularisation is at odds 
with increasing evidence of the lack of prognostic benefit of revascularisation in stable CAD. 
Objectives: Using an independent invasive reference standard, this study aimed to a) define the 
optimal diagnostic thresholds for FFR and iFR and b) to compare the performance of iFR, FFR 
and resting Pd/Pa at detecting functionally significant coronary disease. Methods: Distal 
coronary (Pd) and aortic pressure (Pa) were measured in 75 patients undergoing coronary 
angiography +/- PCI with resting Pd/Pa, iFR and FFR calculated as previously described. 
Doppler flow velocity was simultaneously measured and hyperaemic stenosis resistance 
calculated as hSR=Pa-Pd/APV (where APV=average peak velocity). hSR >0.80mmHg.cm-1.s 
was used as an invasive reference standard for stenosis significance. Results: An FFR threshold 
of 0.75 had the best diagnostic accuracy (84%) whereas for iFR the optimum threshold was 0.86 
(76% accuracy). At these thresholds, the discordance in classification between indices was 11%. 
The accuracy of contemporary thresholds (0.80 for FFR and 0.89 for iFR) was significantly 
lower (78.7% and 65.3% respectively for FFR and iFR) with a 25% rate of discordance between 
indices. The optimal threshold for Pd/Pa was 0.88, which gave an accuracy of 77.3%. When 
comparing the 3 indices at their optimal thresholds, FFR had the best diagnostic performance 
(area under the curve 0.91 FFR vs. 0.79 iFR and 0.77 Pd/Pa, p=0.002).  
Conclusions: Contemporary FFR and iFR thresholds provide suboptimal diagnostic accuracy 
compared to a FFR threshold of 0.75 and an iFR threshold of 0.86 , which are also the thresholds 
in the original derivation studies. Whether the use of the more rigorous thresholds would result 
in selection of a population gaining greater symptom and prognostic benefit needs assessing in 
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future trials of physiology-guided revascularisation. 
 
Condensed Abstract: 
In recent times, there is growing acknowledgement that revascularisation for stable CAD should 
be restricted to patients with functionally significant CAD. FFR and iFR, which have become 
cornerstones of determining functional significance, have seen an ‘upward creep’ in thresholds 
over the last 2 decades, with subsequently more revascularisation. In this study, we have 
determined the optimal threshold for each index, using an independent physiological reference 
standard, to show that contemporary thresholds may have suboptimal diagnostic accuracy to 
those originally described. 
 
Introduction 
The benefit of revascularisation in stable coronary artery disease (CAD) is a contentious issue, 
with mounting evidence suggesting that patients on optimal medical therapy alone have an 
excellent prognosis with significantly improved symptoms, as suggested by the COURAGE 
trial112 and recently the Sham-controlled ORBITA trial113. On the other hand, we have evidence 
suggesting physiology-guided revascularisation, whether it be in the form of Fractional Flow 
Reserve (FFR)3,4,74 or Instantaneous Wave Free Ratio (iFR)11,12, is associated with significantly 
improved symptoms and patient outcomes, compared to revascularisation based on angiographic 
appearances alone. The benefits of revascularisation seem to be greatest in those with a high 
burden of ischaemia7,110. 
The initial derivation studies of FFR were performed against a combination of non-invasive tests 
including SPECT and stress echocardiography and showed an optimum threshold of 0.758,74. 
Following this, subsequent evidence of improved clinical outcomes (driven by a reduction in 
repeat or urgent revascularisation) was demonstrated in the FAME and FAME 2 trials 3,4, using 
the higher threshold of FFR≤0.80, to provide clinicians with the “safety net” of improved 
negative predictive value. FFR≤0.80 has gained such wide acceptance as the dichotomous 
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threshold to detect significant coronary disease that many novel physiological indices, including 
some non-invasive measures111, have been validated against it. The invasive physiological index 
of iFR was also originally derived and validated against an FFR≤0.80 threshold. The ADVISE 
and CLARIFY studies suggested that iFR thresholds of 0.83 and 0.86 provided optimal 
agreement with the FFR threshold of 0.8. Subsequent studies demonstrated discordance of up to 
40% between FFR and iFR16, and an iFR grey-zone of 0.86-0.93 was suggested, whereby cases 
in this range subsequently have FFR-guided management, with an improvement in concordance 
with FFR114.  A drive for a discrete threshold led to further analyses of discordance15,115 and 
eventual adoption of a higher iFR threshold of ≤0.89. Management of stable CAD using 
FFR≤0.80 or iFR≤0.89 has been shown to result in equivalent outcomes in recent trials in 
patients who generally have a good prognosis11,12. Whether the loss of specificity inherent in this 
‘upward creep’ of the diagnostic FFR and iFR thresholds results in patients being 
inappropriately revascularised, in the absence of a substrate for ischaemia, remains unclear.  
This ‘upward creep’ in thresholds has resulted in a ‘physiological greyzone’ between the FFR 
0.75 and 0.8 thresholds. Recent data from the IRIS-FFR registry by Kang et al has suggested 
coronary revascularisation of greyzone-FFR cases is not associated with improved outcomes116. 
This ‘greyzone’ has also existed for iFR, (0.86 - 0.93) with a hybrid iFR-FFR guided strategy  
sometimes used to resolve the uncertainty114. However, recent randomized trials have used a 
single rule-in and rule-out iFR threshold of 0.8911,12.  
This study aimed to assess the optimal diagnostic thresholds for these invasive physiological 
indices against an independent reference standard and in doing so, sought to also compare the 
diagnostic accuracy of these indices at both the contemporary and optimal thresholds. In the 
absence of a true ischaemic gold standard, several noninvasive imaging methods have 
previously been used to further evaluate invasive physiological methods, with the major hurdle 
being these methods only isolate ischaemia in a myocardial territory rather than a specific 
vessel. In this study we therefore used Hyperaemic Stenosis Resistance (hSR) as an invasive 
reference standard of physiological significance. hSR is an invasive index calculated by 
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measurement of both intra-coronary pressure and Doppler flow velocity and so overcomes many 
of the limitations of flow-only and pressure-only based indices 21,42,99. It is recognized as being 
more stenosis specific, having previously been used as an invasive reference standard to 
compare pressure-derived indices, for example in the CLARIFY study87. It is considered to be 




Patients who were scheduled to undergo coronary angiography with a view to proceeding to PCI 
for suspected or confirmed stable ischaemic heart disease were eligible for inclusion. Exclusion 
criteria were significant valvular heart disease, an unstable coronary presentation (myocardial in 
the prior 4 weeks or CCS IV angina), coronary disease that was not suitable for instrumentation 
(as below), previous CABG and contraindications to pharmacological hyperaemia with 
adenosine.  Study protocols were approved by the UK national research ethics committee and all 
patients provided written consent. 
 
Cardiac Catheterization 
Dual antiplatelet therapy was initiated in all participants prior to the procedure. Procedures were 
performed via the right radial artery or right femoral artery using 5 or 6Fr guiding catheters.  
Bolus unfractionated heparin was administered to maintain an activated clotting time >250 
seconds. Following diagnostic coronary angiography intracoronary nitroglycerin was 
administered and a 0.014” dual pressure-Doppler sensor guide wire (ComboWire, Volcano-
Philips, California) was calibrated to aortic pressure  and the tip delivered to the distal epicardial 
vessel.  Aortic pressure was measured via the fluid-filled guide catheter. The Doppler signal was 
optimized and recording commenced. Hyperaemia was achieved using an intravenous (IV) 
infusion (dose 140mcg/kg/min) or intracoronary (IC) boluses (dose 60mcg repeated three times) 
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89. After completion of the infusion or each intracoronary bolus, we waited for baseline 
hemodynamic parameters (Heart Rate, Blood Pressure and Doppler Flow velocity) to return to 
baseline before the next measurement. Offline calculation was subsequently performed of 
Resting Pd/Pa, FFR, iFR, and hSR using Cardiac Waves Software (Kings College London, 
London, United Kingdom). Coronary angioplasty was then performed if indicated. 
 
Data Recording and Analysis 
Pressure data:  For Pd/Pa and iFR, the lowest 5 beat average obtained was recorded with all 
analyses performed in a fully automated manner without manual selection of data time points. 
iFR was calculated using the method descried by Sen et al73, using dedicated MATLAB 
software (CardiacWaves, King’s College London, London, UK), with data showing good 
agreement with proprietary software19,117. For FFR, the value recorded during an IV adenosine 
infusion was the lower 5 beat average, as per the ‘smart minimum’ method47.  Where IC 
adenosine was used, the lowest of 3 beat average reading was taken. 
Pressure/Doppler data: Peak coronary flow velocity, distal coronary pressure (Pd) and central 
aortic pressure (Pa) were ECG-gated and recorded continuously at a sampling frequency of 
200Hz and data exported into a custom-made StudyManager program (Academic Medical 
Center, University of Amsterdam, Netherlands). The raw data was transferred to optical media 
and hSR calculated using the dedicated MATLAB software (CardiacWaves, King’s College 
London, London, UK). In order to account for beat-to-beat variability and reduce the effect of 
noise, signals were ensemble averaged over five consecutive cardiac cycles during stable 
hyperaemia. Premature ectopic beats and the beat preceding were excluded from analysis. hSR 
was calculated as Pa-Pd/APV, with APV being average peak coronary flow velocity. Significant 




All data are expressed as medians [1st quartile; 3rd quartile] or means (standard deviation) for 
continuous variables (compared using a t-test or ANOVA for continuous normal distributed 
variables, and Kruskal-Wallis test if continuous non-normal distributed); categorical variables 
are expressed as absolute and relative frequencies (compared using a Pearson chi-square test). 
Hypothesis testing was two-tailed and p values <0.05 were considered statistically significant. 
 
Diagnostic accuracy was quantified by the area under receiver-operating curve (AUC (95% 
confidence interval) against hSR≥0.8). Bootstrapping was used to calculate Confidence Intervals 
(CI), using 1,000 stratified bootstrap replicates, to compare the AUC between indices and 
calculate the classification function. Diagnostic accuracy was calculated as Σ True positive + Σ 
True negative / Σ Total population for each threshold. Correlation was assessed with Pearsons’s 
R and adjusted R2 by fitting a linear regression model. All statistical analyses were performed 
using R, version 3.4.3 GUI 1.70 (The R Foundation for Statistical Computing), using packages 





Following exclusion of 6 cases due to poor Doppler flow signals, 75 patients, were included in 
the study with baseline demographics summarized in Table 1. Mean age was 62 with 56 % male. 
One vessel was studied per patient, where FFR was 0.78 +/- 0.12 and iFR was 0.85 +/- 0.10.  
 
The median (interquartile range) of FFR, iFR and Pd/Pa in our study population was 0.8 (0.72-
0.87), 0.89 (0.82-0.92) and 0.92 (0.88-0.94) respectively. 80% of cases included in the analysis 
were in the diagnostically challenging range between FFR 0.6 – 0.9. Scatter plots of the 
correlation between FFR vs. iFR and PdPa vs. iFR are shown in Figure 1. The Pearson’s 

















Table: Summary of Patient Demographics 
 
 
Mean Age (years) [IQR] 62 [53;70] 
Gender, n (%): Male  42 (56%)  
Hypertension, n (%)  45 (60%)  
Hyperlipidemia, n (%)  53 (71%)  
Diabetes mellitus, n (%)  23 (31%)  
Smoking, n (%)  20 (27%)  
Previous PCI, n (%)  22 (29%)  
Interrogated vessel, n (%):            
   Left Anterior Descending, LAD  63 (84%)  
   Circumflex, LCx   3 (4%)   
   Right Coronary Artery, RCA  8 (11%)   
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Figure 1: Scatterplots of PdPa versus iFR and FFR versus iFR. Top: Scatterplot of iFR versus 
PdPa. Grey shaded area represents 95% confidence interval of trend line. Pearson’s R value 
0.94, R2 0.88 (P<0.05). Bottom: Scatterplot of FFR versus iFR. Grey shaded area represents 
95% confidence interval of trend line. Pearson’s R value 0.76, R2 0.58 (P<0.05). 
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Diagnostic Performance of Invasive Resting and Hyperaemic Indices 
 
Receiver Operator Curves (ROC) for the performance of iFR, FFR and Pd/Pa in detecting a hSR 
value ≥ 0.8 are shown in Figure 2. FFR had the best diagnostic accuracy (p=0.002 for 
comparison of AUC of FFR versus iFR and Pd/Pa). The AUC to predict hSR≥0.8 was 0.92 
(95% CI 0.84-0.87), 0.79 (95% CI 0.66-0.90) and 0.78 (95% CI 0.64 – 0.9) for FFR, iFR and 
Resting Pd/Pa respectively. 
 
 
Figure 2: ROC curves for FFR, iFR and PdPa with comparison made against hSR>0.8 to 
identify ischaemia. AUC for FFR 0.92 (0.85-0.97 95% CI), iFR 0.79 (0.67-0.89 95% CI) and 
PdPa 0.77 (0.65-0.89 95% CI). FFR AUC was significantly different (P=0.003) compared to iFR 




Figure 3: Charts Showing Diagnostic Accuracy of Varying FFR and iFR Thresholds. Graphs 
comparing diagnostic accuracy of varying thresholds of FFR (Top) and iFR (Bottom). Greyed 
area represents 95% confidence interval. Blue Line represents the optimal threshold identified in 
this study versus an invasive reference standard. Red line identifies the contemporary threshold 
used for each index in current clinical practice. 
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Sensitivity, specificity, NPV, and PPV for the contemporary FFR threshold (≤0.80) were 89.3%, 
73.5%, 92.5% and 65.7% respectively, with an overall diagnostic accuracy of 78.7%. Peak 
diagnostic accuracy was found at FFR thresholds of 0.75 - 0.76 (diagnostic accuracy 84%). 
Sensitivity, specificity, NPV, and PPV for the contemporary iFR threshold (≤0.89) were 78.3%, 
58%, 82.9% and 51.2% respectively, with an overall diagnostic accuracy of 65.3%. Peak 
diagnostic accuracy was found at iFR thresholds of 0.85 - 0.86 (76%). Peak diagnostic accuracy 
for resting Pd/Pa was found at a threshold of 0.88 (55.6% Sensitivity, 89.8% specificity, 78.7% 
NPV, 76% PPV and an overall diagnostic accuracy of 77.3%). A graphical representation of the 
diagnostic accuracy of different thresholds of FFR and iFR is shown in Figure 3. 
 
Using contemporary thresholds, there was discordance between FFR and iFR in 25.3% of cases 
with an equal number of cases where FFR +ve / iFR –ve  and iFR +ve / FFR –ve. There was no 
significant difference (p>0.05) in baseline characteristics or coronary flow reserve (CFR) 
between these discordant groups. When adopting the optimal iFR and FFR thresholds from this 




The main findings of this study are:  
1) The optimal diagnostic thresholds for FFR and iFR were found to be 0.75 and 0.86 
respectively, which are in keeping with the thresholds identified when each index was 
originally derived. These thresholds provide superior diagnostic accuracy than 
contemporary thresholds for FFR (≤0.80) and iFR (≤0.89). 
2) The hyperaemic index FFR provides superior diagnostic accuracy to the resting indices, 
iFR and Pd/Pa, whilst the diagnostic accuracies of the latter are comparable. 
 
Our results suggest that contemporary iFR (0.89) and FFR (0.80) thresholds provide suboptimal 
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diagnostic performance compared to the original thresholds from derivation studies. With 
evidence to suggest the benefits of revascularizing stable CAD may not be as significant as 
originally anticipated and many questioning the role of PCI in stable CAD113, the ‘safety net’ of 
adopting higher thresholds with higher NPVs in exchange for lower overall diagnostic accuracy 
may be unjustified, particularly given the low event rate often seen in large trials of stable 
CAD3,4,11,12. 
Adopting more rigorous thresholds means more targeted revascularisation of those patients with 
a greater burden of ischaemia: with significant evidence existing to suggest greater clinical 
benefit and the recent ACC/AHA Appropriate Use Criteria recognizing patients with a greater 
burden of ischaemia are higher risk and more likely to benefit from revascularisation104. The 
Hachamovitch et al cohort study of over 10,000 patients showed revascularisation compared 
with medical therapy had greater survival benefit (absolute and relative) in patients with 
moderate to large amounts of inducible ischaemia7 and this evidence was supported by the 
nuclear sub-study of COURAGE, demonstrating that patients with a ≥5% reduction of ischaemia 
on MPS had better outcomes from revascularisation compared to medical therapy118. In addition, 
in recent years, meta-analysis of FFR data has suggested lesions with lower FFR values receive 
larger absolute benefits from revascularisation119, with the analysis suggesting that an FFR as 
low as 0.67 provides optimal benefit for a composite of death, MI, and revascularisation. The 
definitive evidence that revascularizing patients with greater ischaemic burden yields greater 
patient benefit will come in the form of the ongoing ISCHAEMIA trial (NCT01471522). Until 
this trial reports, there exists substantial observational data to suggest patients with the greatest 
ischaemic burden are likely to experience most benefit from revascularisation and therefore the 
more rigorous iFR and FFR thresholds that this study supports, may well translate into improved 
clinical outcomes.  
Whilst our study is not the first to demonstrate significant discordance between FFR and iFR, it 
is the first to do so for modern thresholds using an invasive reference standard for ischaemia 
resulting from epicardial CAD. Very few studies have correlated iFR and FFR versus an 
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independent reference standard. Petraco et al used coronary flow reserve (CFR) as an 
independent reference to show that an iFR threshold of 0.9 had better diagnostic discrimination 
than an FFR of 0.8 (iFR AUC 0.82; FFR AUC 0.72; p <0.001)120. Using CFR as a gold standard 
for invasive physiological measures of epicardial coronary disease may be significantly 
confounded by variability in microvascular function. Hwang et al have used PET Relative Flow 
Reserve to show no significant difference in AUC between iFR and FFR (iFR AUC 0.77; FFR 
AUC 0.83; P=0.05) but with FFR showing better discriminatory ability when compared to an 
iFR threshold of 0.9121, in keeping with the findings of our study.  Sen et al previously also used 
hSR, to show similar diagnostic performance of iFR and FFR in 51 patients (iFR AUC 0.93; 
FFR AUC 0.96; P=0.48), although this study included patients with a milder spectrum of 
disease; less than 2/3rd were within the diagnostically challenging range 0.60-0.9087. In 
comparison to these studies we present the largest cohort (n=75) in which an invasive reference 
standard for ischaemia has been applied21,42 with 80% of patients in our study within the 
diagnostically uncertain FFR range between 0.6 and 0.9.   
 
The implications of this work are wide-ranging, including the suggestion that clinicians should 
consider the original and more stringent thresholds in future studies of both FFR and iFR. This is 
further supported by the recent data by Kang et al suggesting PCI of greyzone-FFR cases do not 
derive net clinical benefit116. If future trials for physiology-guided revascularisation did use 
more stringent thresholds, this would mean revascularisation is reserved for a higher risk cohort 
which may yield greater benefit than the surprisingly modest outcomes and weak symptom 
benefit suggested by some recent trials of PCI for stable CAD112,113.  
 
Study Limitations 
We recognize there is currently no gold standard ischaemia test, and this is reflected by the fact 
previous studies have used PET, CFR and hSR as a reference standard, without consensus. We 
used hSR, as this the most theoretically robust invasive vessel-specific physiological test, which 
is known to have greater accuracy in detecting inducible ischaemia21 and has previously been used 
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in derivation work of pressure-derived indices of stenosis severity87. However, hSR lack the 
prognostic evidence base that the pressure derived indices have and given the steep learning curve, 
its use is limited to the research arena. 
 
We also recognize that this study has a relatively small sample size from a single centre. Whilst it 
is certainly the largest study of its kind, lend support to a large multi-centre randomized study, 




Modern FFR and iFR thresholds provide suboptimal diagnostic accuracy compared to a FFR 
threshold of 0.75 or an iFR threshold of 0.86 respectively, which are also the binary cut-offs 
from the original derivation studies. Fractional flow reserve had better diagnostic accuracy than 
either of the resting indices, iFR and Pd/Pa. When used to guide treatment, the less specific 
contemporary thresholds could lead to inappropriate treatment of vessels. Whether the use of the 
more rigorous thresholds would result in selection of a population gaining greater symptom and 























A2: IS HEART RATE RESPONSE A RELIABLE MARKER OF 





Purpose: Growing evidence supports ischaemia-guided management of chest pain, with invasive 
and non-invasive tests reliant upon achieving adenosine-induced coronary hyperaemia (defined 
as increased blood flow to an organ’s perfusion bed). In the non-invasive setting, surrogate 
markers of hyperaemia, such as increases in heart rate, are often used, despite not being formally 
validated.  We tested whether heart rate and other non-invasive indices are reliable markers of 
coronary hyperaemia. Methods: The first part involved Doppler flow-based validation of the best 
pressure-wire markers of hyperaemia in 53 patients. Subsequently, using these validated pressure-
derived parameters, 265 pressure-wire traces were analysed to determine whether heart rate and 
other non-invasive parameters correlated with hyperaemia. Results: In the flow derivation cohort, 
the best determinant of hyperaemia came from having 2 out of 3 of: 1) Ventriculisation of the 
distal pressure waveform, 2) Disappearance of distal dicrotic pressure notch, 3) Separation of 
mean aortic and distal pressures. Within the 244 patients demonstrating hyperaemia, non-invasive 
markers of hyperaemia, such as change in heart rate (p=0.77), blood pressure (p=0.60) and rate-
pressure product (p=0.86), were poor correlates of coronary hyperaemia, with only 37.3% 
demonstrating a ≥10% increase in heart rate that is commonly used to adjudge adenosine-induced 
hyperaemia in the non-invasive setting. Conclusions: We demonstrate, by correlation with 
Doppler-flow data, a validated method of identifying coronary hyperaemia within the catheter 
laboratory using the pressure-wire. We subsequently show that non-invasive parameters, such as 
heart rate change, are poor predictors of coronary hyperaemia during stress imaging protocols that 
rely upon achieving adenosine-induced hyperaemia. 
 
Introduction: 
A growing body of evidence supports ischaemia-guided revascularisation7. Surrogates of 
ischaemia can be assessed non-invasively or during diagnostic angiography, often relying on 
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pharmacological induction of coronary hyperaemia122. The most widely used invasive measure is 
Fractional Flow Reserve (FFR)2,4,10, based on the measurement of distal coronary and aortic 
pressure during adenosine-induced hyperaemia. Intravenous adenosine is also used in stress 
perfusion Cardiac Magnetic Resonance Imaging (CMR). This test is increasingly used to detect 
and quantify ischaemia in patients with suspected coronary disease123 by demonstrating regional 
heterogeneity of coronary blood flow during hyperaemia. Intravenous (IV) adenosine, at a dose 
of 140mcg/kg/min, has been shown to reliably induce near-maximal hyperaemia in most patients, 
with minimal side-effects124 . The net effect of IV adenosine in humans is typically a mild 
reduction in arterial blood pressure associated with increases in heart rate (HR), with multiple 
mechanisms proposed124,125. Due to its non-selectivity, adenosine also activates other receptors 
(A1, A2B and A3), which can also result in cardiac conduction abnormalities, hypotension, flushing 
and bronchospasm126. 
True hyperaemia is best assessed by showing increases in coronary blood flow measured 
invasively using Doppler or Thermodilution techniques, that are difficult to implement outside the 
research setting. Predicting when a patient is experiencing maximal hyperaemia within the 
catheter laboratory is therefore sometimes assessed by awaiting the onset of flushing, 
breathlessness and chest tightness symptoms. Additionally, non-invasive surrogates such as blood 
pressure drop, HR rise and changes in aortic and distal coronary pressure waveforms are relied 
upon to determine the onset of hyperaemia, although no reproducible and objective criteria have 
been identified.  
 
Within the non-invasive CMR setting, where it is not possible to measure such invasive indices, 
subjective symptoms along with objective hemodynamic measures of increasing HR and falling 
systolic blood pressure (SBP) are used as surrogate markers of hyperaemia. 10% or 10 beats per 
minute increase in HR, is commonly considered a marker of adequate hyperaemia within the 
imaging setting, its absence thought to imply inadequate hyperaemic stimulus. In these cases, 
higher adenosine doses are administered or the study is classified as equivocal127. A sub-analysis 
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of the CE-MARC study suggests that inadequate hyperaemic response is considered a recognized 
cause of a false-negative CMR Perfusion scan128.  
 
In this study, we tested the hypothesis that HR changes, and other surrogate non-invasive indices 




Our study population consisted of patients who presented to a single centre for coronary 
angiography +/- proceeding to percutaneous intervention as appropriate. 306 consecutive patients 
undergoing FFR measurements between October 2013 and February 2017 were screened, where 
hyperaemia was induced by IV adenosine infusion. Between this period, 53 patients also had 
simultaneous pressure and Doppler measurements using a CombowireXT guidewire (Philips 
Volcano) as part of a number of studies utilizing detailed intracoronary physiological 
measurements in patients with ischaemic heart disease. All patients received an IV adenosine 
infusion dose of 140 mcg/kg/min through an antecubital vein using a standardized infusion pump 
at a fixed distance from the patient, to minimize variability. For the purposes analysis, FFR was 
defined as the lowest Pd/Pa ratio following the onset of adenosine, averaged over 5 cardiac cycles, 
also known as the ‘smart minimum FFR’47. All participants gave written informed consent in 
accordance with the protocol approved by the local research ethics committee. The study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki. 
 
Standardisation of Invasive Pressure Assessment of Hyperaemia  
Hyperaemia was assessed in the 53 patients using Doppler flow velocity measurements, by 
examining Coronary Flow Reserve (CFR), defined as the ratio of Average Peak Flow Velocity 
(APV) compared to baseline. Doppler measurements of coronary blood flow velocity have been 
shown to have inter- and intra-observer variability of approximately 10%129. A pre-defined CFR 
threshold of 1.2 was therefore used to define hyperaemia (defined as an increase in blood flow to 
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an organ’s perfusion bed) to ensure that the increase in flow at hyperaemia is above the margin of 
measurement error commonly seen with CombowireXT Doppler flow measurements.  
 
In this Doppler cohort, we assessed the diagnostic performance of three commonly-used invasive 
pressure-waveform parameters of hyperaemia, and combinations thereof by calculating their 
sensitivity, specificity and positive and negative predictive values. These are 1) Ventricularisation 
of distal pressure waveform (a presystolic deflection resembling an ‘a wave’, a slower upstroke 
of the waveform and a steeper down-stroke than that of aortic pressure130), 2)Separation of mean 
aortic and distal coronary pressure (>10% difference in (Pa – Pd), over 5 consecutive heart beats, 
compared to the resting gradient) and 3)Disappearance of dicrotic notch from the distal arterial 
pressure trace (see Figure 1). In the absence of an established CFR cut-off for defining 
hyperaemia, the diagnostic performance of the pressure-based parameters at CFR of 1.2 were also 
compared to their performance at a higher CFR of 1.5.  
 
Figure 1 Pressure-bounded invasive parameters  
a. The 3 invasive pressure-based parameters that were investigated and subsequently used to 
define hyperaemia during IV Adenosine infusion. Red trace = Pa (Aortic Wave) Yellow 
trace = Pd (Distal Coronary Wave) b. Magnification of the 3 invasive pressure-bounded 
parameters 
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Assessing Adenosine-Mediated Changes in Coronary Microvascular Resistance and 
Peripheral Vascular Resistance 
The flow cohort enabled characterization of coronary microvasculature resistance (MR) and 
peripheral vascular resistance (via the augmentation index, AIx)131, calculated over five 
consecutive beats at rest and hyperaemia. MR was defined as the distal pressure divided by APV. 
AIx; a measure of central aortic pressure-waveform enhancement by a reflected pulse wave, is 
calculated as the difference between this late systolic pressure P2 and early systolic pressure P1, 
as a percentage of pulse pressure, whereby P1 was identified as the first peak on an aortic pressure 
wave (resulting from the ejection of blood from the heart) and P2 identified as the second peak 
(resulting from reflection of blood due to constriction downstream in the peripheral vascular tree).   
 
Assessing Diagnostic Performance of Heart Rate and Other Non-Invasive Surrogate 
Markers of Hyperaemia 
Based on the diagnostic performance of the invasive pressure parameters (and combinations 
thereof) in the Doppler cohort, the study population (n=265) were dichotomously classified as 
hyperaemic or non-hyperaemic. The predictive accuracy of commonly used non-invasive 
haemodynamic markers (HR, SBP, and rate pressure product [RPP, HRxSBP]) were analysed as 
a percentage change in each parameter in response to IV adenosine-induced hyperaemia. 
 
Statistical Analysis 
Continuous variables were assessed for normality and if found to be normally distributed, were 
expressed as mean±standard deviation. Categorical variables were expressed as counts and 
percentages. Differences in continuous variables were assessed by an independent Student’s t-test, 
whilst differences in categorical variables were evaluated by Fisher’s exact Chi-Squared test. 
Differences in continuous matched variables, such as HR at rest and at hyperaemia were assessed 
using a Paired T–test. The diagnostic accuracy of invasive pressure-waveform parameters at 
detecting a CFR>1.2 was classified in terms of specificity, sensitivity, positive predictive value 
(PPV) and negative predictive value (NPV). Changes in microvascular resistance and peripheral 
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vascular resistance were correlated using Pearson’s Rank Correlation, after testing for normality, 
and results reported a R2 values. Statistical analyses were performed using SPSS software (version 
22.0; SPSS Inc., Chicago, Ill., USA). 
 
Results 
Performance of Invasive Pressure-Indices of Hyperaemia 
In the 53 patients with simultaneous pressure and Doppler measurements, mean FFR was 
0.84±0.1. The individual pressure-waveform indices all had good sensitivity at detecting 
hyperaemia, defined using a CFR threshold of 1.2, but relatively low specificity. Disappearance 
of the dicrotic notch and ventricularisation of the distal pressure waveform were the two 
parameters achieving the best NPV and PPV (Figure 2 and Table I).  The reduced diagnostic 
performance of Pd and Pa trace separation (Figure 2), can be explained by the fact that this 
parameter is difficult to detect in normal coronary arteries (FFR>0.9). In contrast dicrotic notch 
disappearance and ventricularisation were detected easily, regardless of disease burden. 
Combining these indices improved specificity and hence the presence of at least 2/3 pressure 
indices was chosen as the optimum criterion for detecting hyperaemia, forming the basis of 
detecting hyperaemia in the pressure cohort.  
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Figure 2 Relationship between Coronary Flow Reserve (CFR) and the 3 invasive parameters of 
hyperaemia: Graph illustrating the presence and absence of pressure-based parameters of hyperaemia in 
53 patients where simultaneous CFR value were measured. CFR cut-off of 1.2 used as a marker of 
definitive hyperaemia 
 
When a higher CFR threshold of 1.5 was used, the diagnostic performance of the pressure-
bounded parameters was almost identical to a CFR of 1.2. However, by using a CFR threshold of 
1.5, hyperaemic and non-hyperaemic rates were found to be clinically unrealistic at 53% and 47 
% respectively. 
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 Sens Spec NPV PPV 
Dicrotic notch disappearance  84.2 73.3 88.9 64.7 
Separation of Pa and Pd 97.4 20 75.5 75 
Ventricularisation of Pd trace 84.2 53.3 82.1 57.1 
Dicrotic notch disappearance  
 + Ventricularisation 
73.7 93.3 96.6 58.3 
Dicrotic notch disappearance  
+ Separation of Pa and Pd  
81.6 73.3 88.6 61.1 
Separation of Pa and Pd  
 + Ventricularisation  
81.6 60 83.8 56.3 
 
Table I Diagnostic performance of each invasive parameter, and combinations of 2, at a 
CFR threshold of 1.2 Within the validation cohort of patients with pressure and flow data, a 
CFR cut-off of 1.2 was used to calculate sensitivity (Sens), specificity (Spec), negative 
predictive (NPV) and positive predictive value (PPV) of the three pressure based parameters. 




Figure 3 Flow chart: 265 patients with pressure data were analysed using the flow-validated 
pressure indices to determine hyperaemic or not. The predictive accuracy of commonly used 
non-invasive haemodynamic markers (heart rate [HR], systolic blood pressure [SBP] and rate 
pressure product [HR x SBP]) were analysed as % change in each parameter in response to IV 
adenosine from rest to the onset of the lowest Pd/Pa ratio 
 
Changes in Coronary Microvascular Resistance and Peripheral Vascular Resistance 
Using flow data from 53 patients, we found both the MR and AIx significantly dropped from rest 
to hyperaemia (-37±29.76% p<0.001 and -7.13±55.32%, p=0.004). There was no correlation 
between HR change and AIx, R2= 0.031, p= 0.2 (2-sided), or between changes in MR and AIx 
from rest, R2=0.021, p=0.3. 
 
Dichotomization of patients to hyperaemic and non-hyperaemic: 
306 consecutive patients undergoing invasive FFR measurements between October 2013 and 
February 2017 were screened, where hyperaemia was induced by IV infusion of adenosine. 265 
patients were analysed; 41 patients were excluded for reasons specified in the study flow chart 
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(Figure 3). Based on our validated pressure-based criteria, 244 of the 265 patients were determined 
to have developed hyperaemia. 
 
Patient Characteristics 
The enrolled population of 265 patients was 65+/-11 years old with 74% male. We assessed one 
vessel per patient and found the mean FFR, in cases where hyperaemia was adjudged to have been 
reached, was 0.81+/-0.09. Although the proportion of patients with previous PCI was higher 
patients determined to have reached hyperaemia compared to those that did not, there were no 
other significant differences in patient characteristics between the hyperaemic and non-




Table II Demographics of patient population. Comparison of demographics in hyperaemic 
and non-hyperaemic groups. Abbreviations: M, male; F, female; MI, myocardial infarction; PCI, 
percutaneous coronary intervention; CABG, coronary artery bypass graft; ACS, acute coronary 
syndrome. *P value calculated by Independent Samples T Test for age variable and Chi-squared 




Hyperaemic  Non-hyperaemic  P value 
Variables N = 244 % N = 21 % 






Sex (M/F)  181/63 74.2/25.8 16/5 76.2/23.8 0.54 
Hypertension  152 62.3 10 47.6 0.14 
Hypercholesterolemia 181 74.2 16 76.2 0.54 
Diabetes Mellitus  59 24.2 8 38.1 0.13 
Smoker  49 20.1 4 19 0.59 
Patients with a history of MI  61 25 3 14.3 0.21 
Patients with a history of PCI  90 36.9 3 14.3 0.03 
Patients with a history of CABG  10 4.1 0 0 
 
Indication for PCI: Stable 
Elective 












Assessment of Heart Rate and Other Non-Invasive Surrogate Markers of Hyperaemia  
The percentage change in HR from rest did not differ significantly between hyperaemic and non–
hyperaemic groups; 7.9±14.0 and 7.0±16.3 respectively (P=0.78). In addition, there was no 
significant difference in the proportion of patients exhibiting a ³10% increase in HR between 
these groups; 37% vs. 34%, p=0.10 (Figure 4). Similarly, when these non-invasive parameters 
were assessed in the 53 flow-data cohort, there was no significant difference in HR, RPP and SBP 
from rest between hyperaemic and non-hyperaemic patients, as defined by flow. Of the 38 
hyperaemic individuals (as defined by CFR≥1.2), only 47 % showed a ≥10% increase in HR. 
Overall, assessment of the diagnostic performance of HR in the validation cohort revealed a 
sensitivity of 37.3%, specificity of 81%, PPV of 96% and NPV of 10%.  Similarly, when assessing 
HR in the flow-cohort, where hyperaemia was determined using direct Doppler measurements, 
HR showed a sensitivity of 47.4%, specificity of 86.7%, PPV of 90% and NPV of 39.4%. In 
patients where hyperaemia was achieved, the lowest Pd/Pa value occurred at 87.8 ± 32.6 seconds: 
significantly earlier than the mean time to peak HR (Figure 5). Other commonly used non-invasive 
surrogate markers, such as SBP and RPP, also did not vary significantly between hyperaemic and 
non-hyperaemic patients (Figure 6). 
 
 
Figure 4 Heart rate variability.  Pie chart representation of variability in percentage change in 




Figure 5 Variability in Heart Rate and Pd/Pa over time. An illustration of how the mean HR 
and PdPa changed over the course of adenosine infusion in 244 hyperaemic patients 
 
 
Figure 6 Variability of non-invasive surrogate markers of hyperaemia: A comparison of 
haemodynamic markers (RPP, HR and SBP) between patients achieving hyperaemia and those 




In this study, we have demonstrated that the tachycardia associated with IV adenosine infusion is 
an unreliable surrogate marker of maximal hyperaemia, with only 37.3% hyperaemic patients 
exhibiting a 10% increase in HR. This has important implications during non-invasive testing, 
such as perfusion CMR, when a 10% (or 10bpm) increase in mean HR is often used as a marker 
of hyperaemia, although there is no consensus method recommended in the guidelines 132,133. 
 
The first part of this study demonstrated the best performance for assessing hyperaemia came from 
having 2/3 of: 1) Ventriculisation of distal pressure waveform, 2) disappearance of distal dicrotic 
pressure-waveform notch, 3) separation of aortic and distal mean pressures (see Figure 2 and Table 
I). Using ≥2/3 of these parameters, we found 8% of patients did not exhibit a hyperaemic response. 
Other studies measuring coronary flow during IV adenosine administration found similar rates of 
submaximal blood flow124,134,135, however studies that adjudged hyperaemia by only 
demonstrating separation between Pd and Pa traces found higher rates of ‘non-hyperaemic 
response to IV adenosine’135. We demonstrated that this parameter by itself poorly discriminates 
true hyperaemia (Figure 2),  unsurprising in cases of minimal stenoses, where appreciable drops 
in Pd/Pa, even during hyperaemia, may not occur72. A CFR of 1.5 was also assessed and whilst 
similar diagnostic performance was found, the resulting rate of hyperaemia was only 52.8% which 
does not reflect a realistic response to adenosine in the clinical setting, nor does it coincide with 
the rates of hyperaemia reported in previously. Whilst it may be surprising that in the derivation 
cohort of 53 patients, around half had CFR <1.5, this group of patients were pre-selected to consist 
of an intermediate coronary artery disease severity, whereby associated microvascular dysfunction 
may have contributed to overall reduced flow augmentation following adenosine administration. 
A CFR cut-off of 1.2 was therefore used to not only compensate for the classical 10-15% error of 
Doppler measurements, but also to yield clinically realistic PPV, NPV and hyperaemia rates, 
compatible with previous reports124.  
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Nearly two thirds of patients with demonstrable hyperaemia did not have an accompanying ≥10% 
HR increase commonly used to infer hyperaemia non-invasively. Consequently, the NPV of HR 
was found to be poor. The poor performance of HR in the flow-defined group further supports its 
unreliability as a surrogate marker of hyperaemia. Had this arbiter been applied in the perfusion 
MRI setting, these patients would have been misclassified as “non-responders”, potentially 
leading to unnecessarily higher doses of adenosine (with more unpleasant side-effects) without 
added diagnostic value or misclassifying negative perfusion scans as equivocal124,132,136. We have 
also shown that the time-course of HR change may not reflect the onset of maximal hyperaemia 
(Figure 5), with prolonged adenosine infusions subjecting patients to unpleasant symptoms 
unnecessarily. Interestingly, we found 12.3% of patients showed a phasic response to IV 
adenosine; whilst lower than the 39% previously quoted47, if first pass perfusion image acquisition 
occurs during the inter-hyperaemic window, the diagnostic value of the scan may be 
compromised, leading to further diagnostic inaccuracy when using IV adenosine in the non-
invasive setting. 
 
Potential mechanisms underlying variation heart rate response to adenosine 
The ability of adenosine to induce tachycardia is ascribed to peripheral vasodilatation, with the 
assumption that HR change is a direct reflection of peripheral vasodilatation. In addition, both 
direct and reflex baroreceptor-mediated sympathetic activation are thought to play a role137,138. 
Our study has shown that there was no correlation between HR, MR and AIx, and therefore 
highlights the likelihood of other mechanisms, beyond peripheral vasodilatation, by which HR 
increases in response to adenosine; such as action on the sympathetic nervous system139. The lack 
of correlation between HR and peripheral vasodilatation could also be explained by variable 
peripheral vasodilatory responses and known variations within adenosine receptor signalling 
pathways across individuals139,140. 
 
Even in the presence of a significant HR increase, mean peak HR and mean lowest Pd/Pa occurred 
at different times (Figure 5). If peripheral vasodilation is the major determinant of HR increases, 
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this response may be captured at a different time frame to that of maximal coronary vasodilatation 
and it could be inferred that complete saturation of the coronary and peripheral vascular beds may 
be occurring at separate times during adenosine infusion. This is supported by the fact that 
adenosine receptors have been found to vary in affinity for drugs across different vascular 
beds141,142.  
 
If HR is an unreliable surrogate of hyperaemia then what other options exist in non-invasive 
settings, such as CMR? Our data suggests that SBP or RPP changes are similarly unreliable indices 
of hyperaemia (Figure 6). Another option is to focus on non-haemodynamic markers of 
hyperaemia such as splenic blood flow attenuation, which can be assessed during a single breath-
hold without the need for gadolinium and may be a more reliable marker of coronary hyperaemia 
compared to classical haemodynamic markers such as change in HR or SBP143. Another potential 
method of limiting the HR variability is to consider further investigating vasodilator agents with 
more selective A2A-receptor action within the non-invasive imaging setting, such as 
Regadenoson144. 
 
Our study has demonstrated that assessment of hyperaemia in the cardiac catheterisation 
laboratory should rely on a combination of several invasive pressure-waveform based indices. In 
the non-invasive CMR setting, we demonstrate that HR and other haemodynamic surrogates are 
unreliable markers of hyperaemia, owing perhaps to variability in dose responses in different 
vascular beds. Although our study did not specifically evaluate variability in symptoms during 
adenosine-induced hyperaemia, anecdotal variability, e.g. chest tightness, breathlessness and 
flushing, are also likely to be a result of variability in adenosine receptor responses in different 
vascular beds. Whilst we appreciate that symptomatic changes are important to assess, due to the 
retrospective nature of the study, we could not assess these in a standardised way. Perhaps 
assessment of adenosine-induced symptoms in combination with surrogate non-invasive indices 
would provide a better method for detecting hyperaemia in patients receiving IV adenosine until 
alternative indices are developed. 
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Study Limitations 
This is a retrospectively analysed, heterogeneous cohort of patients who may have had different 
levels of pre-medication (including sedation), beta-blockade, tobacco smoking and caffeine intake 
prior to the catheter laboratory visit, confounding their responses to adenosine. However, at our 
institute, patients are advised to abstain from caffeine and anti-anginal medication, especially beta-
blockers, prior to catheter laboratory tests.  
Whilst an increase in coronary blood flow as determined by Doppler (CFR) is the gold standard 
for assessing hyperaemia within the Catheter Laboratory, an absence of flow augmentation does 
not necessarily imply inadequate hyperaemic stimulus. This is partly because CFR is dependent 
on the both epicardial vessels and microvasculature, hence may be an imperfect measure 
hyperaemia, for example in the context of microvascular coronary disease where it may be 
impossible to distinguish inadequate hyperaemic stimulus from diminished responsiveness. In 
patients who truly are non-responsive to adenosine, a different stressor such as Dobutamine or 




An increase in HR has high PPV but poor NPV as a surrogate marker of coronary hyperaemia in 
response to IV adenosine. Even in patients who respond, the time to maximum HR is not always 
an indicator of maximal hyperaemia. In the cardiac catheterisation laboratory, hyperaemia is best 
adjudicated by assessing multiple coronary pressure waveform indices, including dicrotic notch 
disappearance, ventricularisation of the Pd trace and separation of Pd and Pa values, rather than 
reliance on one index alone. In the non-invasive setting, the high PPV of HR as a surrogate marker 
of hyperaemia can be helpful, when no other reliable physiologic parameters are available, but 
should be interpreted cautiously. Further research is needed to develop optimal methods for 
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Name of Researcher:    Dr. Bhavik Modi 
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         Please initial box 
 
1. I confirm that I have read and understand the Patient Information Sheet for ‘ 
Optimising Management of Serial and Diffuse Coronary Artery Disease’ (Version 7 
dated 09.02.2018) for the above study and have had the opportunity to ask questions. 
      
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, and without my medical care or legal rights being 
affected.  
       
 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to my taking 
part in research.  I give permission for these individuals to have access to my records.
    
      
  
4. I agree to take part in the above study.   
 
 
5 I agree to my General Practitioner being informed of my participation in this 
study    
 
6. I agree that my CT data will be anonymised, sent to and analysed by a 3rd party 
company, based in the United States, for the purpose of this research study  
 
 
Name of Participant:   Date:    Signature: 
 




                                    
 
 
      
You are being invited to take part in a research study. Before you decide it is important for you 
to understand why the research is being done and what it will involve. Please take your time to 
read the following information carefully. Ask us if there is anything that is not clear or if you 
would like more information. 
 
‘Optimising Management of Serial and Diffuse Coronary Artery Disease’ 
(REC Study No: 15/LO/2011) 
 
Why is study being carried out? 
Angina and Heart Attacks are caused by narrowings within blood vessels supplying the heart. 
Individual narrowings that need treatment are usually identified by making an educated guess of 
the effect that each will have on blood flow, based on the appearance of the artery on 
angiography (an invasive x-ray procedure which involves injecting dye into each heart artery). 
However, we can now accurately determine the effect of a narrowing on blood flow, using a 
measurement called Fractional Flow Reserve (FFR) during the angiography using a special 
angioplasty wire placed within the heart artery.  
 
Treatment based on FFR yields better outcomes, but FFR is less useful in patients who have 
multiple narrowings in an artery - a common clinical problem. This study will investigate new 
techniques for this scenario of multiple narrowings. One of these techniques is a modification of 
the angiogram and angioplasty assessment that you have already been scheduled for and the 
other is a modification of the data from a Cardiac CT Scan, which you may already have had. 
 
Who is taking part in the study?  
We are inviting patients who have suspected coronary artery disease, who are awaiting coronary 
angiography and potential stenting at St Thomas’ Hospital.  
 
Do I have to take part? 
No, it is entirely voluntary to take part in this study. If you do, you will be given this information 
sheet to keep and be asked to sign a consent form. You are still free to withdraw at any time and 
without giving a reason. A decision to withdraw at any time, or a decision not to take part, will 
not affect the standard of care you receive. 
 
Will I definitely be included in the study if I agree to take part? 
No. If the pattern of disease we find during your angiogram is not appropriate, you may not be 
included in the study even if you have agreed to take part. 
 
What is involved if I say “YES”? 
At present, as part of your normal care, you are scheduled to have a coronary angiogram with 
the possibility of pressure recordings made within narrowed arteries (using a special angioplasty 
wire) to help with choosing the best treatment option (options include stents, medicines, 
operation). 
 
If you consent to the study and your angiogram shows an appropriate pattern of serial/diffuse 
coronary artery disease, you may have additional recordings made using a special angioplasty 
wire (in addition to the pressure recordings made within and narrowed heart arteries as part of 
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your normal care). You may be asked to have a cardiac CT scan prior to having the angiogram 
(if not already performed as part of your normal care).  
 
Participation is entirely voluntary and deciding not to participate will not affect the standard of 
care that you will receive. 
 
What are the potential risks and disadvantages of taking part? 
As part of your normal care, you will have a coronary angiogram and pressure recordings made 
with a special angioplasty wire during an infusion of a drug called adenosine. Adenosine is a 
very safe drug used to dilate the blood vessels of the heart but can occasionally produce very 
short-lived sensations of flushing and chest tightness. If you agree to being part of this study, we 
will use a modified angioplasty wire (already used in clinical practice for other purposes) to 
make additional recordings to normal care during which we will also be using adenosine. In 
taking these additional measurements, the catheter laboratory procedure will be lengthened by 
about 5 to 10 minutes with a small (no more than 1-2 minutes) increase in time exposed to the 
adenosine infusion but with no significant increase in the risk of the procedure. 
The CT scan, if we decide we need one from you as part of the study and if you have not already 
had one, will last for approximately 30 minutes. CT Imaging is safe but does involve exposure 
to a small dose potentially harmful X-rays. Some patients may find the scanner uncomfortable 
and potentially claustrophobic.  
As the catheter laboratory procedure will be lengthened by about 5 to 10 minutes compared to 
normal, there is a small additional radiation exposure. The total amount of radiation you will be 
exposed to will not exceed 71 mSv (milliSievert). This corresponds to about 32 years of natural 
background radiation. Of this total amount of radiation the part that is extra to normal 
treatment could be up to 28.3 mSv, or roughly 13 years of natural background radiation. In most 
cases though, the dose that is extra to normal treatment will not exceed 1.3mSv - or 7 months of 
natural background radiation. All the doses here represent upper estimates, and the typical dose 
is anticipated to be approximately one third of these values. Background radiation is the amount 
of naturally occurring radiation in the environment coming from the earth itself and the suns 
rays 
 
What are the possible benefits of taking part? 
There are no direct benefits from taking part in this study over the usual standard clinical care of 
your condition. We will obtain very useful information from taking the extra measurements in 
the catheter laboratory using the modified specialist angioplasty wires and also the CT scan 
(should it be required and you have not already had one). This information we get might help 
improve the treatment of patients with coronary artery disease in the future. You will not be paid 
for participating in the trial.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers 
who will do their best to answer your questions [Principal Investigator: Dr Divaka Perera, 
Divaka.Perera@kcl.ac.uk, 02071881048].  
 
If you remain unhappy and wish to complain formally, you can do this through the Guy’s and St 
Thomas’ Patients Advice and Liaison Service (PALS) on 020 7188 8801, pals@gstt.nhs.uk. The 
PALS team are based in the main entrance on the ground floor at St Thomas’ Hospital and on 
the ground floor at Guy’s Hospital in the Tower Wing. In the event that something does go 
wrong and you are harmed during the research you may have grounds for  legal action for 
compensation against Guy’s and St Thomas’ NHS Foundation Trust and/or King’s College 
London but you may have to pay your legal costs. The normal National Health Service 
complaints mechanisms will still be available to you (if appropriate).  
 
What will happen if I don’t want to carry on with the study? 
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You can withdraw from the study at any time without giving any reason. All identifiable data 
will be destroyed and only unidentifiable data may be retained. 
 
Will my taking part in this study be kept confidential? 
All the information that is collected about you during the course of this study will be kept 
strictly confidential. The anonymous data may be used in the future for further studies. The data 
collected from the CT Scan will be also anonymised and sent to a 3rd party company (Heartflow) 




¨ Dr Bhavik Modi, Research Registrar, Dept of Cardiology, St Thomas’ Hospital, 
bhavikmodi@hotmail.com; +44 (0) 207 188 3026; +44 7931400880 
¨ Prof Divaka Perera, Consultant Cardiologist, St Thomas’ Hospital 
¨ Prof Michael Marber, Dept of Cardiology, The Rayne Institute, St Thomas' Hospital, 
London SE1 7EH, Tel: +44(0)20-7188-1008, Fax +44(0)20-7188-097 
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